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General introduction
1
End-of-life care and forgoing medical interventions
Improvement of medical care has resulted in an increase in life expectancy in the last 
decades.(1) Since 1950, life expectancy at birth has increased with almost 10 years to 
being over 82 years in 2015.(2) In addition to this rise in life expectancy, improvement 
of medical care has resulted in changes in causes of death. In the 1950s most patients 
died as a result of acute illness, such as myocardial infarction, stroke, and infectious 
diseases.(3) Nowadays, chronic diseases, such as cancer and chronic heart failure, are 
the leading causes of death, accounting for around 60% of all deaths in the Netherlands.
(4) This percentage will further rise in the next twenty years.(5) 
An important driver of improvement of medical care in the last decades 
is that our knowledge regarding the pathophysiology of diseases has increased. As 
a result, new medical interventions have been introduced and optimized, such as 
cardiopulmonary resuscitation to treat a patient with a cardiac arrest, antiretroviral 
medications to suppress human immunodeficiency virus (HIV), and chemotherapy 
and targeted therapy to treat cancer. 
Although the benefits of (improved) medical care are widely acknowledged, 
there are also negative effects to be aware of. Negative effects that may concern almost 
every medical intervention, especially at the end of life, are physical side effects and 
complications, sometimes even resulting in (earlier) death. Medical interventions may 
also cause psychological, social or existential problems, such as false hope and the 
denial of approaching end of life in patients and their relatives.(6)  
Especially in patients who will ultimately die from their chronic disease, there may 
at some stage during the illness trajectory be a turning point at which the disadvantages 
of a medical intervention start to outweigh its potential benefits. It is important that 
caregivers regularly consider whether medical interventions should be continued, adapted 
or discontinued in such patients. This applies particularly to medical interventions that in 
all probability can be withheld or withdrawn without negatively affecting the underlying 
disease. However, for other medical interventions it is also important that caregivers 
consider whether they should be adapted or discontinued to prevent potential harms 
outweighing potential benefits. When a medical intervention causes more harm than 
good, its use is referred to as ‘overuse’.(7) Overuse may result in physical, psychosocial, 
and financial harms,(8) and is therefore seen as poor-quality care.(9) 
This thesis concerns the practice of withholding and withdrawing medical 
interventions in the last phase of life. It focuses on medical interventions in general, 
and on cardiopulmonary resuscitation and medication discontinuation in particular. 
In the studies that are described in this thesis, the last phase of life is defined as having 
a life expectancy of three months or less. In addition, specific attention is paid to the 
dying phase. This is a phase in which dying is imminent and generally concerns the 
last days and hours before the patient’s actual death. 
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Do-not-resuscitate (DNR) decisions
Cardiopulmonary resuscitation (CPR) is an emergency procedure to maintain 
circulatory flow and oxygenation in a patient who is in cardiac arrest. The procedure 
consists of the use of closed-chest compressions and artificial ventilation. In the early 
years after its introduction, in the 1960s, the procedure was seen as simple and very 
successful.(10, 11) However, it soon became clear that not every patient will benefit 
from CPR. In fact, the majority of the patients who receive CPR die. Until 2000, 
survival after in-hospital CPR remained below 20 per cent.(12-14) On average, out-
of-hospital CPR has even lower survival rates,(15-17) although survival rates in the 
Netherlands have increased to almost 20 percent since the introduction of widely 
available automated external defibrillators (AEDs) in the last decade.(18) As the costs 
resulting from CPR are very high,(19) it has been suggested that CPR is a particularly 
cost-ineffective medical intervention, with costs being more than 220.000 per gained 
quality-adjusted life year.(20, 21) These costs include medication costs, costs of staying 
in the hospital, and labour costs, among others. Moreover, CPR may involve a death 
that is traumatic for both the patient and his relatives.(10) In the 1970s, so-called do-
not-resuscitate (DNR) orders were introduced.(10) Such orders involve the decision 
not to apply cardiopulmonary resuscitation in a patient experiences a cardiac arrest. 
From their introduction until now, DNR orders have evoked huge controversy as they 
might result in withholding patients a potentially life-saving treatment at the end of 
life.(10, 22) There are three ways in which the DNR decisions can be taken:  
1. A competent patient asks not to be resuscitated; 
2. The attending physician together with the patient decides that the burden of CPR 
outweighs its potential benefit;
3. The attending physician unilaterally decides that resuscitation is medically useless. 
A DNR decision should in principle always be disclosed to patients and their 
relatives.(23) Ideally, patients are involved in a DNR decision in order to respect 
patients’ autonomy.(24) It has been shown that between 1990 and 2001 a growing 
percentage of DNR decisions in the Netherlands was made together with the patient.
(25) However, in 2001 still more than half of all DNR decisions were made without 
involving the patient.(25) 
Medication discontinuation 
Many recently introduced medications have been shown to be very successful in 
enhancing patients’ quality of life and in prolonging life. As a consequence, patients 
use more and more medications.(26, 27) Especially older patients who may have 
different comorbidities often use many medications.(27, 28)
11
Introduction
1
As with other medical interventions, each medication has its harmful profile. 
An important potential harm relates to so-called adverse drug reactions.(29) The more 
medications a patient uses, the greater the chance of adverse reactions,(30) including 
the chance of drug-drug interactions.(31) Another potential harm is pill burden: the 
effort patients need to take their medications.(32) Especially fragile patients may have 
problems with taking medications, such as lodging of the medication in the mouth or 
throat.(33) 
When potential adverse effects outweigh the expected benefits of medications, 
these medications are called ‘potentially inappropriate medications’ (PIMs).(5) 
Medications can also be regarded as PIMs when they are overprescribed (i.e. excessive 
dosages or duration, or when their effect is only achievable beyond the life expectancy of 
the patient) or misprescribed (i.e. prescribing medication for which there is no proper 
indication).(34) The process of medication discontinuation is called ‘deprescription’.
(11)
Especially older patients and patients with a limited life expectancy are prone 
to use one or more PIMs, as medications may not be as effective as they were in earlier 
stages, treatment objectives may change during life time, and organ functions may 
deteriorate. Exposure to PIMs for this group is associated with an increased risk of 
adverse drug reactions.(35) A meta-analysis showed a 1.6-fold increased mortality 
when using one or more PIMs compared to no use of PIMS.(36) The use of PIMs 
in older patients ranges from 35% up to 77%.(37-41) In order to decrease the use of 
PIMs among patients in a nursing home, in the early 1990s Beers et al defined a list of 
medications that generally should be avoided in a nursing home.(5) The Beers criteria 
were based on a combination of evidence from scientific literature and a modified 
Delphi method with an expert panel. These criteria were expanded and revised several 
times between 1997 and 2015 to finally include all settings of geriatric care.(42-45) 
In the meantime, other lists of PIMs for older patients have been developed, among 
which the Screening Tool of Older person’s Potentially inappropriate Prescriptions 
(STOPP).(26) Both the Beers criteria and the STOPP have been proven to not only 
reduce the use of PIMs,(27, 40) but more importantly, to improve patients’ quality of 
life.(46) 
Less is known about the use of PIMs in (younger) patients with a limited life 
expectancy due to a chronic life-threatening disease. However, it is also important 
that medication use of these patients is reconsidered, perhaps even more than in older 
patients, especially because the time-until-benefit of many medications may exceed 
a patient’s life expectancy.(47) In 2006, a framework for appropriate medication 
prescribing for patients with a limited life expectancy was published in order to support 
the discontinuation of inappropriate medications.(48) This framework was built on 
four components, namely the ‘remaining life expectancy of the patient’, ‘time until 
benefit of the medication’, ‘goals of care’ (in which the patient expresses his/her priorities 
12
Chapter 1
1
in life), and ‘treatment targets’ (e.g. life prolongation or prevention of morbidity). In 
the years that followed, different retrospective chart review studies have highlighted 
that patients with a limited life expectancy are often prescribed medications that are 
potentially inappropriate until the very end of life. As also many medications need to 
be started for symptom relief, these patients use many medications in the last months 
and days of life.(5, 28, 49-53) Little is known about patients’ and physicians’ opinions 
regarding medication management at the end of patients’ lives. Moreover, reasons for 
the continuation of PIMs in this last phase of life are unclear and the perspectives of 
patients, their relatives and caregivers are not yet known. 
Care in the dying phase 
Most patients who die from a chronic illness, such as cancer or chronic heart failure, 
die after a period of imminent dying which normally takes several days to hours.(54) 
It is not always possible to recognize this dying phase, due to the lack of objective 
parameters. When the dying phase is recognized and acknowledged, interventions can 
and should be focused at providing patients with all the comfort they need and wish. 
All other interventions, such as those with the aim of curing disease or extending life, 
should be forgone, as the dying phase is a period of irreversible deterioration, where 
no interventions can affect the outcome.(55) Continuing or starting interventions to 
prolong life during the dying phase can therefore be seen as medical overuse.(7) This 
also accounts for diagnostic interventions, such as measurement of blood pressure and 
blood sampling for laboratory tests.(7) 
International studies have shown that aggressive care, such as intensive care 
unit admission and invasive and burdensome diagnostic or therapeutic procedures, is 
used in more than half of all dying patients.(56-58) An increasing trend over time has 
been found towards more aggressive medical interventions when death is approaching.
(59, 60) As these medical interventions are not only applied to patients in whom the 
inevitability of dying at short notice is recognized, but also to patients in order to prevent 
them from dying, it may be difficult to judge retrospectively whether or not continuing 
or starting medical treatment in patients in the last days of life was ‘right’ or ‘wrong’.
It is stated that end-of-life care in the Netherlands is less aggressive compared to 
other western countries; e.g. relatively few patients with advanced diseases ultimately 
die on an intensive care unit in the Netherlands.(61) However, it is unknown how 
many and which diagnostic and therapeutic interventions are applied by physicians 
in Dutch hospitals in dying patients. It is also unexplored whether awareness of 
impending death of the attending physician is associated with the application of these 
interventions.
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This thesis
This thesis aims to investigate the practice of forgoing medical treatment at the end of 
life and to formulate recommendations to further improve end-of-life care.   
The main research questions are:
DNR decisions 
1. What is the frequency of individual DNR decisions and patient involvement in 
such decisions over the past two decades?
Dying phase
2. How many and which medical treatments are applied by physicians for patients in 
the last days of life?
Medication discontinuation
3. What are the opinions and experiences of physicians regarding medication 
discontinuation during the last days to months of life? 
4. What factors influence the continuation of (potentially) inappropriate medical 
treatment during the last days to months of life? 
5. What are possible solutions to decrease (potentially) inappropriate medical 
treatment during the last days to months of life? 
To answer these research questions, data were used from nationwide studies on end-
of-life decision making practices, the MEDILAST project, and the PalTeC-H project. 
To reflect further on the different topics that are investigated, this thesis also contains 
some descriptions of personal experiences. 
Nationwide study on end-of-life decision making practices 
To answer research question 1, we analyzed data from repetitive nationwide studies 
on end-of-life decision making practices (‘Sterfgevallenonderzoek’).(62) The purpose 
of these studies is to make reliable estimates of the frequency of medical practices 
pertaining to the end of life, and to assess trends in these frequencies. The study was 
performed firstly in 1990, and repeated every five years, most recently in 2015. In 
each of these years, stratified samples of death certificates were drawn from the central 
death registry of Statistics Netherlands. For all sampled cases for which the cause of 
death did not preclude an end-of-life decision, attending physicians were mailed a 
questionnaire that focused on the characteristics of the end-of-life decision making 
that may have preceded the death of the patient involved. In 1990, 2001 and 2010 the 
questionnaire contained a question about DNR decisions. 
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PalTeC-H project 
The PalTeC-H project was performed between June 2009 and July 2012, and included 
cases of patients who died in one of 18 non-intensive care wards of Erasmus MC, a 
1300-bed university hospital in Rotterdam, the Netherlands. Aims of the study were 1) 
to explore and understand the impact of the quality of care on the quality of life during 
the last three days of life and the quality of dying, and 2) to investigate the contribution 
of a quality improvement intervention which consisted of the implementation of a 
network of palliative care nurse champions.(63) Within the PalTeC-H project, 
attending physicians were asked to fill out a questionnaire within one week after a 
patient had died. Data from this questionnaire were used together with findings on 
diagnostic and therapeutic interventions as documented in the medical records to 
answer research question 2.  
MEDILAST project
To answer research questions 2 to 5, we used data from the MEDILAST project. The 
MEDILAST (MEDIcation management in the LAST phase of life) project was carried 
out from February 2013 to December 2015 by the VU University Medical Center, 
Radboud University Medical Center, and Erasmus University Medical Center. The 
aim of the project was to understand current medication use in the last phase of life 
and to formulate recommendations to improve medication management at the end of 
life. A mixed-method approach was used, consisting of 1) a retrospective chart review 
study including a convenience sample of 179 patient records from hospices, hospitals, 
and home settings, 2) qualitative interviews with 17 patients, 12 relatives, 20 clinical 
specialists, 12 general practitioners, and 15 nurses, 3) a questionnaire study among 321 
clinical specialists and general practitioners, and 4) a two-round Delphi study with 
involvement of 42 international experts in the field of medication management and 
palliative care.  
Outline of this thesis
This thesis is divided into three parts. In Part I, current practices are described. In 
chapter 2, the frequency of DNR decisions in cases of non-sudden death and patients’ 
and relatives’ involvement in these decisions are reported. Chapter 3 describes 
medication use in the last seven days of life of patients in the hospital, hospice and 
home setting. In chapter 4, a case of a patient with metastatic pancreatic cancer, and 
a history of diabetes mellitus type II is described. Chapter 5 presents the number and 
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type of diagnostic and therapeutic interventions in hospitalized patients with cancer in 
their last three days of life. In addition, it explores whether or not physician awareness 
of impending death affects the use of these interventions. 
Part II explores the perspectives of patients, their relatives and physicians 
regarding (potentially) inappropriate medications, in chapters 6 and 7, respectively. 
In Part III, possible solutions for improvement of medical care at the end of life 
are described. Chapter 8 presents recommendations for improvement of medication 
care in the final months of life based on an international Delphi study. In chapter 9, 
a research design for deprescribing trials is proposed. Chapter 10 describes the final 
days of my father’s life and proposes possible solutions to prevent patients from dying 
an undignified death. Finally, in chapter 11, the main findings and conclusions of the 
studies are summarized and discussed.
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2Abstract
Objective: To assess trends in the frequency of do-not-resuscitate (DNR) decisions in 
the Netherlands over the past two decades. 
Design: A retrospective survey in three stratified samples of people whose death 
were reported to Statistics Netherlands in 1990, 2001, and 2010. Attending physicians 
received a questionnaire about the medical decision making that had preceded death.
Results: The frequency of individual DNR decisions among non-sudden deaths rose 
sharply from 46% in 1990 to 81% in 2010. The involvement of patients in individual 
DNR decisions rose from 23% (1990) to 45% (2001), and 55% (2010). In most cases 
in which the DNR decision was made without patient involvement, the patient 
was incompetent (56% in 1990, 71% in 2001, and 72% in 2010). The main cause of 
incompetence was unconsciousness (69% in 1990, 40% in 2001, and 43% in 2010).
Conclusions: Non-sudden deaths are increasingly preceded by DNR decisions, which 
are increasingly discussed with patients. However, patients are not involved in almost 
half of the DNR decisions, usually because they are unconscious. This implies that 
DNR decisions are often made late in the illness trajectory. Work needs to be done to 
establish real patient centered care in case of DNR decisions.
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2Introduction
There is an increased awareness that cardiopulmonary resuscitation (CPR) is not 
always in the patient’s best interests.(1) As a result, decisions have to be made about 
who should and should not receive CPR in case of cardiac arrest. Ideally, the physician 
and patient together decide in advance when CPR is considered either appropriate 
or inappropriate. This decision should take into account the patient’s care goals and 
clinical judgment of the patient’s prognosis.(2) 
However, it has been shown that advance do-not-resuscitate (DNR) decisions 
are discussed insufficiently,(3) particularly in the out-of-hospital setting. (4) DNR 
decisions are often made very late in the course of a terminal illness.(5, 6) In addition, 
many of these decisions are made without direct patient involvement, either due to the 
severity of underlying illness or impaired decision-making capacity.(3, 5) 
In the Netherlands, a DNR decision is based on the patient’s wish and the 
medical utility of resuscitation. Physicians may ultimately over-ride the choice of the 
patient or his relatives when they consider CPR inappropriate, e.g. in imminently dying 
patients. A decision not to offer CPR should be disclosed to patients and relatives. 
In addition to these individual DNR decisions, there are so-called institutional 
DNR decisions, which concern all patients who are permanently staying within an 
institution. Such decisions are based on the assumption that resuscitation is futile 
for the patients concerned. Until recently, such institution-wide DNR policy was the 
rule rather than the exception in many nursing homes in the Netherlands, as was also 
true for several nursing homes in the United States.(7) However, as stated in recent 
American and Dutch directives,(8, 9) these institutional DNR decisions should be 
abandoned, because individualized care should be the norm. 
It has been shown that between 1990 and 2001 a growing percentage of DNR 
decisions in the Netherlands was made with the patient or relatives.(10) In order to 
assess trends in the frequency of individual DNR decisions and patient involvement 
over the past two decades, we performed a follow-up study by means of nationwide 
surveys on end-of-life decision making practices.
Methods
Setting
We used data from subsequent nationwide Dutch studies on end-of-life decision 
making practices, that were performed in 1990, 2001, and 2010. (11) In each of these 
years stratified samples of death certificates were drawn from the central death registry 
of Statistics Netherlands, to which all causes of death are reported. Every case was 
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2assigned to one of five strata: in stratum one, the cause of death precluded any end-
of-life decision (e.g. sudden death from a car accident); stratum 2 contains sudden 
deaths in the presence of pre-existent disease; stratum 3, non-sudden deaths due to 
chronic disease; stratum 4, deaths due to cancer and other deaths that were (probably) 
preceded by longer-term terminal disease; and stratum 5, where the death certificate 
suggested that a physician had assisted in dying. The final sample contained 8,3% of 
the cases in strata 1 and 2, 12.5% of those in stratum 3, 25% of stratum 4, and 50% of 
stratum 5.
Patients 
For all sampled cases for which the cause of death did not preclude end-of-life 
decision making (all but stratum 1), the attending physician was asked to fill out a 
written questionnaire. The response percentages were 76% (1990), 74% (2001), and 
74% (2010); the numbers of cases studied were 5,197, 5,617, and 6,263, respectively. 
The questionnaire focused on end-of-life decision making that might have preceded 
the death of the patient involved. If the attending physician reported a death to have 
occurred suddenly and unexpectedly, the case was classified as a sudden death. All 
other cases were classified as non-sudden deaths. We excluded cases in which the 
deceased patient was younger than one year.  
Study design
In 1990, 2001, and 2010 the questionnaire contained a similar question about a DNR 
decision: “Did you or another physician clearly agree in advance that in the event 
of a cardiac and/or respiratory arrest no attempt would be made to resuscitate the 
patient (a so-called do-not-resuscitate decision)?” Answer options distinguished 
individual DNR decisions, which are made for individual patients, and institutional 
DNR decisions. Individual DNR decisions can be agreed upon with the patient, the 
patient’s relatives, and/or with other health care professionals. 
Details about the competency of the patient were only asked in cases where 
death had actually been preceded by an end-of-life decision that concurred with DNR 
decisions, i.e. a decision to refrain from potentially life-prolonging interventions or to 
provide medication with a possible or certain life-shortening effect, e.g. high doses of 
opioids. The competency of the patient to be involved in this end-of-life decision was 
asked. 
The study designs were nearly similar in the three study years. The only 
exception is that the question about a DNR decision in 2001 was only asked in case an 
end-of-life-decision had preceded death. 
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2The data were weighted to adjust for the sampling procedure and for 
differences in response rates by age, gender, and cause and place of death of patients. 
Multivariate logistic regression analysis was done to identify potential differences in 
the characteristics of patients for whom DNR decisions were made.
According to Dutch policy, the study did not require review by a Research 
Ethics Committee, because the data were collected anonymously. 
Results
Frequencies
In Table 2.1, the frequencies of DNR decisions are presented. The frequency of 
individual DNR decisions among non-sudden deaths rose from 1990 to 2010, from 
46% in 1990 to 81% in 2010. The frequency of institutional DNR decisions decreased, 
from 9% of all non-sudden deaths in 1990 to 3% in 2010.
Table 2.1 Do-not-resuscitate decisions in non-sudden deaths, in 1990, 2001 and 2010a
1990 2001 2010
All non-
sudden 
deaths
N=3983
%
Non-sudden 
deaths 
preceded by 
an end-of-
life decision
N=2343
%
All non-
sudden 
deathsb
Non-sudden 
deaths 
preceded by 
an end-of-
life decision
N=2763
%
All non-
sudden 
deaths
N=4933
%
Non-sudden 
deaths 
preceded by 
an end-of-
life decision
N=3581
%
Individual DNR decision 46 55 60 81 85
Institutional DNR decision 9 11 8 3 3
No DNR decision 42 31 17 14 10
Missing 3 3 15 2 2
a  All percentages were weighted
b  In 2001, the question about do-not-resuscitation decisions was only asked for non-sudden deaths that 
were preceded by an end-of-life decision
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2Characteristics 
In Table 2.2, the likelihood is shown of individual DNR decisions in non-sudden 
deaths in 2010 by patient characteristics. Individual DNR decisions were more often 
made if patients were 65-79 years (82%) or 80 years or older (85%) when they died, as 
compared to patients who were 1-64 years old (77%). Cancer (78%) or cardiovascular 
disease (80%) as the cause of death involved a somewhat lower probability of 
individual DNR decisions than other causes of death (88%). The highest frequency 
of individual DNR decisions concerned patients for whom the attending physician at 
the time of death was a clinical specialist (91%) or a nursing home physician (92%). If 
the attending physician was a general practitioner the frequency was lower (71%). The 
characteristics of patients for whom a DNR decision was made in 1990 and 2001 were 
comparable to those in 2010 (not in table). 
Table 2.2 Likelihood of individual do-not-resuscitate decisions in non-sudden deaths by patient characteristics, 
in 2010a
N Individual do-not-
resuscitate decision
%
Odds ratio 95% confidence 
interval
Age (years)
1-64
65-79 
≥80
1158
1630
2047
77
82
85
1
1.22
1.37
1.01
1.09
- 1.48
- 1.73
Gender
Male 
Female 
2432
2403
82
84
1
1.10 0.94 - 1.30
Cause of death
Cancer
Cardiovascular disease
Other or unknown
2875
525
1435
78
80
88
1
1.02
1.57
0.84
1.25
- 1.25
- 1.98
Type of physician
General practitioner
Clinical specialist
Nursing home physician
2587
1135
1113
71
91
92
1
1.33
5.06
1.00
4.03
- 1.75
- 6.37
a  All percentages were weighted
Patient’s involvement
The proportion of DNR decisions that were made with patient involvement increased 
between 1990 and 2010 (Table 2.3). However, in 2010 almost half of the individual 
DNR decisions, 45%, were still made without involving the patient. In most of these 
cases the decision was made with relatives. In 56% of the cases in 1990 where the 
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2Table 2.3 Patient involvement in individual do-not-resuscitate decisions, in 1990, 2001 and 2010a 
1990
N=1563
%
2001
N=1579
%
2010
N=3871
%
Individual do-not-resuscitate decision was made …
with patient 23 45 55
not with patient, but with relatives 40 51 43
not with patient or relatives, but with health care professionals 37 4 1
a All percentages were weighted
DNR decision was made without patient involvement, the patient was incompetent to 
make end-of-life decisions; this percentage was 71% in 2001, and 72% in 2010 (not in 
table). The main causes of incompetency were that the patient was in a state of reduced 
consciousness or unconscious (in 1990, 69%, in 2001, 40%, and in 2010, 43%) or that 
the patient had dementia (in 1990, 30%, in 2001, 37%, and in 2010, 38%) (not in table). 
Discussion
We studied the development of DNR decision making in the Netherlands over the 
past 20 years. The percentage of individual DNR decisions that were discussed with 
patients or relatives has risen sharply between 1990 and 2010. 
Despite the increasing percentage of individual DNR decisions and the 
decreasing percentage of institutional decisions in our study, there seems to be room 
for improvement. Almost half of all individual DNR decisions were made without 
involvement of the patient. In a minority of these cases the patient was probably 
competent, and thus could have been involved. In most of the cases the patient was 
incompetent. Non-involvement of incompetent patients may often imply that DNR 
decisions are made rather late in the illness trajectory.(5) 
Earlier end-of-life decisions, including DNR orders, could give patients a better 
chance to be involved in making decisions about their care.(6) The high percentage 
of non-involved patients indicates that only some improvement has been made 
concerning patient-centered care in the last three decades. 
Non-involvement of patients in DNR decision making may decrease by advance 
care planning (ACP);(12) the process in which patients are invited to anticipate and 
discuss future (end-of-life) treatment options. Indeed, a recent study found that with 
an intervention designed to facilitate end-of-life decision making for patients with 
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2metastatic cancer DNR decisions were made earlier.(13) Especially general practitioners 
might be able to engage with their patients in these discussions earlier in the illness 
trajectory, because they often have a long-standing and committed relationship with 
their patients. Interestingly, in our study general practitioners reported relatively few 
individual DNR decisions in comparison with other types of physicians.
In the Netherlands, recently two guidelines were introduced that should 
stimulate physicians to talk timely with patients about their preferences for and 
expectations about care at the end of life,(14) and specifically about resuscitation.(9) 
These measures should contribute to an increase of involvement of competent patients 
in important decisions about medical care at their end of life. 
Conclusions
The frequency of individual DNR decisions substantially increased in the last two 
decades. However, almost half of these decisions are still made without patient 
themselves. Work needs to be done to establish real patient-centered care with regard 
to DNR decisions.
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Medication use in the last 
days of life in hospital, hospice 
and home settings in  
the Netherlands
3Abstract
Objective: To describe medication use in the last week of life for patients dying in 
hospital, hospice and home settings in the Netherlands.
Design: Retrospective chart review study of medical records of patients who had died 
in hospice, hospital or at home in three different regions in the Netherlands that cover 
more than half of the country. 
Results: 179 records were analyzed. Medications most frequently used in the last week 
of life were analgesics (n=168, 94.1%) and psycholeptics (n=150, 84.7%), in particular 
by hospice patients. The mean number of medications used per patient was nine 
during day 7 before death and six on the day of dying. On the day of death 48 (26.8%) 
patients used a preventive medication. This percentage was highest for patients dying 
in the hospital or at home.
Conclusions: Patients who die an expected death receive many medications in the 
last week of life, part of which are preventive medications. Medication management in 
patients’ final days of life can be improved, especially in the hospital and home setting. 
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3Introduction
Medications are important in supporting patients for curing, treating, and preventing 
disease, and in alleviating patients’ symptoms. However, all medications have 
drawbacks, such as the occurrence of side effects, the potential burden of their 
administration, and their costs. Reconsidering medications is needed when they have 
more conceivable adverse than beneficial effects, especially during the terminal phase 
of a patient’s life.(1, 2) When death becomes imminent, medications may become 
inappropriate due to 1) the lag time of their effect; 2) their increased risk of side effects 
as organ functions changes and 3) changed treatment objectives.(3) These medications 
are the so-called potentially inappropriate medications (PIMs).(4) In contrast, 
pharmacological treatment of symptoms is important in the last phase of life, because 
symptoms such as pain and dyspnoea are common and may jeopardise the patient’s 
comfort and quality of dying.(5)
Research that explores end-of-life medication prescribing patterns has 
particularly focused on the use of unnecessary, futile medications, such as lipid-
lowering and anti-osteoporosis agents.(6-10) They demonstrated that many of these 
medications are continued until the very end of life. Recently, an observational 
analysis of medication records from patients with a life expectancy of less than one 
year revealed that these patients use on average more than 10 medications, with a 
significant amount of PIMs.(11)Le Blanc et al. have reviewed the literature on studies of 
medications used at the end of life of patients with cancer and a limited life expectancy.
(4) The six included studies showed that as patients approach death, the number of 
medications they take usually increases, due to an increase of medications aimed at the 
alleviation of symptoms combined with the continuation of medications for comorbid 
diseases. All studies focused on medications taken by patients who received care in 
hospices or from specialized palliative care services. Recently, another multicenter 
study in hospices underlined the finding of increased symptom-specific medications 
and continuation of medications for comorbid diseases at the end of life.(12) Hospice 
care is seen as an example for best practice care at the end of life.(13) The ultimate goal 
of hospice care is to enable patients to be comfortable. Consequently, medications to 
treat symptoms will ideally have much more weight than medications with the aim to 
treat or prevent diseases. 
There is scarce information on the use of medications by patients in their last 
days of life in hospital and in home care settings. The only three studies that assessed 
medication use in a general hospital setting during the final days showed that many 
patients receive PIMs, and even medications that are clinically definitely futile in the 
last days of life.(5, 14, 15) To our knowledge, there have been no studies done in home 
care settings. It is unknown whether the number and type of medications in patients 
with a limited life expectancy depend on the place where end-of-life care is provided. 
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3The aim of this study was to describe the medication prescriptions for patients dying 
in hospice, hospital and home care settings in the Netherlands. 
Methods
Study design
This study consisted of a retrospective chart review within the MEDILAST (MEDIcation 
management in the LAST phase of life) project. MEDILAST is a multi-center mixed-
methods research project with the aim of understanding current medication use in 
the last phase of life. The project is carried out by VU University Medical Center, 
Erasmus University Medical Center and Radboud University Medical Center in the 
Netherlands.
Chart review
We selected a convenience sample of medical records of patients who had died in 
hospice, hospital or at home by asking physicians to select their two to three most 
recent cases of patients who had died expectedly from a chronic condition. We 
aimed at including 3x60 medical records in the regions of Amsterdam, Rotterdam 
and Nijmegen, respectively, and in each region 3x20 medical records from the 
hospice, hospital and home setting, respectively. For the hospital setting, we included 
records from patients who had died at geriatrics, neurology, oncology, cardiology 
or pulmonology departments in a peripheral or academic hospital. In each region, 
the hospice setting included one high care hospice, where a physician with training 
in palliative care is at all times available for consultation. Finally, family physician 
practices were approached by telephone. Following acceptance to participate in the 
study, three physician-researchers (J.J.A., E.C.T.G., M.K.D.) visited the individual 
practices and clinical departments to collect the data. 
A structured electronic form (MS Access 2013) was used to retrieve the 
information from the medical records. Demographics included place of death, age at 
the time of death and diagnoses. Information about medication use in the last week 
of life was registered which included medication generic names, start and stop dates, 
administration routes and doses. The physician’s notes were manually screened for 
information about the decision-making on medication use. We reviewed the guidelines 
for data collection from medical records as developed by Jansen et al.(16) 
The Medical Ethics Review Committee from the VU University Medical Center 
approved the study protocol. Thereafter, approval from the board of directors or relevant 
authority was obtained prior to data collection in all other participating centers.
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3Statistical analysis
Medications were coded using the World Health Organization Center for Drug 
Statistics Methodology’s Anatomical Therapeutic Chemical classification (ATC) at the 
level of therapeutic subgroup (2nd), pharmacological subgroup (3rd) and chemical 
substance (5th).(17) Descriptive statistics were used to describe the frequency of 
medication prescription per setting. If it was not clear whether or not a medication was 
prescribed for preventive reasons, e.g. antihypertensives that may be used to prevent 
the complications of high blood pressure but also to relieve symptoms of dyspnea, we 
did not classify this as a preventive medication. Statistical analyses were conducted 
using IBM SPSS Statistics 21 (IBM Corporation, 2012). Two-sided p-values < 0.05 
were considered statistically significant. 
Results
A total of 180 medical records were reviewed in this study. One patient died within 24 
hours of admission to a hospice and was not included in the analysis. Table 3.1 shows 
the characteristics of patients per setting. Hospital patients (n=59, 32.8%) comprised 
the wards of geriatrics (n=8, 13.5%), oncology (n=16, 27.1%), neurology (n=12, 
20.3%), cardiology (n=12, 20.3%) and pulmonology (n=11, 18.6%); participating 
centers included 3 academic and 7 peripheral hospitals. In addition, 3 high care 
hospices (n=61, 33.9%), and 32 primary care practices which contributed with two 
to three medical records each (n=59, 32.8%) were included. Patients’ age at the time 
of death ranged from 40 to 103 years. Most patients had a malignancy (n=109) with 
larger proportions in the home care and hospice settings as compared to the hospital 
Table 3.1 Patient characteristics per setting
Characteristics Home care
n=61
Hospice
n=59
Hospital
n=59
Total
n=179
p-value
Age, mean (SD) 76.05 (14.13) 72.56 (12.57) 74.42 (11.57) 74.24 (12.82) 0.328a
Male gender, No. (%) 27 (44) 27 (46) 31 (53) 85 (48) 0.755b
Region, No. (%)
Amsterdam
Rotterdam
Nijmegen
21 (34)
20 (33)
20 (33)
20 (34)
20 (34)
19 (32)
20 (34)
20 (34)
19 (33)
61 (34)
60 (34)
58 (32)
0.998b
Primary diagnosis cancer, N (%) 39 (64) 50 (85) 20 (34) 109 (61) <0.001b
SD: standard deviation
a  One-way ANOVA
b  Chi-squared
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3setting. Most cancer diagnoses involved malignancies of the bronchus/lung (n=29) 
or gastrointestinal tract (n=15). Non-cancer diagnoses included heart failure (n=25), 
cerebrovascular accident (n=12), chronic obstructive pulmonary disease (n=9), 
ischemic heart disease (n=3), and other conditions (n=21).
Patients used 304 different chemical substances corresponding to 113 
pharmacological subgroups and 61 therapeutic subgroups. During the last week 
of life, analgesics (e.g. morphine, fentanyl, paracetamol) were used by 168 (94.1%) 
patients, psycholeptics (e.g. midazolam, haloperidol, temazepam) by 150 (84.7%) 
patients, medications for acid related disorders (e.g. pantoprazole, omeprazole, 
esomeprazole) by 110 (62.1%) patients, medications for constipation (e.g. macrogol, 
lactulose, sodium ducosate) by 100 (56.4%) patients, and antithrombotic agents (e.g. 
nadroparin, acetylsalicylic acid, acenocoumarol) by 87 (49.1%) patients.
The five medications that were most frequently started in the last week of life 
were opioids (n=66, 80.5%), hypnotics and sedatives (n=63, 52.5%), antipsychotics 
(n=47, 26.3%), anxiolytics (n=28, 15.6%) and diuretics (n=22, 12.3%). The median 
(IQR) number of days before death at which these new prescriptions were started was 
2 (1-5) days for opioids, 2 (1-4.25) days for hypnotics and sedatives, 3 (2-5) days for 
antipsychotics, 4.5 (2.5-6) days for anxiolytics, and 4 (2-7) days for diuretics.
The five medications that were most frequently stopped in the last week of 
life were medications for peptic ulcer and gastro-esophageal reflux disease (n=64, 
35.8%), antithrombotic agents (n=50, 27.9%), non-opioid analgesics (n=48, 26.8%), 
medications for constipation (n=46, 25.7%), and diuretics (n=38, 21.2%). The median 
(IQR) number of days before death at which these prescriptions were stopped was 2 
(1-4) for medications for peptic ulcer and gastro-esophageal reflux disease, 2 (1-4) for 
antithrombotic agents, 1 (1-3.75) for non-opioid analgesics, 3 (1-4) for medications 
for constipation, and 2 (1-6) for diuretics. 
The preventive medications most frequently used were antithrombotic agents 
that were used by 87 (48.6%) patients, vitamins by 36 (20.1%) patients, cholesterol-
lowering medications by 16 (8.9%) patients, calcium by 10 (5.5%) patients, and iron 
supplements by 5 (2.7%) patients. Although there was a tendency to stop preventive 
medications in the last week of life, 48 (26.8%) patients still used preventive medication 
on the last day of life.
Table 3.2 shows the differences in medication use between settings in the last 
week of life for the 15 most frequently used pharmacological subgroups. There were 
statistically significant differences between settings for hypnotic, sedatives and anxiolytics, 
non-opioid analgesics and antipyretics, medications for constipation, antithrombotic 
agents, diuretics, antihypertensive agents, antibiotics, and belladonna derivatives. These 
differences were mostly related to the fact that the hospice setting differed from both 
other settings. Medications used for symptom control (for instance hypnotics and 
sedatives; non-opioid pain medication) tended to be used in more patients in the hospice 
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3Table 3.2 Most frequently used medication in the last week of life
Medication pharmacological 
subgroup
Home care
n=61 (%)
Hospice
n=59 (%)
Hospital
n=59 (%)
Total
n=179 (%)
Chi squared
p-value
Opioids 53 (86.9) 58 (98.3) 52 (88.1) 163 (91.1) 0.065
Hypnotics, sedatives or anxiolytics 46 (75.4) 55 (93.2) 38 (64.4) 139 (77.7) 0.002
Drugs for peptic ulcer and GORDa 33 (54.1) 38 (64.4) 38 (64.4) 109 (60.9) 0.322
Non-opioid analgesics and antipyretics 26 (42.6) 42 (71.1) 29 (40.7) 97 (54.2) 0.006
Drugs for constipation 24 (39.3) 43 (78.9) 33 (55.9) 100 (55.9) 0.001
Antithrombotic agents 28 (45.9) 16 (27.1) 43 (72.9) 87 (48.6) <0.001
Antipsychotics 28 (45.9) 33 (55.9) 24 (40.7) 85 (47.5) 0.303
Diureticsb 25 (41) 14 (23.7) 35 (59.3) 74 (41.3) <0.001
Corticosteroids for systemic use 16 (26.2) 28 (47.5) 22 (37.3) 66 (36.9) 0.054
Antihypertensive agentsc 25 (41) 13 (22.0) 34 (57.6) 72 (40.2) <0.001
Propulsives 15 (24.6) 23 (39) 16 (27.1) 54 (30.2) 0.205
Drugs for obstructive airway diseased 15 (24.6) 20 (33.9) 22 (37.3) 57 (31.8) 0.251
Antibioticse 8 (13.1) 3 (5.1) 23 (39) 34 (19) <0.001
Antiepileptics 8 (13.1) 11 (18.6) 11 (18.6) 30 (16.8) 0.612
Belladona and derivatives 3 (4.9) 13 (22.0) 5 (8.5) 21 (11.7) 0.010
a  Gastro-oesophageal reflux disease
b  High-ceiling diuretics + potassium-sparing agents
c  Betablockers, angiotensin converting enzyme inhibitors, vasodilators
d  Inhaled adrenergics, other drugs for obstructive airway disease
e  Beta-lactam antibacterials, quinolones
setting, whereas predominantly preventive medications (for instance antithrombotics, 
statins) tended to be used more in both the hospital and home care setting.
The median number of medications used per patient in the last week of life was 
nine from day 7 through day 2 before death, eight on day 1 before death and six on 
the date of death. In the home setting the median number of medications per patient 
was seven during the entire week. Overall, a larger variation in the median number of 
medications used per patient per day was observed in the hospital setting (seven on day 
7 and 6 before death, five on day 5 before death, seven on day 4 before death, five on day 
3 before death, six on day two before death, and three 1 day before death and on the day 
of death) whilst no variation was seen in the home setting. The tendency in both hospice 
and hospital settings is a reduction in the median number of medications per patient.
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3When comparing settings with regard to medications that were frequently 
started in the last week of life it was found that diuretics were started more often in 
the hospital (18 patients, 38.3%) than in the home (3 patients, 7.5%) and hospice 
(1 patients, 2.1%) setting (p<0.001). Although not reaching statistical significance, 
opioids were started more often in the hospice (12 patients, 92.3%) and hospital (37 
patients, 86%) than in the home (17 patients, 65.4%) setting (p=0.056). 
When comparing settings with regard to medications frequently stopped in the 
last week of life it was found that antithrombotic agents were stopped more frequently 
in the hospital (29 patients, 49.2%) than in the home (13 patients, 21.3%) and the 
hospice setting (8 patients, 13.6%) (p < 0.001); this was also the case for diuretics which 
were stopped more often in the hospital setting (20 patients, 33.9%) when compared to 
the home (9 patients, 14.8%) and the hospice setting (9 patients, 15.3%). 
The medications most frequently continued until death in the home and 
hospice setting were opioids (48 and 54), hypnotics and sedatives (35 and 46), and 
antipsychotics (25 and 24). In the hospital setting these were opioids (49), hypnotics 
and sedatives (25) and antithrombotic agents (14), respectively.
The comparison between settings of medications classified as preventive is 
shown in Table 3.3. The use of thromboprophylaxis, vitamins and cholesterol-lowering 
medications was consistently lower in the hospice setting, but no differences were 
found in the use of calcium or iron supplements.
Table 3.3 Use of preventive medication in the last week of life
Preventive medication Home care
n=61(%)
Hospice
n=59(%)
Hospital
n=59(%)
Total
n=179
Chi squared
p-value
Thromboprophylaxis
Anticoagulant medication
Antiplatelet medication
28 (46)
15 (25)
18 (30)
16 (27)
10 (17)
9 (15)
43 (73)
37 (63)
20 (34)
87 (49)
62 (35)
47 (26)
< 0.001 
Vitamins and trace elements
Vitamin D
Folic acid
Vitamin B12
Vitamin B6
Vitamin B1
Vitamin B complex
19 (31)
8 (13)
4 (6.5)
3 (4.9)
0
0
1 (1.6)
1 (1.6)
1 (1.6)
0
0
0
0
0
16 (27)
7 (12)
2 (3.3)
0
1 (1.6)
3 (5.1)
3 (5.1)
36 (20)
16 (8.9)
6 (3.3)
3 (1.6)
1 (0.5)
3  (1.6)
4 (2.2)
< 0.001 
Cholesterol-lowering drugs 2 (3.2) 1 (1.6) 13 (22) 16 (8.9) < 0.001 
Calcium supplement 4 (6.5) 0 6 (10) 10 (5.5) 0.051
Iron supplement 4 (6.5) 0 1 (1.6) 5 (2.7) 0.076
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3Discussion
This study showed that the number of medications patients used decreased in the final 
week of life regardless of whether patients die at home, in a hospice, or a hospital. As 
could be expected, the number of medications aimed at the alleviation of symptoms, 
such as opioids and sedatives, increased in the final week. The percentage of patients 
using such symptom alleviators was the largest in hospices, followed by the percentage 
in the home setting and in hospital. In all three settings, some patients used preventive 
medications until the very last days of life, but this most often occurred in patients 
dying at home and in hospital: more than a third of these patients used one or more 
preventive medications on the day before their death. 
The importance of adapting the use of medications to a patient's life expectancy 
is increasingly acknowledged.(4) In a Delphi study, palliative care clinicians from nine 
countries came to the consensus that, ideally, medications aimed at the alleviation 
of symptoms (opioids, benzodiazepines, antipsychotics and antimuscarinics) should 
always and everywhere be available for dying patients.(18) In our study, we found 
that virtually all the patients in the hospice setting used morphine and sedatives and 
in more than half of them antipsychotics were used. In the home situation and in 
particular in the hospital, less patients received these medications. Antimuscarinics 
were not prescribed except for a few patients in the hospice. The added value of these 
medications to prevent death rattle is doubtful as two placebo controlled randomized 
studies found no favorable effect of antimuscarinics.(19, 20) 
Another important reason for adapting medications for patients with a limited 
life expectancy is their futility: some medications have a lag time that exceeds the 
patient’s expected life span and therefore might only do harm.(21) This applies 
primarily to preventive medications. For example, it has been proven that stopping 
statins in patients with an estimated life expectancy of less than one year is safe and 
may improve quality of life.(22) Our findings reveal that preventive medications are 
least often used by patients in the hospice, except for thromboprophylaxis. In the 
home setting and in hospital, on the other hand, more than 50% of the patients used 
one or more preventive medications in the week prior to death, including preventive 
medication other than thromboprophylaxis. For example, nearly a quarter of hospital 
patients used a statin one week before death. This finding also underlines that in the 
hospice medication management seems more appropriate and in line with intended 
care for patients in the last phase of life.(13) 
In total, almost 50% of the patients were administered thromboprophylaxis in 
the week prior to their death, which was often continued until death. In the most 
recent NICE guideline, it is advised to review decisions about thromboprophylaxis 
for patients at the end of life on a daily basis, taking into account the views of patients 
and their relatives and the multidisciplinary team.(23) It seems that many physicians 
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3struggle with the question as to whether thromboprophylaxis should be prescribed 
to patients who only have a limited life expectancy, mainly due to the lack of studies 
demonstrating positive and negative effects.(24) 
Our study showed that some types of medication were started or continued 
in the last week of life for some patients, whereas they were stopped in others. Some 
of these medications have in the literature been classified as PIMs.(4, 5) Our findings 
underline the difficulty to categorize medications in the end of life as inappropriate. 
For example, diuretics can be considered to be PIMs when they are solely used as 
antihypertensive. However, they may relieve a patient’s symptoms in case of dyspnea 
and not at all be inappropriate. It may therefore be better to follow a patient-centered 
approach rather than an explicit list of – potentially – inappropriate medications.(25) 
An exception should be long term preventive medications, such as statins, which are 
medically futile anyway.(9)  
Our study had some limitations. First, the reasons for medication prescription 
were seldom described in the records. Therefore, we cannot draw conclusions about 
the intention of their administration. Secondly, we cannot rule out the possibility that 
medications have been discontinued in practice, without it being registered in the 
records. However, especially in hospice and hospital settings, it is common practice to 
administer only medications that are listed in the medical record in order to prevent 
any misunderstandings. Thirdly, differences between settings could be accounted for 
the illness and stage of disease of patients as well as for the background of the treating 
physician, however, the distinction between the two could not be established with our 
data.
Despite these limitations, our study demonstrates that the medication 
management in patients' final phase of life can be improved, especially in home care 
and hospital setting. 
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Sense and nonsense of 
treatment of comorbid 
diseases in terminally  
ill patients:  
a teachable moment
4Story From the Front Lines
A 69-year-old woman was diagnosed with metastatic pancreatic cancer. She had 
a history of diabetes type II, diagnosed 7 years earlier. Initially, her diabetes was 
controlled by strict adherence to a healthy lifestyle. For example, she had stopped 
eating ice cream, which she was very fond of. Two years prior to the cancer diagnosis 
metformin was started and HbA1C levels of 6.8% were achieved. 
She was treated with palliative chemotherapy and during each cycle she received 
dexamethasone to reduce associated nausea. During the first two cycles, blood glucose 
levels rose as high as 288 mg/dl, for which she received short-acting insulin.
At home, without dexamethasone, blood glucose levels occasionally were 
slightly above the upper limit of target values. During the third treatment cycle, the 
patient’s husband told the ward physician that his wife treated the slightly high blood 
glucose levels by not eating until levels came down to normal. The physician – who 
had an interest in palliative care – told the patient and her husband that higher glucose 
levels were not a problem as long as they caused no symptoms. Because of her limited 
life expectancy, development of long-term organ damage was unlikely. 
This information was very disconcerting to the patient, who subsequently asked 
the nurse whether the physicians had thrown in the towel and whether she was going 
to die soon. She had always been told that it was of utmost importance that glucose 
levels not exceed target values. The physician repeated that higher glucose levels were 
unlikely to do her any harm, especially in the absence of symptoms of hyperglycemia. 
He emphasized that her caregivers were not going to abandon her. In contrast, they 
were in fact applying tailored therapy. The patient appreciated this explanation and 
despite her nausea she was keen to eat her beloved ice cream, ignoring its effect on 
blood glucose levels. 
Teachable Moment
Pharmacotherapy is the appropriate use of drug therapy aimed at preventing and 
treating a disease or to relieve symptoms. In the final phase of life, the goals of treatment 
change, and drugs used to prevent or treat chronic diseases need to be reconsidered.
(1) In diabetic patients without complications, no benefit of tight glucose control can 
be expected for at least a decade.(2) In addition to limiting burden and side effects, 
discontinuing drugs in patients with limited life expectancy may actually improve 
quality of life and survival. In a recent randomized trial, discontinuation of statins in 
patients with a less than one year life expectancy led to improved quality of life and 
a trend toward longer life span in comparison with continuation of these drugs.(3) 
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4Continuing medications at the end of life also has important impacts on healthcare 
costs. Discontinuing statins alone in patients with a life expectancy of less than one 
year could save the US healthcare system $603 million annually.(3)
General considerations when prescribing medication for patients at the end of 
life include the patient’s life expectancy, time until potential benefit of treatment, goals 
of care, and treatment targets.(4) Guidelines for treatment of diabetes in terminally ill 
patients recommend reducing or eliminating frequent blood glucose measurement, 
significantly increasing tolerated glucose levels, and minimizing or discontinuing 
medications.(5) 
As in our patient, decreasing or discontinuing medications at the end of life 
may run counter to previous management and lead patients to worry that they are 
being abandoned.(1) Physicians need, therefore, to consider both the physical and 
psychosocial effects of withdrawing treatment. In our case, the physician initially 
failed to address the patient’s fears, but after full explanation of the altered aims of 
treatment, she was very satisfied with her care.      
Pharmacotherapy in terminally ill patients is not a simple task, since physicians 
must adapt drug treatments to new objectives.(1) This case illustrates that such 
adapted management may improve quality of life and potentially reduce unnecessary 
and costly pharmacotherapy.  
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Interventions in the last days 
of hospitalized patients with 
cancer:  
importance of awareness of 
impending death
5Abstract
Objective: We examined the number and type of diagnostic and therapeutic medical 
interventions in hospitalized patients with cancer in their last days of life. In addition, 
we investigated if physician awareness of impending death affected the use of these 
interventions. 
Design: Attending physicians of patients who died in a university hospital between 
January 2010 and June 2012 were asked whether they had been aware of the patient’s 
impending death. The use of diagnostic and therapeutic interventions and medications 
was assessed by studying patients’ charts. We included 131 patients.
Results: In the last 72 and 24 hours of life, 59% and 24% of the patients received one or 
more diagnostic interventions, respectively. Therapeutic interventions were provided 
to 47% and 31%. In the last 24 hours of life, patients received on average 5.8 types of 
medication. 
Awareness of a patient’s impending death was associated with a significant lower use 
of diagnostic interventions (48% vs 69% in the last 72 hours; 11% vs 37% in the last 
24 hours) and several medications that potentially prolong life (e.g. antibiotics and 
cardiovascular medication). 
Conclusions: Many patients with cancer who die in hospital receive diagnostic 
and therapeutic interventions in the last days of life of which their advantages are 
questionable.  To improve end-of-life care, medical care should be adapted. 
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5Introduction
Hospital care is typically focused on cure and prolongation of life. As a result, dying 
patients may receive interventions that are not aimed at promoting their comfort.
(1) This has important negative consequences for both patients and their relatives 
and is therefore in conflict with what has been found to constitute ‘a good death’.(2) 
For patients it means that they may suffer from pain and other symptoms and that 
they may not have time to prepare for the end of life.(3) Further, continued efforts to 
prolong life, e.g. by admitting irreversibly dying patients to the Intensive Care Unit 
(ICU) or providing them with cardiopulmonary resuscitation (CPR), are associated 
with complicated grief of bereaved relatives.(3) In addition to negatively affecting 
patients’ quality of dying and bereaved relatives’ grieving, futile interventions involve 
unnecessary costs. Health care costs have been shown to increase sharply when life 
approaches its final weeks.(4, 5) Data on medical interventions in the last days of life 
are scarce, but they indicate that expensive interventions are sometimes administered 
to patients for whom dying is inevitably imminent.(6-8) Unnecessary, burdensome 
and costly interventions should whenever possible be avoided in dying patients.(1, 9)
In almost all patients with advanced incurable cancer, death is preceded 
by a more or less clear period of imminent dying.(10) When it is recognized and 
acknowledged that the dying phase has started, interventions can and should be 
focused at providing patients with all the comfort they need and wish.(1) In two 
retrospective studies, one of them including only patients dying in hospitals, it was 
shown that patients in whom impending death was recognized received significantly 
fewer undesirable interventions compared to patients in whom the dying phase was 
not recognized.(7, 8) However, another study demonstrated that patients for whom a 
comfort plan was used because death was expected at short notice, still received life 
prolonging treatment.(11) 
The purpose of this study was to investigate 1) how many and which diagnostic 
and therapeutic interventions are applied by physicians in hospital in the last 72 hours 
of life of inpatients with cancer, and 2) whether awareness of impending death of the 
attending physician is associated with the application of these interventions.  
Methods
This study is part of a study to explore and understand palliative and terminal care 
in the hospital (PalTec-H).(12) We studied medical care for inpatients with cancer 
who died between January 2010 and June 2012 during their stay in Erasmus MC, a 
1300-bed university hospital in Rotterdam, the Netherlands. All inpatient wards of 
the hospital participated, with the exception of the department of psychiatry and the 
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5intensive care departments. Attending physicians were asked to fill out a questionnaire 
within one week after a patient had died. We studied the patients’ medical charts. 
Patients who died within 72 hours of their hospital admission were excluded.
The questionnaire included a question about the physicians’ awareness of a 
patient’s impending death. Physicians were asked: ‘had it prior to death been clear 
that the patient would die within hours or days?’ They could answer ‘yes’, ‘more or 
less’, or ‘no’. When physicians answered ‘yes’ they were asked: ‘when did this become 
clear?’ This question could be answered with ‘more than three days before death’; ‘at 
day 3 (72-48 hours) before death’; ‘at day 2 (48-24 hours) before death’; ‘24-12 hours 
before death’; ‘12-6 hours before death’. We defined a physician as having been aware 
of a patients’ impending death when he answered that it had been clear that the patient 
would die within hours or days more than 24 hours before the patient actually died. 
The questionnaire also included a question on whether the patient was treated with a 
curative or palliative intent. 
Two physician researchers (EG, MvdG) and one medical student (SvN) 
reviewed the medical chart of each patient about whom physicians filled out a 
questionnaire. All diagnostic and therapeutic medical interventions in the last three 
days were registered, as well as medication use during this period. We assessed whether 
or not an intervention or medication was used in either of two periods: the last 72 
hours and the last 24 hours of life. All medications were coded using the World Health 
Organization Center for Drugs Statistics Methodology’s Anatomical Therapeutic 
Chemical Classification (ATC).(13)   
The PalTec-H-study was approved by the medical ethical research committee 
of the Erasmus MC. According to Dutch policy, informed consent of patients was not 
required as the data were obtained after patient’s death and all data were processed 
anonymously. 
Statistical analysis
The statistical significance of bivariate associations between physicians’ awareness of a 
patient’s impending death and the use of diagnostic and therapeutic interventions was 
analyzed with chi-square tests. An alpha of 0.05 was used as the cutoff for significance. 
We used Statistical Package for Social Sciences (SPSS), version 24.0, for all calculations. 
Results
Physicians completed the questionnaire for 150 patients with cancer who died during 
the study period. Data of 19 patients could not be analyzed, either because of missing 
information on the physician’s awareness of the patient’s impending death or because 
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5of an incomplete medical chart. Data about 131 patients could be used for the analysis. 
The characteristics of these 131 patients are summarized in Table 5.1. In 63 patients 
(48%), physicians had been aware of the patient’s impending death. The mean age 
of patients for whom the physician had or had not been aware of their impending 
death was 62 years (standard deviation (sd) 12,8 years) and 63 years (sd 11,2 years), 
respectively. The mean duration of the final hospital stay was 13 days for both groups 
(sd 11,0 and 10,3, respectively). The most common cancer types were lung cancer 
(n=21), cancer of the urological tract (n=17), and hematological cancer (n=15). 92% 
of all patients were treated with a palliative intent during their stay in the hospital 
(Table 5.1).
Table 5.1 Patient characteristics 
Total
N=131
N (%)
Physician had been 
aware of impending 
death 
N=63
N (%)
Physician had 
not been aware of 
impending death
N=68
N (%)
P-valuea
Age (years)
<50
50-64
65-79
≥80
19 (15)
52 (40)
55 (42)
5 (4)
12 (19)
21 (33)
27 (43)
3 (5)
7 (10)
31 (46)
28 (41)
2 (3) 
.352
Duration of final hospital stay (days)
3-7
8-14
>14
40 (31)
54 (41)
37 (28)
17 (27)
30 (48)
16 (25)
23 (34)
24 (35)
21 (31)
.358
Female gender 51 (39) 25 (40) 26 (38) .865
Cancer type
Lung
Gastrointestinal 
Urological 
Hematological
Head and neck 
Breast 
Melanoma
Other
Unknown
21 (16)
18 (14)
17 (13)
15 (11)
13 (10)
11 (8)
6 (5)
27 (21)
3 (2)
7 (11)
11 (17)
6 (9)
5 (8)
7 (11)
9 (14)
2 (3)
15 (24)
1 (2)
14 (21)
7 (10)
11 (16)
10 (15)
6 (9)
2 (3)
4 (6)
12 (18)
2 (3)
.131
Treatment intention
Curative
Palliative
Unknown
4 (3)
120 (92)
7 (5)
2 (3)
59 (94)
2 (3)
2 (3)
61 (90)
5 (7)
.568
a Chi-square test
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5Diagnostic interventions
In the last 72 and 24 hours of life, 59% and 24% of the patients, respectively, received 
one or more diagnostic interventions, mostly blood sampling and radiologic 
procedures (Table 5.2). Among patients for whom the physician had been aware of 
their impending death, 48% received one or more diagnostic interventions in the last 
72 hours compared to 69% of the patients in the other group (p=0.013) (Table 5.2). In 
the last 24 hours of life, these percentages were 11% and 37% (p=0.001), respectively. 
Table 5.2 Diagnostic interventions in the last days of life
Total
n=131
n (%)
Physician had 
been aware of 
impending death
n=63 
n (%)
Physician had 
not been aware of 
impending death
n=68
n (%)
p-valuea
Diagnostic interventions in the last 72 hours
Blood samplingb 67 (51) 24 (38) 43 (63) .004
Cultures other than blood culture 31 (24) 5 (8) 26 (38) .000
Urinalysis 13 (10) 3 (4) 10 (16) .028
Radiology 45 (34) 14 (22) 31 (46) .005
Electrocardiography 13 (10) 3 (5) 10 (15) .057
Fine needle aspiration and/or biopsy 6 (5) 1 (2) 5 (7) .115
Otherc 2 (3) 0 (0.0) 2 (2) .170
Any diagnostic intervention 77 (59) 30 (48) 47 (69) .013
Diagnostic intervention in the final 24 hours
Blood samplingb 27 (21) 6 (10) 21 (31) .003
Cultures other than blood cultures 6 (5) 0 (0.0) 6 (9) .016
Radiology 10 (8) 1 (2) 9 (13) .012
Electrocardiography 3 (2) 0 (0.0) 3 (4) .092
Fine needle aspiration and/or biopsy 3 (2) 0 (0.0) 3 (4) .092
Otherd 2 (3) 0.0 2 (2) .170
Any diagnostic intervention 32 (24) 7 (11) 25 (37) .001
a  Chi-square test
b  Including vena punctures (lab or culture), arterial blood gas sampling, glucose measurement
c  Concerned: in one patient a gastrointestinal endoscopy and echocardiography, and in one patient a 
bone marrow puncture and electroencephalogram
d  Concerned: in one patient a bone marrow puncture and electroencephalogram, and in one patient 
urinalysis
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In the last 72 hours and 24 hours of life, 47% and 31% of the patients received one or 
more therapeutic interventions, respectively. The interventions that were most often 
applied were intravenous fluids and enteral tube feeding. In almost all patients who 
received enteral tube feeding, this feeding was continued until the patient passed away. 
Two patients for whom the physician had not been aware of impending death were 
shortly admitted to the ICU in the last 24 hours of life. One of these patients was treated 
Table 5.3 Non-pharmacological therapeutic interventions in the last days of life 
Total
n=131
n (%)
Attending physician 
had been aware of 
impending death
n=63
n (%)
Attending physician 
had not been aware 
of impending death
n=68
n (%)
p-valuea
Interventions in the last 72 hoursb
Blood transfusion 17 (13) 5 (8) 12 (18) .098
Intravenous fluids (>500ml/24 hours) 43 (33) 16 (25) 27 (40) .081
ICU-admission 4 (3) 0 (0.0) 4 (6) .051
Intervention radiology 8 (6) 4 (6) 4 (6) .911
Resuscitation 2 (2) 0 (0.0) 2 (3) .170
Enteral tube feeding 18 (14) 12 (19) 6 (9) .089
Other therapeutic interventionsc 4 (3) 1 (2) 3 (4) .348
Any therapeutic intervention 62 (47) 27 (43) 35 (51) .324
Interventions in the final 24 hoursa
Blood transfusion 7 (5) 1 (2) 6 (9) .066
Intravenous fluids (>500ml/24 hours) 24 (18) 5 (8) 19 (28) .003
ICU-admission 2 (2) 0 (0.0) 2 (3) .170
Resuscitation 2 (2) 0 (0.0) 2 (3) .170
Enteral tube feeding 16 (12) 10 (16) 6 (9) .218
Other therapeuticsd 1 (1) 1 (2) 0 (0.0) .297
Any therapeutic intervention 40 (31) 15 (24) 26 (38) .075
a  Chi-square test
b  Two times or more
c  Concerned: in one patient in which the physician was aware of impending death intervention radiology; 
in two patients radiotherapy, and in one patient operation
d  Concerned: intervention radiology
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5Table 5.4 Use of medication in the last 72 hours of life
Total
n=131
n (%)
Physician had 
been aware of 
impending death
n=63
n (%)
Physician had 
not been aware of 
impending death
n=68
n (%)
p-valuea
Opioidsb 100 (76) 50 (79) 50 (74) .43
Benzodiazepines 69 (53) 37 (59) 32 (47) .18
Antipsychotics 58 (44) 31 (49) 27 (40) .27
Medications for constipation treatment 54 (41) 22 (35) 32 (47) .16
Other analgesicsc 45 (34) 19 (30) 26 (38) .33
Cardiovascular medications 42 (32) 13 (21) 29 (43) .007
Antithrombotics 41 (31) 18 (29) 23 (34) .52
Antimicrobialsd 37 (28) 13 (21) 24 (35) .06
Medications for acid related disorders 36 (27) 15 (24) 21 (31) .36
Antiemeticse 35 (27) 21 (33) 14 (21) .10
Medications for obstructive airway diseases 23 (25) 6 (10) 17 (25) .02
Corticosteroids 21 (16) 10 (16) 11 (16) .96
Minerals-electrolytesf 18 (14) 9 (14) 9 (13) .86
Anesthetics 15 (11) 8 (13) 7 (10) .67
Glucose lowering medications 10 (8) 3 (5) 7 (10) .23
Antiepileptics 8 (6) 3 (5) 5 (7) .54
Antidepressantsg 4 (3) 2 (3) 2 (3) .94
Vitamins 3 (2) 2 (3) 1 (2) .51
Antihemorragics 3 (2) 2 (3) 1 (2) .51
Antimuscarinicsh 2 (2) 2 (3) 0 (0.0) .14
Lipid modifying agents 2 (2) 2 (3) 0 (0.0) .14
Othersi 23 (18) 8 (13) 15 (22) .16
Mean number of different medications (range) 7.2 (0-20) 6.7 (1-18) 7.6 (0-20) .12
a  Chi-square test
b  Including strong-acting opioids, not tramadol 
c  Including paracetamol, tramadol, and antirheumatics 
d  Including antibiotics, antifungals, antivirals 
e  Including aprepitant, domperidon, and metoclopramide
f  Including treatment of mineral supplement, magnesium, potassium, treatment of hyperkalemia, 
combinations Including amitryptillin
g Including amitryptillin
h  Belladonna 
i  Other medications that were prescribed to less than four patients (including opioid dependence, 
loperamide, melatonin, baclofen, pamidronate, ferrous, folic acid, levetiracetam, levothyroxin, 
chlorhexidin, somatostatin, clemastin, methylnaltrexone, multienzymes, nicotin, oxybutynin, phyto-
menadione, methylphenidate, clemastine
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5Table 5.5 Use of medication in the last 24 hours of life
Total
n=131
n (%)
Physician had 
been aware of 
impending death
n=63
n (%)
Physician had 
not been aware of 
impending death
n=68
n (%)
p-valuea
Opioidsb 99 (76) 49 (78) 50 (74) .57
Benzodiazepins 69 (53) 37 (59) 32 (47) .18
Antipsychotics 52 (40) 26 (41) 26 (38) .83
Medication for constipation treatment 49 (37) 21 (33) 28 (41) .35
Other analgesicsc 42 (32) 18 (29) 24 (35) .41
Cardiovascular medications 37 (28) 11 (17) 26 (38) .008
Antithrombotics 36 (27) 15 (24) 21 (31) .36
Medications for acid related disorders 33 (25) 13 (21) 20 (29) .25
Antimicrobialsd 32 (24) 8 (13) 24 (35) .00
Antiemeticse 30 (23) 17 (27) 13 (19) .28
Medication for obstructive airway diseases 20 (23) 5 (8) 15 (22) .02
Corticosteroids 18 (14) 8 (13) 10 (15) .74
Anesthetics 13 (10) 7 (11) 6 (9) .66
Minerals-electrolytesf 11 (8) 5 (8) 6 (9) .85
Glucose lowering medications 8 (6) 2 (3) 6 (9) .18
Antiepileptics 7 (5) 3 (5) 4 (6) .78
Antidepressantsg 4 (3) 2 (3) 2 (3) .94
Vitamins 3 (2) 3 (5) 0 (0.0) .07
Antihemorragicsh 3 (2) 2 (3) 1 (2) .51
Antimuscarinics 2 (15) 2 (3) 0 (0.0) .14
Lipid modifying agents 1 (1) 1 (2) 0 (0.0) .30
Othersi 19 (15) 8 (13) 11 (16) .57
Mean number of different medications taken 
(range)
5.8 (0-17) 5.2 (0-15 ) 6.4 (0-17) .038
a  Chi-square test
b  Including strong-acting opioids, not tramadol 
c  Including tramadol, and antirheumatics 
d  Including antibiotics, antifungals, antivirals
e  Including aprepitant, domperidon, and metoclopramide
f  Including treatment of mineral supplement, magnesium, potassium, treatment of hyperkalemia, combination
g  Including amitryptillin
h  Belladonna
i  Other medications that were prescribed to less than four patients in the last day of life (Including 
opioid dependence, loperamide, melatonin, baclofen, pamidronate, ferrous, folic acid, levothyroxin, 
chlorhexidin, somatostatin, clemastin, methylnaltrexone, multienzymes, nicotin, oxybutynin)
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5with a palliative intent, for the other patient treatment intention is not known. Two 
other patients, both treated with a curative intent, were resuscitated in the last 24 hours 
of life. Chemotherapy was not provided to any of the patients in the last 72 hours of life.
Awareness of impending death was not significantly associated with receiving 
therapeutic interventions in the last 72 and 24 hours of life (Table 5.3).
Medication 
On average, patients used 7.2 types of medication (sd 4.38) in the last 72 hours of life 
(Table 5.4) and 5.8 (sd 4.24) in the last 24 hours of life (Table 5.5). Patients for whom 
the physician had been aware of their impending death used fewer medications in the 
last 24 hours of life than patients for whom the physician had not been aware of their 
impending death, but this difference was not statistically significant (mean 5.2 vs 6.4, 
p=0.38). 
The percentage of patients who used cardiovascular medications and 
medications for obstructive airway diseases in the last 72 hours and 24 hours of life 
was significantly lower when the imminence of death had been acknowledged (Table 
5.4 and 5.5). In the last 24 hours of life, antibiotics were less often prescribed to patients 
in whom the physician had been aware of impending death. There were no significant 
differences in the use of other medications.  
Discussion
Our study shows that many patients with cancer who died in hospital received 
diagnostic and therapeutic interventions in the last days of life. Our study also indicates 
the importance of physicians’ awareness of impending death, as it may reduce the use 
of – often burdensome and futile – interventions. 
There are roughly four different scenarios for the last days of life of a patient 
who dies from a chronic disease, where physicians either do (scenario 1 and 2) or 
do not (scenario 3 and 4) acknowledge a patient’s impending death, and either do 
(scenario 2 and 4) or do not (scenario 1 and 3) provide life-prolonging interventions. 
In our study physicians had been aware of impending death more than 24 hours before 
they actually died in about half of the patients. This is in line with another hospital 
study in which awareness of dying was present in 51% of the patients more than 
24 hours before they died.(14) However, this study also included patients who died 
unexpectedly without having serious life-threatening conditions. Our findings may be 
indicative of the difficulty of diagnosing dying. In current practice, clinical experience 
and team decision making seem to be key elements in accurately diagnosing dying.
(10) When diagnosing dying, caregivers cannot rely on vital sign changes, such as 
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5a decreased systolic blood pressure or increased heart rate, as many patients with 
chronic diseases have normal vital signs until very shortly before death; in addition, 
these signs are also common in patients who are not dying.(15, 16) Other clinical 
signs, such as death rattle and cyanosed extremities, are rather specific for imminently 
dying patients, but tend to occur very late in the dying process.(10)
Ideally, when the attending physician is aware of the imminence of a patient’s 
death, burdensome interventions with the aim of prolonging life are avoided (scenario 
1).(1, 17) Although some patients in whom the attending physician had been aware of 
the imminence of death received one or more diagnostic or therapeutic interventions 
with the potential of prolonging life (scenario 2), our study shows that acknowledgment 
of the imminence of death is associated with less diagnostic interventions. This finding 
is in line with earlier research in which diagnostic interventions were also found to be 
applied significantly less often in patients for whom the dying phase was recognized.
(8) We did not find an association between awareness of patient’s impending death 
and therapeutic interventions. Veerbeek et al’s findings in a study on end-of-life care 
in hospitals and other settings were similar.(8) It should be noted that in Veerbeek’s 
study, interventions such as daily washing and routine turning, were also included as 
therapeutic interventions. In our study, we focused on medical interventions.  
In many cases where patients received therapeutic interventions despite the 
fact that their imminent dying was acknowledged, the intervention involved enteral 
tube feeding. The use of enteral tube feeding in the dying phase is highly questionable 
as it may cause harm as a result of complications, such as aspiration and sepsis.(18) 
However, its withdrawal may lead to distress for the patient and their family members.
(19, 20) This may be an important reason why in almost all patients in our study who 
received enteral tube feeding this intervention was continued until the last 24 hours 
before death, regardless of whether impending death was recognized.
Our study suggests that extensive interventions, such as resuscitation and 
mechanical ventilation, are rare in the last three days of life of hospitalized patients. 
This is contrary to the landmark-trial Support, in which about half of the patients 
who died in hospital received mechanical ventilation within three days of death.
(21) This difference may be explained by the fact that, in contrast to the SUPPORT 
trial, we did not include patients who died in the ICU. In the Netherlands, very few 
patients with advanced cancer are admitted to an ICU.(22) Further, after the 1990s, 
when the SUPPORT-trial was conducted, awareness of the limited value of extensive 
procedures at the end of life may have increased.(23) Finally, interventions to prolong 
life at the end of life may be used more often in the United States as compared to the 
Netherlands.(22)  
Although extensive interventions were used in only a small percentage, many 
patients received other interventions in their last days of life, also if their imminent 
death was acknowledged (scenario 2). There seems to be room for improvement as 
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5even less extensive interventions could have great impact on dying patients and their 
relatives.(24) A plausible reason for the use of these interventions until shortly before 
death may be that caregivers just persist in their daily routine of work.(7, 8) 
Our study highlights that patients use many medications in the last 72 
and 24 hours of life, either with the potential of prolonging life or of symptom 
control. Awareness of a patient’s impending death slightly decreased the number of 
medications. However, both patients in whom the attending physician had or had not 
been aware of the imminence of death used so-called preventive medications, such 
as statins, which can be considered inappropriate in the last phase of life as they have 
no short-term benefit.(25) In two recent retrospective studies it was also shown that 
many inappropriate medications are continued until shortly before death.(26, 27) In 
order to decrease the number of (potentially) inappropriate medications at the end of 
life, evaluation of the medication list should be performed routinely for patients with 
a limited life expectancy.(28) In addition, guidelines should be developed as there is 
a lack of guidance on which medications can be discontinued safely in the last phase 
of life.(23, 29) Further, many patients experience severe suffering due to symptoms 
such as pain during their dying phase.(30) It is important to prescribe medications 
to alleviate these symptoms. We did not find significant differences in prescriptions 
of medication to relieve symptoms such as opioids; our study design precludes 
inferences on whether this indicates that symptom control was adequate regardless of 
the acknowledgment of the imminence of death. 
Some limitations of this study need to be considered. First, this was a 
retrospective study which has inherent limitations such as recall bias among 
physicians when answering the question on whether or not they were aware of the 
patient’s impending death. Second, this study was performed in one hospital which 
limits its generalizability. Third, we cannot rule out the possibility that interventions 
were discontinued without this being registered in the charts. However, in hospital 
settings, it is common practice that all interventions that are listed in the medical chart 
are actually applied and that all interventions that are applied are registered, in order 
to prevent any misunderstandings.
To obtain more insight into medical care in the last days of life, prospective 
studies are needed in which patients are followed until death and where recall bias can 
be avoided. In addition, further studies, such as ethnographic studies, are needed to 
find explanations for continuing or starting medical interventions that are undesirable 
for dying patients.  
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Understanding the 
continuation of potentially 
inappropriate medications  
at the end of life:  
perspectives from individuals 
and their relatives and 
physicians
6Abstract
Objective: To identify barriers and considerations which contribute to continued use 
of potentially inappropriate medications (PIMs) in the final phase of life. 
Design: Semi structured face-to-face interviews with 17 patients with an estimated life 
expectancy of less than three months, 12 of their relatives, 20 of their attending clinical 
specialists and 12 of their family physicians. All interviews were transcribed verbatim. 
Two researchers independently coded the first interviews, after which the codes were 
discussed until consensus was reached. Then, an adapted coding scheme was used for 
further use. Finally, the ultimate coding scheme was grouped into tentative categories 
and key themes. 
Results: Patients, their relatives and physicians felt that PIMs should ideally be 
discontinued at the end of life. Patients and their relatives are willing to discontinue 
medications. Still, patients reported that stopping might give them the feeling that 
their physician has given up on them. Physicians mentioned several reasons for not 
considering withdrawal of PIMs: limited awareness, low priority and uncertainty about 
the consequences. Other reasons were concerns that by discussing discontinuation of 
PIMs patients can be confronted with their impending death and might think they are 
not receiving optimal medical care. 
When physicians communicate with patients about discontinuing medications, they 
tend to focus on the inappropriateness of continuing PIMs instead of on the advantages 
of stopping them.
Conclusions: Physicians have pragmatic reasons not to discuss discontinuation of 
PIMs at the end of life, but also mention concerns about the reaction of patients and 
relatives. However, patients report to be open to discuss discontinuation of PIMs. 
Careful communication about the benefits of discontinuing PIMs seems of the essence.
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6Introduction
Patients with a limited life expectancy often use a range of medications.(1) Some 
of these might have been prescribed at an earlier stage to treat or prevent (chronic) 
illnesses. They might also have been prescribed to reduce the burden of symptoms. 
Symptom alleviation is primarily administered during the last months of life, when 
the burden is at its height.(2)
The administration of medication with a focus on the prevention and treatment 
of illnesses should be reconsidered in the final stages of life, i.e. when a patient’s life 
expectancy is only months or weeks.(1, 3, 4) There are ample medical reasons to do so. 
Firstly, medications are not as effective anymore, given the limited life expectancy. This 
mainly applies to preventive medication – such as statins – that have benefits which 
take months to years to accrue. Secondly, treatment objectives may change at the end of 
life. An example is the treatment of diabetes mellitus. In general, it is recommended to 
keep a patient’s glycated hemoglobin (A1C) value below 7% in order to avoid long-term 
complications.(5) If a patient has a limited life expectancy, however, it may be better to 
raise this upper level to prevent short-term complications, such as hypoglycaemia.(6) 
A third reason for the reconsideration of prescribed medication is that organ functions 
may undergo changes when death is nearing. Blood pressure may drop, for instance, so 
that anti-hypertensive medication may no longer be necessary.(7) 
In practice, however, reconsidering a patient’s medication use in the last phase 
of life seems to be rare.(8-10) Patients often take multiple medications that may not 
have beneficial effects in view of their limited life expectancy and changing organ 
function: so-called potentially inappropriate medications (PIMs).(3, 11-13) PIMs can 
have different side-effects – some of them harmful – and may pose patients with the 
burden of taking them.(3, 13) In addition, the use of PIMs involves costs.(13) 
Factors contributing to continuing PIMs are largely unknown. We performed an 
interview study to identify barriers and considerations which contribute to continued 
use of PIMs in the final phase of life, from the perspectives of patients, relatives and 
physicians. This insight may contribute to the development of guidelines to improve 
medication prescription for patients who are in the final phase of life.  
Methods
Design and setting
This study is part of a larger research project (MEDILAST: MEDIcation management 
in the LAST phase of life), that has the aim of understanding current practices of 
medication prescription in the last phase of life. 
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6In this qualitative study, we interviewed patients who were estimated to have 
a life expectancy of less than three months. In addition, if possible, a relative of each 
patient, the attending clinical specialist(s), and the patient’s family physician were 
interviewed.
Recruitment and sampling
We recruited patients by asking physicians whether they cared for a patient who fulfilled 
inclusion criteria described below and, if so, to inform them about the interview study 
and ask them if they could be approached by the investigators. The inclusion criteria 
were that the patient: 1) had a life expectancy of less than three months; 2) knew their 
life expectancy was limited; 3) was compos mentis and was able to participate in an 
interview.
The physicians who were asked to suggest patients were employed in a general 
or academic hospital, a hospice or in a home care setting. Only one patient per 
physician was included. 
Patients who were willing to participate in the study received written 
information about the interview from the investigators. In case a patient consented to 
participate, they were contacted by the interviewer. 
After the patient signed an informed consent form the interview took place. 
Afterwards, the patient was asked for permission to approach a relative, their family 
physician and their attending clinical specialist(s) to participate in an interview. If the 
patient agreed, the same process of recruiting took place for these potential participants. 
Purposive sampling was used to ensure diversity in patients’ age, diagnosis, 
social background and religious beliefs. To further maximize variation, we included 
comparable numbers of patients from the three different care settings.
The study was approved by the Medical Ethics Committee of the Radboud 
University Medical Centre. In addition, approval from the Board of Directors or 
relevant authority was obtained in all the settings where the patients were recruited.
Interviews
Data for this study were collected from October 2013 to February 2015 through face to 
face, semi-structured interviews. The interviews were conducted by E.G., M.D., B.H., 
J.A. and R.P. and lasted 30-60 minutes. We interviewed the patients and their relatives 
in their home, a hospital or in a hospice. The interviews with health care professionals 
took place in their office. 
We used a topic list that was developed by the project team, guided by a review 
of the literature on this topic and interviews with experts. The topic list was refined on 
the basis of new insights during the interviews. 
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6Data analysis
All the interviews were audio-recorded and transcribed verbatim. The transcripts 
were subjected to qualitative analysis by using the constant comparative method. This 
method is part of the grounded theory approach in which concepts emerge as theory 
is formed. The analysis was facilitated by using qualitative research software (ATLAS.
ti version 7.5.6). Two researchers (E.G. and M.T.) independently read through the first 
few interviews in each respondent group and attached open codes to all issues that 
seemed relevant to provide insight into our research topic. 
Thereafter, the codes were discussed until consensus was reached. Then, 
an adapted coding scheme was developed for further use, after which E.G. and 
M.T. coded the remaining interviews. New codes could be added. We decided that 
saturation had been reached after 59 interviews. The final codes of the two researchers 
were compared and discussed again to reach consensus, and then were grouped into 
tentative categories. These categories were discussed and summarized in key themes 
with the whole project group.        
Results
Characteristics
Interviews were held with 17 patients, 12 relatives, 20 clinical specialists and 12 GPs. 
Most patients had cancer (n=12). Their average age was 71 years (range 47-91), and 
the average age of their relatives was 53 years (range 20-75). Three patients were still 
alive six months after the interview. The other 15 patients deceased on average 55 
days after interviewing them (range 5-117 days). Ten of the 20 clinical specialists were 
specialized in internal medicine, 5 of whom focusing on oncology or hematology. The 
average age of the GPs involved was 40 years (range 29-66), and for specialists it was 
42 years (range 30-64).     
Thoughts about discontinuation
The patients and their relatives as well as the medical professionals indicated that 
PIMs should ideally be discontinued when the final phase of life is reached. However, 
patients and relatives stated that they had never thought about the appropriateness 
of the medications that were prescribed. They fully relied on the knowledge of their 
attending physician.
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6Experiences with discontinuation
It was the experience of the physicians that if PIMs were discontinued, this mostly 
followed so-called reference moments that usually occurred just before the patient's 
death. Such reference moments were: the start of the dying phase, patients' inability 
to swallow medication and the occurrence of side effects of the medication. Patients' 
and their relatives' concerns about the amount of medication could also be a reason to 
discontinue medication. 
Consideration of discontinuation
Physicians stated that they are not very aware of opportunities to discontinue 
medications at an earlier stage of the disease. 
Clinical specialist (CS16): I don’t think it [discontinuation] is always looked into. No, and 
this is speaking for myself, you understand, I do think it should be. Now that I’ve been 
asked to collaborate in the study, well you start thinking about it.
Further, in cases where the use of medications is considered, no actions follow due to 
time constraints and lack of priority. In addition, uncertainty about the consequences of 
discontinuation also makes it difficult for physicians to stop PIMs. Some physicians said 
they were afraid that the discontinuation of certain medications could lead to serious 
medical problems. They indicated that when more evidence of the potential consequences 
of discontinuation would be available, this would be supportive in their decision-making. 
Negative consequences
Although physicians believed that patients should preferably use as few medications as 
possible in the last phase of life, they also thought that discontinuation can be harmful. 
Physicians are concerned that raising the topic of discontinuation can confront patients 
with their approaching death and make them feel that they may receive less care than 
needed, or that the attending physician is throwing in the towel. 
Family physician (FP15): If you stop something, it also makes people feel like, ‘Well 
apparently it’s no use anymore to treat me in the long term because…,’ and this confronts 
people with death, with finiteness, I think.
This particularly applied to cases where physicians were unsure as to whether patients 
were aware that their life expectancy was limited. The physicians stated that this 
uncertainty stopped them from discussing the discontinuation of medications, as they 
felt the patient might not be receptive to the idea.  
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6Patients and relatives, however, said that they do not want to be given false hope 
and preferred health care professionals to tell them the truth. 
Interviewer: If so [when discontinuing medication], would it feel as if the end was 
approaching rapidly? 
Patient (P2): Yes, perhaps a teeny bit, but I would not like him to give me false hope and 
just continue swallowing them either, no, I would not like that either. No, this would 
actually be a very honest way of openly discussing whatever is or isn't of any use anymore. 
At the same time, their statements confirmed physicians' beliefs that the suggestion to 
stop PIM’s might give them the idea that their end was near and that they were given 
up upon, especially if they were still undergoing life-extending treatment. The feeling 
of 'being abandoned' was explicitly mentioned by patients and relatives.  
Patient (P3): Then you’re beyond treatment; then they can’t really do anything else for 
you; and only then does this way [discontinuation of medication] come up.
Interviewer: Is this a good moment to get rid of several medications?
Patient: Yes, the previous times it wasn’t an issue, and now it is.
Interviewer: Imagine that the doctors had discussed such matters with you at an earlier 
stage, how would you have felt about it then?
Patient: Yes, I find that difficult. No, I believe I would then have felt something like: ‘Guys, 
do you want to get rid of me or something’ [chuckles].
Communication about discontinuation
Physicians said that in their communication with patients they primarily focus on the 
medical uselessness of PIMs in relation to the patient's limited life expectancy. 
Clinical Specialist (CS11): Yes, it sometimes happens that they’re still taking statins and 
certain medications that may make you wonder, ‘Is it any use continuing with those?’ 
But, on the other hand, as a doctor it’s sometimes confrontational to say, ‘Right, you’ll 
never get well again.’ You often also have to say, ‘We’ve run out of treatment options.’ Bad 
news, I must say,… I personally find it sometimes difficult to say, ‘Oh, well, you don’t need 
this statin anymore either.’
For patients and their relatives, the use of terms such as medical uselessness can lead 
to misunderstanding and even anger.  
Patients and their relatives indicated that they would better understand 
suggestions to discontinue medication if other reasons are provided, such as stable 
blood count and other stable body parameters (e.g. blood pressure) which make 
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6the use of medication redundant. Some physicians indicated that when discussing 
discontinuation of PIMs they focus on the positive effects of discontinuation. In their 
experience, this approach results in patients being virtually always prepared to stop 
taking one or more medications. Moreover, patients believed that starting with a 
temporary discontinuation would make the final discontinuation less of an issue.  
Discussion 
The patients and relatives as well as the physicians believed that, ideally, PIMs should 
be discontinued in the final stage of life. The interviews with physicians made it clear 
that there are various reasons why, in practice, medication is usually continued until 
very late in the terminal phase. Insufficient awareness and lack of priority and fear of 
negative medical consequences seem to be important factors. Further, physicians fear 
that breaching the topic of the discontinuation of PIMs may do the patient mental 
harm. When physicians breach the subject to the patient, they primarily discuss the 
medical uselessness of the continuation of PIMs, whereas patients and their relatives 
expressed that they would certainly be prepared to stop taking them if the positive 
reasons would be emphasized.
The finding that physicians are hardly aware of the importance of discontinuing 
PIMs and attach little priority to the matter, corresponds to a prior study that 
looked into the factors that play a role in the continuation of potentially superfluous 
medications among the general population.(11) In current practice, therefore, the 
discontinuation of PIMs is mostly reactive, in response to problems, rather than 
proactive. According to experts, physicians should more often consider to discontinue 
PIMs.(12) In order to safeguard optimal pharmacotherapeutical care for patients with 
a limited life expectancy, the prescribed medications should be evaluated at an earlier 
stage, as soon as it becomes clear that the patient has an advanced disease that cannot 
be cured.(12, 14) Reconsidering medication policy can be regarded as an element of 
advance care planning.(15)
Another important reason to continue medications is fear for the medical 
consequences of discontinuation. This fear has to do with the limited availability of 
scientific evidence of the consequence of discontinuation, among other things.(3, 12) 
This applies specifically to the consequences for patients with a limited life expectancy.
(3) To date, only one randomized study has been conducted into the consequences of 
stopping medications in patients with an estimated life expectancy of less than one 
year, which revealed that patients could safely stop using statins.(13) However, this 
study had its methodological limitations, such as contamination among patients in the 
control group.(16) 
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6Physicians indicated that a main obstacle for breaching the topic of the 
discontinuation of PIMs is their idea that this might upset patients. A similar result 
was found in a focus group study on the discontinuation of PIMs for vulnerable elderly 
patients with multimorbidity among GPs.(17) 
Our interviews with patients and relatives, however, revealed that they were 
actually willing to stop taking medication. A questionnaire study among patients 
with multiple chronic morbidities also found that virtually all patients (>90%) 
are in principle willing to discontinue medication.(18) However, when it comes to 
practice, they seem less willing.(19) It should be noted here, however, that the studies 
that found a low percentage of patients willing to stop medication looked into the 
discontinuation of medication that may result in dependency, such as benzodiazepines.
(19) A 'deprescribing' study among vulnerable elderly patients in which the entire 
list of medications was reviewed, also revealed a high percentage of patients who 
were prepared to stop.(20) For virtually all of these patients, one or more potentially 
superfluous medications could indeed be successfully discontinued. 
Our finding that patients and relatives preferred the health care professionals 
to tell them the truth underlines the outcomes of another interview study, which 
found that prognostic disclosure is of great importance to patients with a limited life 
expectancy and their family members.(21) 
An important finding from our interview study is that communication with 
patients about deprescription could be improved. In practice, this communication 
seems to have a negative connotation due to the emphasis that is put on the uselessness 
of continuing certain medications given the limited life expectancy.(22) This can make 
the discontinuation of PIMs an extremely precarious subject, both for patients and 
relatives and for physicians.(14) Emphasizing the positive aspects of quitting – e.g. to 
reduce the risk of adverse effects and the burden of taking pills – may increase patients’ 
willingness to stop medications.(23)  
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7Abstract
Objective: To explore physicians’ opinions and experiences regarding medication 
management during the last phase of life, and to identify factors influencing the 
continuation of potentially inappropriate medications. 
Design: A questionnaire study among 500 general practitioners and 500 clinical 
specialists working in three regions in the Netherlands that represent more than half 
of the Dutch population.  
Results: Questionnaires were returned by 321 physicians (response rate: 37%). The 
majority of them (73%) agreed with the statement that patients who are in the last 
phase of life use too many medications. When presented with a vignette of a patient 
with end-stage COPD with different limited life expectancies, preventive medications 
would be stopped right early before death (e.g. 90% of the physicians would discontinue 
a cholesterol inhibitor when life expectancy was about three months). Medications 
to relieve symptoms, e.g. paracetamol, would not be stopped or stopped right before 
death. For medications to treat (chronic) illnesses, e.g. metformin, there was a huge 
inter-physician variability. 
All statements about possible reasons why medications are continued in the last phase 
of life, e.g. patients feeling abandoned and lack of time, were agreed upon by a small 
minority of respondents. 
Conclusions: Although physicians agree that patients use too many medication at the 
end of life, they quite regularly seem to give patients medications for chronic diseases 
for which the benefit at the end of life may be debatable. More scientific evidence on 
whether or not these types of medication might be discontinued in the last phase of 
life is needed. 
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7Introduction
Many patients who are in the last phase of life use multiple medications that are 
continued until shortly before they ultimately die.(1-5) On the one hand, this seems 
inevitable, because patients’ symptom load generally increases when their death 
approaches.(6, 7) Furthermore, patients who are in the last phase of their life often 
have multiple comorbidities for which different medications are needed.(8) On the 
other hand, the benefit of a considerable number of medications at the end of life is 
debatable. This is especially the case for preventive medications, which are often used 
for positive effects that occur beyond the life-expectancy of the patient. Moreover, in 
the last stage of life potential disadvantages may outweigh the benefits of several types 
of medication, such as blood glucose lowering medications.(9) In practice, however, 
such potentially inappropriate medications (PIMs) are often continued until death.(4, 
10) 
There is increasing awareness that medications at the end of life should be 
reconsidered.(11, 12) The scarce literature on medication management in the final 
phase of life suggests that when a patient has a life expectancy of only months to 
weeks, physicians should especially reconsider medications that are not aimed at 
symptom relief.(12, 13) However, the clinical effects of the discontinuation of many 
PIMs are not well known.(11, 14) A recently published meta-analysis showed a 1.6-
fold increased mortality in patients older than 60 years who were using one or more 
PIMs as compared to patients who did not use such medications.(15) So far only 
one randomized study on discontinuing medications in patients with a limited life 
expectancy has been published.(16) This study evaluated the safety of discontinuing 
statins for patients with an estimated life expectancy between one month and one year. 
The results made clear that statins can be safely stopped and discontinuation may even 
be associated with improved quality of life. However, generalizability of the results was 
limited.(17) 
Little is known about physicians’ opinions regarding medication management 
at the end of patients’ lives. A recent interview study reported that physicians prefer to 
wait with the discontinuation of medications in patients with a limited life expectancy 
until patients themselves accept their illness and limited life expectancy and then 
attach less importance to taking certain medications.(18) In a previous interview study 
we identified several reasons why physicians may fail to stop PIMs, including lack of 
priority and fear of negative medical consequences.(19) Until now, there is a lack of 
quantitative data about the opinions of physicians regarding medication management 
in the last phase of life. 
The purpose of this study was to determine physicians’ opinions on and 
experiences with medication management during the final phase of life, and to identify 
factors influencing the continuation of PIMs at the end of a patient’s life. 
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7Methods
Study design
We conducted a questionnaire study among general practitioners and clinical specialists 
working in the regions of Amsterdam, Rotterdam, and Nijmegen, respectively. This 
study was part of the MEDILAST (MEDIcation management in the LAST phase of 
life) project with the aim of understanding current medication use in the last phase 
of life. This project was carried out by the VU University Medical Center, Radboud 
University Medical Center, and Erasmus University Medical Center. 
Study participants and recruitment
We randomly selected physicians from a database (Cegedim) of addresses of physicians. 
Eligibility criteria were:
1. physicians working in the region of Amsterdam, Nijmegen, or Rotterdam 
(adherence areas of the above-mentioned three medical centers). These regions are 
in the western and eastern part of the Netherlands and represent more than half of 
the Dutch population;  
2. physicians working as general practitioners or as clinical specialists in geriatrics, 
cardiology, pulmonology, medical oncology, or neurology. 
The selection contained 500 general practitioners and 100 physicians from each 
clinical specialty. The invitation letters and paper questionnaires were sent in May 
2014. A web-based reminder was sent by e-mail to non-respondents till 28 weeks after 
the original invitation. Recruitment was completed in February 2015.     
Questionnaire
We developed a questionnaire based on insights from a literature search on this 
topic. The questionnaire was pilot-tested by four physicians filling it out; two general 
practitioners and two clinical specialists. Their comments were discussed within our 
research team and addressed in the final version of the questionnaire. 
The questionnaire consisted of three sections. Section one included questions 
on the respondents’ age, gender, medical specialty, and working experience. Section 
two included a vignette about a patient with multimorbidity (Box). In the first part of 
the vignette the patient’s life expectancy was unspecified; subsequently it was added 
that the patient’s life expectancy was three months and one week, respectively. For each 
situation, respondents were asked whether or not they would discontinue medication, 
and, if yes, which types of medication. Respondents were invited to comment on their 
answer. In order to identify whether the patient’s attitude towards life-prolonging 
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Box: vignette
Mrs Bruin is an 88-year-old woman with COPD Gold stage III-IV. A week ago she came 
back from hospital where she had been treated for an exacerbation of her COPD, the 
third admission within two months. In addition to COPD, her medical history includes 
a cerebrovascular accident (two years earlier), hypertension, diabetes mellitus type 2 and 
severe arthralgia. During the most recent hospital admission she was also diagnosed with 
deep venous thrombosis in her left lower leg. Besides shortness of breath, she has no 
other complaints. Her blood pressure is 135/70 mmHg and her blood glucose level is 6.2 
mmol/L (112mg/dl). 
Her medication list includes salmeterol/fluticasone 50ug/500ug BID one inhalation; 
prednisolone QD 5 mg; enalapril QD 20mg; hydrochlorothiazide QD 12,5mg; metformin 
TID 500mg; paracetamol TID 1000mg; simvastatin QD 40mg; carbasalate calcium QD 
100mg; omeprazole QD 40 mg; acenocoumarol.    
Version A: Mrs Bruin has decided she does not want to be admitted to the hospital 
anymore. She is aware of her limited life expectancy and is comfortable with her situation. 
Version B: Mrs Bruin knows that her condition is deteriorating. Nevertheless, she enjoys 
life as much as she can, together with her children and grandchildren. She is eagerly 
looking forward to the birth of her first great grandchild, which is expected in about three 
months.
7
treatment options had an impact on the respondents’ opinions on medication 
management, we presented the vignette in two versions. In version A, the female 
patient had a fulfilled life and was aware of and accepted upcoming death. In version B, 
the patient enjoyed her life being with her family, In addition, she expected to become 
a great-grandmother within three months (Box). Section three of the questionnaire 
comprised several statements about medication management for patients with a life 
expectancy of three months or less. Respondents were asked whether they agreed with 
each statement on a 5-point Likert scale: strongly disagree, disagree, neutral, agree, 
and strongly agree. 
We coded the questionnaires in order to guarantee anonymity. The study was 
approved by the Medical Ethics Review Committee from the VU University Medical 
Center.
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7Statistical analysis
Frequencies, proportions and means with standard deviations were calculated where 
appropriate. To examine differences between subgroups we used chi-square tests 
and McNemar tests. P-values of less than 0.05 were considered to indicate statistical 
significance. We recoded responses to the statements into disagree, neutral and agree. 
We used the Statistical Package for Social Sciences (SPSS), version 24.0, for all analyses. 
Results
Respondent characteristics
In total, 122 of the selected physicians had retired from working, did not work as 
a physician, or could not be reached because the right contact address was lacking. 
The final sample therefore included 878 physicians. 321 physicians completed the 
questionnaire, resulting in a response rate of 37%. Of these physicians, 174 (54%) were 
general practitioners and 147 (46%) were clinical specialists (Table 7.1). The majority 
Table 7.1 Background characteristics of respondents 
General practitioners Clinical specialists Total
All
N
174
%
100
N
147
%
100
N
321
%
100
Age (yrs)
<40
40-49
≥50
124
27
23
71
16
13
50
36
60
34
25
41
174
63
83
54
20
26
Gender
Male
Female
50
124
29
71
89
58
61
39
139
182
43
57
Specialty
Medical oncologist
Geriatrician
Cardiologist
Pulmonologist
Neurologist
33
35
25
25
29
22
24
17
17
20
Working experience (yrs) experiencea
0-9
10-19
20-29
≥30
137
13
12
9
80
7.6
7.0
5.3
66
43
28
9
45
29
19
6,2
203
56
40
18
64
18
13
5,7
a  Missing values range from 1 to 10 physicians
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7of the general practitioners were female (71%). The mean age (SD) of the general 
practitioners was 38.5 (8.8) years and their mean working experience (SD) was 7.2 
(8.9) years. The mean age (SD) of the clinical specialists was 46.4 (9.2), with a mean 
working experience (SD) of 12.5 (9.6) years.
Vignette
Table 7.2 shows the preferences of respondents with regard to the discontinuation 
of medications for the patient presented in the vignette (both versions). For 
patients with a limited but unspecified life expectancy a majority of respondents 
preferred stopping the cholesterol inhibiting drug (simvastatin) (71%) and the anti-
clotting drug (carbasalate calcium) (62%). More clinical specialists than general 
practitioners preferred stopping carbasalate calcium (68% and 57%, respectively, 
Table 7.2 Physicians’ opinions on medication management for a vignette of a patient with a limited life 
expectancy
Patient’s life 
expectancy is 
unspecified
N (%)
Patient’s life 
expectancy is 
three months
N (%)
P-valuea,b
N=321c
Patient’s life 
expectancy is 
one week
N (%)
P-valued
N=321c
Physician would prefer to stop:
Acenocoumarol 43 (13) 85 (26) .000 253 (79) .000
Salmeterol/fluticason 3 (0.9) 3 (0.9) 39 (12) .000
Prednisolone 16 (5.0) 26 (8.1) .006 100 (31) .000
Enalapril 85 (26) 158 (49) .000 285 (89) .000
Hydrochlorothiazide 123 (38) 191 (60) .000 278 (87) .000
Metformin 57 (18) 104 (32) .000 224 (70) .000
Omeprazole 31 (10) 68 (21) .000 163 (51) .000
Simvastatin 227 (71) 289 (90) .000 293 (91) .344
Carbasalate calcium 199 (62) 239 (74) .000 280 (87) .000
Paracetamol 14 (4.4) 21 (6.5) .016 59 (18) .000
None of the above 34 (11) 15 (4.7) .005 2 (0.6) .000
a  McNemar
b  Comparison between uncertain life expectancy with life expectancy of three months
c  1 missing value
d  Comparison between life expectancy of three months versus one week
91
Medication discontinuation at the end of life
7Table 7.3 Physicians’ opinions on medication management for a vignette of a patient with a limited life 
expectancy: importance of patient’s attitude towards death
Version A
N=150
N (%)
Version B
N=171
N (%)
P-Valuea Total
N=321b
N (%)
Patient’s life expectancy is unspecified  
Preference physician to stop:
Acenocoumarol 30 (20) 13 (7.6) .001 43 (13)
Salmeterol + fluticason 0 (0.0) 3 (1.8) .103 3 (0.9)
Prednisolone 10 (6.7) 6 (3.5) .195 16 (5.0)
Enalapril and/or hydrochlorothiazide 85 (57) 69 (40) .004 154 (48)
Enalapril 53 (17) 32 (10) .001 85 (26)
Hydrochlorothiazide 68 (45) 55 (32) .015 123 (38)
Metformin 33 (22) 24 (14) .062 57 (18)
Omeprazole 18 (12) 13 (7.6) .183 31 (9.7)
Simvastatin 123 (82) 104 (61) .000 227 (71)
Carbasalate calcium 96 (64) 103 (60) .488 199 (62)
Paracetamol 4 (2.7) 10 (5.8) .164 14 (4.4)
None of the above mentioned 15 (4.7) 19 (5.9) .747 34 (11)
Patient’s life expectancy is three months
Preference physician to stop:
Acenocoumarol 50 (33) 35 (20) .009 85 (26)
Salmeterol + fluticason 0 (0.0) 3 (1.8) .103 3 (0.9)
Prednisolone 13 (8.7) 13 (7.6) .727 26 (8.1)
Enalapril and/or hydrochlorothiazide 115 (77) 109 (64) .012 224 (70)
Enalapril 83 (55) 75 (44) .040 158 (49)
Hydrochlorothiazide 101 (67) 90 (53) .007 191 (60)
Metformin 55 (37) 49 (29) .126 104 (32)
Omeprazole 41 (27) 27 (16) .012 68 (21)
Simvastatin 140 (93) 149 (87) .064 289 (90)
Carbasalate calcium 123 (82) 116 (68) .004 239 (74)
Paracetamol 8 (5.3) 13 (7.6) .412 21 (6.5)
None of the above mentioned 3 (0.9) 12 (3.7) .034 15 (4.7)
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7p=0.041). Cardiologists and neurologists were less eager to stop the cholesterol 
inhibiting drug than other clinical specialists (52-62% and 71-82%, respectively, 
p=0.016). Most frequently mentioned reasons to stop cholesterol inhibiting drugs 
were medical futility because of the patient’s limited life expectancy and potential 
side effects of the medication. Carbasalate calcium would be stopped most often 
due to concomitant treatment with acenocoumarol. 
When the life expectancy of the patient was stated to be about three 
months, 90% of the respondents preferred stopping the cholesterol inhibitor 
and 74% preferred stopping the anti-clotting drug. In addition, antihypertensive 
treatment (enalapril and/or hydrochlorothiazide) would be stopped by 70% of the 
respondents, 26% would stop anticoagulant therapy (acenocoumarol). Cardiologists 
and neurologists preferred stopping enalapril and hydrochlorothiazide less often 
than other clinical specialists (40-55%, and 71-73%, respectively, p=0.004). Most 
frequently mentioned reasons to discontinue enalapril and hydrochlorothiazide or 
Version A
N=150
N (%)
Version B
N=171
N (%)
P-Valuea Total
N=321b
N (%)
Patient’s life expectancy is one week
Preference physician to stop:
Acenocoumarol 120 (80) 133 (78) .627 253 (79)
Salmeterol + fluticason 21 (14) 18 (11) .342 39 (12)
Prednisolone 52 (35) 48 (28) .203 100 (31)
Enalapril and/or hydrochlorothiazide 142 (95) 154 (90) .124 296 (92)
Enalapril 134 (89) 151 (88) .771 285 (89)
Hydrochlorothiazide 136 (91) 142 (83) .045 278 (87)
Metformin 110 (73) 114 (67) .194 224 (70)
Omeprazole 89 (59) 74 (43) .004 163 (51)
Simvastatin 140 (93) 153 (89) .221 293 (91)
Carbasalate calcium 136 (91) 144 (84) .084 280 (87)
Paracetamol 30 (20) 29 (17) .483 59 (18)
None of the above mentioned 0 (0.0) 2 (0.6) .184 2 (0.6)
a  chi-square test
b  1 missing value
Table 7.3 Continued
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7acenocoumarol were medical futility because of the patient’s limited life expectancy 
and potential side-effects of the medications. Another reason to discontinue 
enalapril and hydrochorothiazide was that the patient’s blood pressure was already 
low enough. 
When the patient’s life expectancy was stated to be limited to one week, 
the physicians preferred stopping the majority of medications. For all types of 
medication significantly more physicians stated that they preferred to stop in case 
of a life expectancy of one week in comparison with a life expectancy of three 
months, except for the cholesterol inhibitor that was already discontinued by the 
large majority when the patient had a life expectancy of three months. The most 
frequently mentioned reason to stop medications in case of a life expectancy of 
one week of life was that they would not contribute to improved quality of life. 
In the version in which the patient with an unspecified life expectancy or a 
life expectancy of three months stated that she had a fulfilled life and had accepted 
her impending death (version A), physicians significantly more often stated that 
they would stop medication than in the version in which the patient enjoyed her 
life and expected to become a great-grandmother (version B) (Table 7.3). The 
patient’s attitude towards death did not have an impact on physicians’ preferences 
about medication management in case the patient had a life expectancy of only 
one week.  
Statements about medication management in the last phase of life 
The majority of the respondents (73%) agreed with the statement that patients who 
are in the last phase of life use too many medications (Table 7.4). In addition, most of 
the respondents (79%) agreed that patients’ views about possible discontinuation of 
drugs that are no longer medically necessary are very important to them. Opinions 
about the importance of nurses’ views about medication management were divided. 
Clinical specialists more often than general practitioners stated that nurses’ views are 
very important to them (44% vs 25%, p=0.002).   
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7Experiences with medication management in the last phase of life 
In Table 7.5, respondents’ experiences with medication management in patients 
with a limited life expectancy are presented. Virtually all respondents stated that 
they regularly check if symptom treatment is still adequate for patients in the last 
phase of life (96%); about 80% stated that they regularly check which drugs may be 
discontinued. Further, the large majority of respondents (91%) stated that patients 
with a limited life expectancy often accept their proposal to stop certain medications. 
All statements about possible reasons why medications are continued in the 
last phase of life were agreed upon by a small minority of respondents. Statements 
that were agreed upon most often were: the unknown consequences of medication 
discontinuation (16%) and the expectation that patients may feel abandoned (13%). 
General practitioners more often than clinical specialists agreed that medications are 
continued as a result of a lack of insight in the potential consequences of discontinuation 
(21% and 10%, respectively, p= 0.006). 
Of the respondents, 21% stated that they are often not able to evaluate the use of 
medications of patients with a limited life expectancy due to lack of time. Significantly 
more general practitioners than clinical specialists agreed with this statement (26%, 
and 16%, respectively, p= 0.005). 
Table 7.4 Physicians’ views on medication management at the end of life
N(%)a,b
321(100)
Disagree (%) Neutral (%) Agree (%)
Patients with a limited life expectancy use too many 
medications
37 (12) 49 (15) 235 (73)
Evaluating a patient’s use of medications together with the 
patient provides me with a good opportunity to discuss his/
her impending death 
86 (27) 110 (35) 121 (38)
Patients’ views about the discontinuation of medications 
that are not medically necessary are very important to me 
19 (6.0) 47 (15) 251 (79)
Relatives’ views about the discontinuation of medications 
that are not medically necessary are very important to me 
67 (21) 100 (32) 150 (47)
Nurses’ views about the discontinuation of medications that 
are not medically necessary are very important to me
101 (32) 108 (34) 107 (34)
a Missing values range from 0 to 5 physicians (0.0% to 1.6 %)
b All statements concern patients with a life expectancy of < three months
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7Table 7.5 Experiences of physicians with medication management at the end of life
N(%)a,b
321(100)
Disagree 
N(%)
Neutral 
N(%)
Agree 
N(%)
What is your general policy for patients with a limited life expectancy: 
I check regularly which medications may be discontinued  because of 
a patient’s limited life expectancy
14 (4.4) 50 (16) 255 (80)
I check regularly if symptom treatment is still adequate 4 (1.3) 10 (3.1) 305 (96)
I regularly discontinue a medication in patients with a limited life expectancy if:
That medication has no therapeutic benefit 6 (1.9) 21 (6.6) 292 (92)
Side effects may be expected more frequently 26 (8.2) 59 (18) 234 (73)
The patient is not capable to take his/her medication 6 (1.9) 23 (7.2) 290 (91)
Costs of that medication are not proportional to the expected benefits 268 (84) 0 (0.0) 51 (16)
I consider discontinuation of a certain medication in patients with a limited life expectancy if:
Limited life expectancy is sufficiently certain 18 (5.6) 48 (15) 253 (79)
Treatment goals have changed (i.e. from curative to palliative) 12 (3.8) 37 (12) 270 (85)
Side effects occur 7 (2.2) 10 (3.1) 302 (95)
The patient feels burdened by the number of medications he/she has 
to take 
7 (2.2) 36 (11) 276 (87)
If I propose to stop certain medications to a patient with a limited life expectancy, it regularly happens that
The patient accepts this proposal 3 (0.9) 25 (7.9) 290 (91)
The patient asks for explanation before he/she will accept this proposal 29 (9.1) 91 (29) 198 (62)
The patient does not accept this proposal 244 (83) 39 (13) 10 (3.4)
I continue medications more regularly than I discontinue them because:
It is not known what the consequences of discontinuation are 177 (56) 90 (28) 50 (16)
It is difficult for me to talk with patients about their impending death 276 (87) 31 (9.8) 10 (3.2)
Discontinuation may give the patient the feeling that he/she is 
abandoned
209 (66) 66 (21) 42 (13)
Discussing medication withdrawal may result in patient’s emotional 
reactions
255 (80) 39 (12) 23 (7.3)
a  Missing values range from 2 to 28 physicians (0.6% to 8.7%)  
b  All statements below devote to patients with a limited life expectancy (i.e. < three months)
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7Discussion
The results of our study suggest that physicians believe that patients use too many 
medications at the end of life. In a vignette, if the patient’s end of life was imminent, 
many physicians preferred stopping medications, particularly preventive medications. 
However, preferences varied widely and some physicians indicated that they would 
continue some medications for which potential disadvantages, in view of the limited 
life expectancy, may outweigh the benefits. 
Discontinuing medications in a vignette
We found that in a vignette physicians preferred stopping several medications if 
the patient’s life expectancy was limited, which is in line with recommendations for 
medication management in the final phase of life.(11, 12) The vignette made clear 
that there are roughly three groups of medications that would be stopped at different 
times before death. First, preventive medications, e.g. statins, that would be stopped 
relatively early. Second, medications patients frequently use for a long time to treat 
(chronic) illnesses, e.g. metformin and enalapril. We found a huge inter-physician 
variability in preferences regarding if and when such medications should be stopped. 
Third, medications that are prescribed to alleviate symptoms. Physicians preferred 
not stopping these medications or to stop them right before death. Especially for the 
second group of medication, more scientific evidence on whether or not they might be 
discontinued is needed. Until now, physicians seeking guidance regarding medication 
use in patients with a limited life expectancy have to rely on a handful of so-called 
implicit criteria that state if and when medications should be reconsidered, based on, 
for example, their potential benefit compared with the risk of current or future harm.
(12, 13) In addition to such implicit guidelines, an expert opinion-based guideline 
is available that provides explicit guidance on how to proceed when patients with 
diabetes mellitus are in the final phase of life.(20) This guideline states that if a patient’s 
life expectancy is only weeks to months, metformin can be discontinued, as it barely 
reduces glucose levels and is especially aimed at preventing long-term complications. 
It is possible that awareness of this guideline among physicians is poor.  
There is also a lack of clear guidance regarding medications that should 
be continued, or tapered, during the final phase of life.(21) In the vignette, 31% of 
physicians indicated that they would stop prednisolone during the last week of life. 
However, (abrupt) discontinuation of prednisolone may cause adrenal insufficiency, 
or even an adrenal crisis,(22) which can influence the last days of life in a negative 
manner. 
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7Reasons for continuing medications
The finding that physicians indicated that they prefer stopping medications, such 
as statin therapy, if the patient had a limited life expectancy is in contrast with the 
reality of patients continuing medications up till death.(1-5) Only a small minority 
of physicians recognized some potential drivers of continuing potentially futile 
or harmful medications in the last phase of life. It thus remains unclear why such 
continuation is common practice. Possibly, continuation of PIMs is not considered or 
recognized as a problem in clinical practice. This lack of awareness also emerged from 
our interview study.(19) 
There were, however, several statements in our questionnaire that were agreed 
upon by small groups of physicians and may reflect important reasons why physicians 
continue medications in clinical practice. First, the unknown consequences of 
withdrawing medication, as highlighted above. General practitioners especially agreed 
with this explanation while they may be best positioned to discontinue medications as 
they often have a long and trusted relationship with patients.(23) Second, physician’s 
expectation that patients may feel abandoned if medications are discontinued. As a 
consequence, there is a risk that physicians do not discuss medication discontinuation 
with their patients at the end of their life.(19, 24, 25) Most patients with a limited life 
expectancy are in fact willing to discontinue PIMs.(18, 19) Further, the large majority 
of respondents (91%) of our questionnaire study stated that patients with a limited life 
expectancy often accept their proposal to stop certain medications. Third, lack of time 
to evaluate the use of medications. Of course, discussing medication management in 
the last phase of life is time-consuming and just one of many other issues in end-of-
life care. In our opinion, medication management in the last phase of life should be 
incorporated into advance care planning, which informs and empowers patients to 
have a say about their current and future treatment, and positively impacts the quality 
of end-of-life care.(26, 27) 
Limitations
Our study has some limitations. First, the response was low, similar to other physician 
surveys,(28) and therefore there is a possibility of nonresponse bias. A second 
limitation concerns the possibility of social desirability bias, i.e. that respondents have 
answered questions based on their views of what is socially most acceptable. Third, 
the vignette may contain too little clinical information to guide the respondents in 
their decision making preferences. For example, laboratory test results (such as blood 
glucose levels) were not available. 
98
Chapter 7
7References
1. McNeil MJ, Kamal AH, Kutner JS, Ritchie CS, Abernethy AP. The Burden of Polypharmacy in 
Patients Near the End of Life. Journal of pain and symptom management. 2016;51(2):178-83 e2.
2. Morin L, Vetrano DL, Grande G, Fratiglioni L, Fastbom J, Johnell K. Use of Medications of 
Questionable Benefit During the Last Year of Life of Older Adults With Dementia. Journal of the 
American Medical Directors Association. 2017;18:551.e1-551.e7.
3. Todd A, Husband A, Andrew I, Pearson SA, Lindsey L, Holmes H. Inappropriate prescribing of 
preventative medication in patients with life-limiting illness: a systematic review. BMJ supportive 
& palliative care. 2017;2:113-21.
4. van Nordennen RT, Lavrijsen JC, Heesterbeek MJ, Bor H, Vissers KC, Koopmans RT. Changes in 
Prescribed Drugs Between Admission and the End of Life in Patients Admitted to Palliative Care 
Facilities. Journal of the American Medical Directors Association. 2016;17(6):514-8.
5. Arevalo JJ, Geijteman EC, Huisman BAA, Dees MK, Zuurmond WWA, van Zuylen L, van der 
Heide A, Perez RSGM. Medication Use in the Last Days of Life in Hospital, Hospice and Home 
Settings in the Netherlands. Journal of Palliative Medicine. 2018;21(2):149-55. 
6. Chaudhry SI, Murphy TE, Gahbauer E, Sussman LS, Allore HG, Gill TM. Restricting symptoms 
in the last year of life: a prospective cohort study. JAMA internal medicine. 2013;173(16):1534-40.
7. Kehl KA, Kowalkowski JA. A systematic review of the prevalence of signs of impending death 
and symptoms in the last 2 weeks of life. The American journal of hospice & palliative care. 
2013;30(6):601-16.
8. Nobili A, Licata G, Salerno F, Pasina L, Tettamanti M, Franchi C, et al. Polypharmacy, length of 
hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The 
REPOSI study. European journal of clinical pharmacology. 2011;67(5):507-19.
9. Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes 
mellitus in older adults with tight glycemic control. JAMA internal medicine. 2015;175(3):356-62.
10. Mullvain JA, Kozak KR, Moody JS, Campbell TC. Statin use in cancer patients with brain 
metastases: a missed communication opportunity at the end of life. Supportive care in cancer : 
official journal of the Multinational Association of Supportive Care in Cancer. 2015;23(9):2643-8.
11. LeBlanc TW, McNeil MJ, Kamal AH, Currow DC, Abernethy AP. Polypharmacy in patients 
with advanced cancer and the role of medication discontinuation. The Lancet Oncology. 
2015;16(7):e333-41.
12. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate 
polypharmacy: the process of deprescribing. JAMA internal medicine. 2015;175(5):827-34.
13. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness 
for patients late in life. Archives of internal medicine. 2006;166(6):605-9.
14. Lindsay J, Dooley M, Martin J, Fay M, Kearney A, Barras M. Reducing potentially inappropriate 
medications in palliative cancer patients: evidence to support deprescribing approaches. 
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in 
Cancer. 2014;22(4):1113-9.
99
Medication discontinuation at the end of life
715. Muhlack DC, Hoppe LK, Weberpals J, Brenner H, Schottker B. The Association of Potentially 
Inappropriate Medication at Older Age With Cardiovascular Events and Overall Mortality: 
A Systematic Review and Meta-Analysis of Cohort Studies. Journal of the American Medical 
Directors Association. 2017;18(3):211-20.
16. Kutner JS, Blatchford PJ, Taylor DH, Jr., Ritchie CS, Bull JH, Fairclough DL, et al. Safety and benefit 
of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized 
clinical trial. JAMA internal medicine. 2015;175(5):691-700.
17. Geijteman EC, Tiemeier H, van Gelder T. Selecting the Optimal Design for Drug Discontinuation 
Trials in a Setting of Advanced, Life-Limiting Illness. JAMA internal medicine. 2015;175(10):1724-5.
18. Todd A, Holmes H, Pearson S, Hughes C, Andrew I, Baker L, et al. 'I don't think I'd be frightened 
if the statins went': a phenomenological qualitative study exploring medicines use in palliative 
care patients, carers and healthcare professionals. BMC palliative care. 2016;15:13.
19. Geijteman EC, Dees MK, Tempelman MM, Huisman BA, Arevalo JJ, Perez RS, et al. Understanding 
the Continuation of Potentially Inappropriate Medications at the End of Life: Perspectives from 
Individuals and Their Relatives and Physicians. Journal of the American Geriatrics Society. 
2016;64(12):2602-4.
20. End of life diabetes care: full strategy document commissioned by diabetes UK. Second edition 
October 2013.
21. Westdorp H, Langenberg SM, Kramers C, et al.: Use of comedication during palliative sedation 
[Dutch]. Ned Tijdschr Geneesk. 2017;161(0):D773
22. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to 
the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, 
asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical 
Immunology. 2013;9(1):30.
23. http://dx.doi.org/10.1136/ejhpharm-2016-000967. Accessed July 9, 2018.
24. Cruz-Jentoft AJ, Boland B, Rexach L. Drug therapy optimization at the end of life. Drugs & aging. 
2012;29(6):511-21.
25. Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly 
patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC family practice. 
2012;13:56.
26. Brinkman-Stoppelenburg A, Rietjens JA, van der Heide A. The effects of advance care planning 
on end-of-life care: a systematic review. Palliative medicine. 2014;28(8):1000-25.
27. Detering KM, Hancock AD, Reade MC, Silvester W. The impact of advance care planning on end 
of life care in elderly patients: randomised controlled trial. Bmj. 2010;340:c1345.
28. Kellerman SE, Herold J. Physician response to surveys. A review of the literature. American 
journal of preventive medicine. 2001;20(1):61-7.
100
Chapter 7
7101
Medication discontinuation at the end of life

Solutions

Submitted
Bregje A.A. Huisman, Eric C.T. Geijteman, Marianne K. Dees, Lia van Zuylen, 
Agnes van der Heide, Roberto S.G.M. Perez†
†Deceased
Better drug use in  
advanced disease:  
an international Delphi study
8Abstract
Objective: To identify possible solutions for difficulties concerning medication 
management and formulate recommendations to improve medication management 
at the end of life.
Design: A two-round Delphi study with experts in the field of medication management 
and end-of-life care (based on ranking in the citation index in Web of Science and 
relevant publications) were invited to participate. We developed a questionnaire with 
58 possible solutions for problems regarding medication management at the end of life 
that were identified in previously performed studies.
Results: A total of 42 experts from 13 countries participated. Response rate in the first 
round was 93%, mean agreement between experts for all solutions was 87% (range 
62-100%); additional suggestions were given by 51%. The response rate in the second 
round was 74%. Awareness, education and timely communication about medication 
management came forward as top priorities for guidelines. In addition, solutions 
considered crucial by many of the experts were development of a list of inappropriate 
medications at the end of life and incorporation of recommendations for end-of-life 
medication management in disease-specific guidelines.
Conclusions: In this international Delphi study, experts reached a high level of 
consensus on recommendations to improve medication management in end-of-life 
care. These findings may contribute to the development of clinical practice guidelines 
for medication management in end-of-life care.
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8Introduction
Patients with a limited life expectancy use many medications, including potentially 
inappropriate medication.(1-3) Use of multiple medications might lead to adverse 
effects.(4) The impact and burden of using potentially inappropriate medications in end-
of-life care is not clear. In geriatrics, however, negative consequences of inappropriate 
medication use and polypharmacy have been demonstrated: this practice e.g. results in 
an increased rate of hospitalizations, an increased risk of falls and cognitive impairment.
(5) Physicians, nurses, patients and their relatives agree that inappropriate medications 
should be discontinued at the end of life.(6) However, in clinical practice a medication 
review and timely discontinuation of potentially inappropriate medications is not self-
evident.(7)
Several barriers impede adequate medication management by health care 
professionals. Physicians show a limited awareness of the issue and report a variety of 
reasons for not considering withdrawal of potentially inappropriate medications, which 
include low priority, uncertainty about the consequences, and avoiding confronting patients 
with their impending death.(8) Preliminary recommendations have been formulated for 
(dis)continuing medication groups at the end of life, such as antihyperglycemic agents, 
antimicrobials, cholinesterase inhibitors and bisphosphonates.(9, 10) However, no 
comprehensive guidelines are available for medication management in end-of-life care.
A recent interview study illustrates the framework of medication management 
at the end of life and decisions concerning (dis)continuation of specific medications. 
Also the perspectives on medication management and priorities in end-of-life care 
of patients, their relatives, nurses and physicians, their roles in decision-making, 
organizational aspects and communication should be taken into account.(6) The 
aim of our study was to identify possible solutions for impediments and formulate 
recommendations for adequate medication management at the end of life. Therefore, 
we decided to consult international experts on recommendations regarding all relevant 
aspects of medication management in end-of-life care, and perform a Delphi study. 
Methods
This study was conducted within the MEDILAST (MEDIcation management in the 
LAST phase of life) project. MEDILAST is a multi-center mixed-methods research 
project with the objective of understanding current medication use in the last three 
months of life and the associated process of decision-making, and formulating 
recommendations to optimize medication management in end-of-life care. The project 
is carried out in a collaboration of VU University Medical Center, Erasmus University 
Medical Center and Radboud University Medical Center in the Netherlands.
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8Experts
A two-round Delphi survey was conducted among experts in the field of medication 
management and end-of-life care. Considering the scope of this Delphi procedure, 
we sought for experts with a clear track record in palliative care, and experts with 
a relevant background in medication management in care for the elderly. We aimed 
to include experts with different professional backgrounds in order to account for 
the multidisciplinary nature of palliative care. The selection of experts was based on 
ranking in the citation index in Web of Science (Search: Palliative Care / Terminal 
Care / Hospice Care AND Medication / Drug Utilization / Inappropriate Prescribing/ 
Drug Prescriptions / Polypharmacy) and relevant publications regarding medication 
management. In addition, experts from the Dutch multidisciplinary guideline on 
polypharmacy in elderly (11), Palliative care practice guidelines (12) and Palliative 
care expertise centers (13) in the Netherlands were invited to participate. We aimed for 
an expert panel of about 40 experts. We used purposive sampling to ensure diversity of 
background and nationality. Experts who did not respond received a reminder e-mail 
four weeks after sending the original invitation. In total 76 experts were invited, until 
at least forty participants had given their written consent. 
Questionnaire and study design
From literature and previous studies in our MEDILAST-project (medical record 
review, in-depth interviews and a questionnaire study), barriers for adequate 
medication management at the end of life were identified.(6, 8, 14) Based on these 
findings we formulated possible solutions addressing these barriers. The solutions were 
reviewed internally by our project group (that consists of a general practitioner (MD), 
internal medicine resident and clinical pharmacologist (EG), medical oncologist (LZ), 
anesthesiologist (BH), medical doctor-philosopher (Wim J.M. Dekkers) and two 
researchers in palliative care (AH, RP)) and pilot tested among colleagues, forming a 
list of statements or recommendations. These were divided in the seven domains that 
were identified in our interview study (6): awareness and organization (5 solutions), 
education (8), research and development (8), tools (2), roles (18), decision-making 
(7) and communication (10). Participants were provided with definitions of central 
concepts in this study (see Box).
The Delphi study was performed in 2015. The first round questionnaire included 
58 solutions. The experts were asked if they agreed or disagreed with the solutions, 
or they could tick ‘no answer’. Participants were asked to suggest modifications or 
additional solutions. Besides, experts were requested to answer eleven questions 
concerning their background.
The second round questionnaire was also reviewed within the project group. 
This questionnaire consisted of two parts. First, the list of solutions that resulted from 
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8round 1 was presented, including the items additionally suggested or adapted by 
the experts. The participants were then requested to give a top ten ranking score of 
the solutions they considered most relevant to formulate guidelines for medication 
management in end-of-life care (most relevant as number 1; 2 for next most relevant, 
and so on). Second, the solutions discarded in the first round were presented. Experts 
could indicate if they agreed with rejection of these solutions, or whether they 
considered them crucial for guidelines about medication management at the end of 
life.
The questionnaires were sent by electronic mail. Experts were asked to respond 
within four weeks for the first round and within six weeks for the second round. A 
reminder was sent in the case of non-response within the given time range.
Data processing
The data were processed using MS Excel 2010 (Microsoft Corporation, Redmond). We 
defined the first round cutoff value for inclusion in the second round questionnaire 
as agreement of 75%. Based on the top ten ranking score given in the second round a 
priority score was calculated (10 points for the first, nine for the second, etc.) for each 
solution to provide a ranked rating of the most important solutions as suggested by 
the experts. 
Results
Figure 1 shows a flowchart of the Delphi process. In total 76 experts were invited. Two 
invitations were returned by the recipient’s mail server as undeliverable, eight experts 
were not available or on leave, two considered themselves not an expert in the field, 
two had no time, two refused because of a possible conflict of interest and 18 did not 
respond. Forty-two experts agreed to collaborate in our Delphi study. 
Round 1
The response rate was 93% (39 out of 42). The respondents had a mean age of 53 years 
(range 35-59 years), and a mean working experience of 19 years (range 4-41 years). 
In addition, they originated from the Netherlands (n=19), Argentina (n=1), Australia 
(n=2), Brazil (n=1), Czech Republic (n=1), Germany (n=2), Israel (n=1), Italy (n=1), 
Northern Ireland (n=1), Norway (n=1), Slovenia (n=1), Sweden (n=2), and the 
USA (n=5). Of one expert the nationality was unknown. Different specialties were 
represented: family medicine, nursing care, geriatrics, elderly care, cardiology, oncology, 
pulmonology, anesthesiology, neurology, psychiatry, pharmacy, pharmacology and 
109
Better drug use in advanced disease
Box: Definitions of concepts used in the questionnaires
Medication management: patient-centered care to optimize safe, effective and 
appropriate use of prescription and over-the-counter drugs
Medication review: an assessment of the pharmacotherapy based on a structural and 
critical evaluation of the medical, pharmaceutical and clinical information
End of life: the last 3 months of life
Patient and/or family: indicating the family especially when the patient is not mentally 
competent.
Palliative care specialist: physician or nurse specialist/practitioner with a formal training 
in palliative care medicine or equivalent expertise due to clinical experience. (Added in 
Round 2)
8
palliative medicine. Moreover, ethicists, researchers and medical advisors participated. 
The mean level of agreement for 58 statements was 87.7% (median 89.7%, range 62-
100%, SD 9.2, IQR 10.3). “No answer” was selected by a mean of 5.9% (range 0-20.5%). 
Suggestions were given by 51.3% of the experts, ranging from new statements, general 
comments or experiences, to adjustment of solutions or the vocabulary.
Because the degree of agreement was much higher than expected, we adjusted 
the cut-off value for selection of statements for the second round to the mean 
agreement found in this first round. Thirty-one solutions exceeded this new cut-
off point (87.7%). For seven of these statements the wording was slightly adapted 
based on suggestions of the participants. Based on the comments in the first round 
a definition of palliative care specialist was added in the second questionnaire (see 
Box). Twenty-seven solutions were deleted in the second questionnaire and twelve 
additional solutions were presented.
Round 2
The response rate in the second round was 74% (29 experts). One participant was on 
leave, one withdrew consent and eight experts did not respond. Only two out of 43 
solutions were not included in the ranking by any of the experts. The scores calculated 
for the different solutions ranged from 5 to 133 (mean 36.8, median 28). The solutions 
with a score above the average are presented in Table 8.1. The experts graded solutions 
concerning roles, awareness, education and communication as most important. 
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8Experts indicated that the physicians should primarily discuss the end of life 
and wishes, treatment goals and priorities regarding medication management at the 
end of life with the patient. Awareness is considered crucial: medication management 
should be an integral part of end-of-life care and be performed duly. Participants 
Table 8.1 Top 15 solutions based on their ranking score (and their category)
Solution Score
1 Physicians should discuss the wishes, treatment goals and priorities regarding medication 
management at the end of life with the patient in a timely manner. (Roles)
133
2 A medication review should be an integral part of the care for patients at the end of life. 
(Awareness)
130
3 Physicians should discuss the end of life with the patient in a timely manner. (Roles) 90
4 Medication management at the end of life should be individualized, based on the patient's 
clinical situation. (Awareness - Newly added in round 1)
89
5 Health care professionals should be trained in communicating with patients and/or their 
family about decision-making on medication management at the end of life. (Education)
74
6 Education in medication management at the end of life should be incorporated in all medical 
training (nursing school, medical students, residencies and fellowships). (Education - Newly 
added in round 1)
71
7 It should be discussed with the patient and/or family that the goal of medication 
management at the end of life is improving/maintaining the quality of life. (Communication)
70
8 Education in medication management at the end of life should be organized for health care 
professionals. (Education)
61
9 Health care professionals should be trained in the pharmacological treatment of symptoms at 
the end of life. (Education)
60
10 Palliative care specialists should be available for consultation regarding medication 
management for patients at the end of life. (Awareness)
56
11 A list of drugs with a high risk of inappropriateness at the end of life should be developed. 
(Research)
54
12 In communicating about medication management at the end of life nurses and 
physicians should take into account the norms and values of the patient and/or family. 
(Communication)
52
13 It should be discussed with the patient and/or family how the medication can be adjusted at 
the end of life and what can be expected of these changes. (Communication)
37
14 Patient or proxy based assessment tools (e.g. ESAS, EORTC, symptom diary, PPS, PPI) 
should be used to aid symptom assessment and treatment at the end of life. (Tools)
36
14 At the end of life each drug should be revised for its potential congruence with the clinical 
aims of the specific situation in a specific patient. (Research - Newly added in round 1)
36
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8agree that this should be an individualized process, based on the patient's clinical 
situation. Moreover, they agreed that palliative care specialists should be available for 
consultation. 
Specific domains that should be addressed in the education of health care 
professionals were mentioned. Physicians should be trained in communication with 
patients and their family about medication management at the end of life. Further, 
education in pharmacological treatment of symptoms at the end of life was considered 
necessary. Accordingly, education in medication management at the end of life should 
be part of health care professionals training, in residencies, fellowships, medical 
schools and in nursing schools. Besides, such education should also become available 
for health care professionals. The main concern regarding communication was that it 
should include conversations about the goals of end-of-life care in relation to quality 
of life. 
Twenty-seven out of 29 experts selected one or more of the 27 solutions which 
were initially rejected in the first round. Solutions considered crucial for guidelines 
about medication management by more than one third of the experts are presented 
in Table 8.2. Participants most frequently prioritized solutions regarding research 
Table 8.2 First round solutions selected by more than one third of experts not to be rejected
Solution Score
1 In current treatment guidelines (e.g. for hypertension, heart failure, diabetes etc.) 
recommendations for medication management at the end of life should be incorporated. 
(Research)
20
2 A list of drugs that could be tapered off or discontinued at the end of life under certain 
conditions should be developed (e.g. anticoagulant, antihypertensive, blood glucose 
lowering, antibiotic, antipsychotic, antidepressant or anticonvulsive drugs). (Research)
17
3 Physicians lacking experience with medication management at the end of life should consult 
a palliative care specialist. (Awareness)
16
4 Marking of the end of life should be part of education for health care professionals. 
(Education)
12
The primary treating physician should formulate an end-of-life care plan with the patient 
and/or family. (Roles)
12
The general practitioner is the primary treating physician when the patient resides at home. 
(Roles)
12
5 The primary treating physician is responsible for recording the medication management at 
the end of life. (Roles)
10
Nurses should contribute to medication management at the end of life by providing 
information, explanation and advice to the patient and/or family. (Roles)
10
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8and development, awareness, education and roles. Specific suggestions for research 
and development included incorporation of recommendations for medication 
management at the end of life in disease-specific clinical practice guidelines and 
development of a list of medications that could be tapered or discontinued at the end of 
life. Regarding awareness, the experts stressed that physicians lacking experience with 
medication management at the end of life should consult a palliative care specialist. 
Explicit identification of the last phase of life was added as a focus for education for 
health care professionals. They stated that the primary treating physician is responsible 
for recording the medication management and for formulating an end-of-life care plan 
with the patient. For patients residing at home the general practitioner is considered to 
be the primary treating physician. Nurses should have a supportive role by providing 
information, explanation and advice to the patient and relatives. 
Discussion
This Delphi study shows that experts in palliative care and medication management 
from different professions in thirteen countries agree on the most important issues 
concerning medication management at the end of life. Key solutions indicated by the 
experts concern the central role of the physician in medication management, necessity 
of awareness on medication management at the end of life, the need for education on 
medication management for health care workers and trainees, and the importance of 
timely communication with the patient in the process of medication management. 
Physicians’ awareness of medication management
This Delphi study makes clear that according to experts the physician has a central role 
in medication management at the end of life. Two highly-ranked solutions indicate that 
it is up to the physicians to discuss the medication and do this evaluation with patients 
in a timely manner. The urge for attention on a medication review and discussion with 
the patient is in line with several studies indicating the high prevalence of potentially 
inappropriate medications (PIMs) used by patients at the end of life.(2, 15) Physicians 
do affirm that patients at the end of life use too many medications and that they should 
not use PIMs (16), but apparently discontinuation of PIMs is still not standard practice. 
As Anderson et al. discuss in their study, awareness on PIMs refers to the level of 
insight a prescriber has into the appropriateness of his/her prescribing. They found 
that poor insight was an observed rather than reported barrier and that prescriber 
beliefs at a population level did not necessarily translate to prescribing practices for the 
individual patient.(17) Similar findings came forward in an interview study on views 
of patients, relatives, nurses and physicians on medication management at the end of 
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8life.(6) Although all involved parties agreed that PIMs should be discontinued and 
that in this process physicians should take the lead, a medication review was generally 
not a matter of course. These findings, altogether with the five recommendations of 
the experts of this Delphi study regarding education, urgently call for education on 
medication management in end-of-life care.
Timely communication
Multiple factors are described in literature as deprescribing barriers explaining the 
discrepancy between the ideal situation and practice, like lack of time, established 
beliefs in the benefits and harms of medication use, unknown consequences of 
withdrawing medications and avoidance of negative consequences.(6, 18) Even more 
importantly, physicians need to recognize a limited life expectancy of their patient and 
initiate end-of-life conversations as a prerequisite for decision-making conversations.
(19) Hancock et al. describe that many health care professionals express discomfort 
at having to broach the topic of a limited prognosis, and may withhold information 
or not disclose prognosis. These difficulties perceived by healthcare professionals in 
regard of speaking to patients with limited life expectancy may act as a barrier toward 
discontinuing medication.(2) Conforming to these barriers in communication, ex-
perts in our Delphi study stress the importance of communication with patients and/
or their family about decision-making on medication management at the end of life 
and the need for training of health care professionals specifically in communication 
concerning this topic.
Implications
Before starting the MEDILAST project, no guidelines for medication management 
in end-of-life care were available. Many tools and guidelines are available to manage 
medication for the aged, for example the Beers criteria,(20) (21) STOPP and START 
criteria (22) and the Medication Appropriateness Index (MAI).(23) Meanwhile, the 
OncPal deprescribing guideline (24) and Screening Tool of Older Persons Prescriptions 
in Frail adults with limited life expectancy (STOPPfrail) (25) were published. Lindsay 
et al. developed the OncPal deprescribing guideline to assist in the de-escalation of 
specific medications or medication classes (like aspirin, dyslipidemia medications 
and antihypertensives) in patients with advanced cancer.(24) Lavan and colleagues 
published the STOPPfrail, a list of 27 criteria determined in a Delphi consensus 
survey. The criteria relate to medications that are potentially inappropriate in frail 
older patients with limited life expectancy and may assist physicians in deprescribing 
medications in these patients.(25) Our Delphi study indicates that translation of 
these tools into practice as a deprescribing guideline will also need to address the 
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8other steps of the deprescribing process, like communication about treatment goals, 
planning medication withdrawal (tapering if required), monitoring, and follow-up 
after cessation. 
Experts in our study gave specific suggestions for research and development. 
Whereas a substantial part of medications in end-of-life care are prescribed for comorbid 
diseases,(14) there is an urge for reflection on how to manage those medications at 
the end of life and to address this issue in treatment guidelines. Pharmacological 
guidelines rarely give any recommendations for discontinuation. Experts in our study 
suggested research investigating discontinuation or tapering off medications at the 
end of life under certain conditions, for example in chronic conditions like diabetes 
and cardiovascular disease. Koekkoek et al. give a good example of how to deal with 
oral anticonvulsants in the end of life of patients with glioma who develop swallowing 
difficulties.(26) Although this applies to a very specific patient group, their suggestions 
could be extrapolated to other populations.
Strengths and limitations
A strength of our study is the systematic and rigorous approach adopted in this Delphi 
procedure (27) and the inclusion of views of experts from all over the world and 
coming from primary care, hospital and hospice care. The response was satisfactory, 
namely 93% in the first Delphi round and 74% for the second round.
There were some limitations. First, since half of the consulted experts were 
Dutch, solutions may have been biased towards those relevant for the health care 
system in the Netherlands. However, in both rounds of the Delphi study there 
appeared to be a high degree of consensus among all experts. Although experts of 
different professions participated and the average length of working experience (19 
years) suggests that our panel represents a broad and experienced group, it is not 
possible to determine if the panel is representative of the population of palliative care 
and medication management experts. 
Secondly, a pre-Delphi survey or focus group might have contributed to prepare 
the first survey of our Delphi study to address the study aim. Finally, the consensus 
for the first round was predefined as 75% agreement, a cut-off common according 
to acknowledged Delphi guidelines.(28) The high degree of consensus in our study 
(87.7%) drove us to redefine the cut-off point. The exact limit could be a matter of 
discussion.
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Letter to the editor to the article ‘Safety and benefit of discontinuing statin 
therapy in the setting of advanced, life-limiting illness: a randomized clinical 
trial’ JAMA Intern Med. 2015;175:1724-5
Eric C.T. Geijteman, Henning Tiemeier, Teun van Gelder
Selecting the optimal design 
for drug discontinuation trials 
in a setting of advanced, life-
limiting illness
9To the Editor 
We read with great interest the article by Kutner et al.(1) The authors showed that 
discontinuing statins in patients with a limited life expectancy is safe and may lead 
to improved quality of life. The accompanied editorial(2) states that the statin trial 
provides a starting point for deprescribing trials in frail patients with advanced illness. 
We argue that the design of the statin trial(1) (a conventional block randomized 
controlled trial) is not the most suitable design and should not be the norm for future 
deprescribing trials. First, the high refusal rate of eligible patients limits generalizability 
of the study’s results. Second, the design can impact the validity of the results because 
of contamination among patients in the control group. Due to the consent procedure, 
these patients might think their drug is not worth taking anymore. Subsequently, 
their compliance with drug therapy may be reduced. Third, asking patients with a 
limited life expectancy whether they are prepared to discontinue a drug can lead to 
feelings of depression and abandonment.(3) This is particularly true if physicians do 
not sufficiently take such feelings into account,(3) as may be the case during study 
enrollment. As a consequence, the trial may harm eligible patients. 
In 1979, a design was proposed(4) in which randomization takes place before 
consent to participate: the postrandomized consent design, or Zelen’s design. There 
are 2 variants of this design: the single consent and double consent methods. In the 
single consent method, only patients allocated to the experimental group are asked 
whether they consent to their treatment. Control treatment consists of best standard 
care. In the double consent method patients allocated to the control group are also 
asked to consent, and if they decline, they may cross over to the other treatment.(5) 
Zelen’s design typically results in a more representative patient sample.(5) However, 
due to lack of patient consent, the design has been much discussed and contended. 
Not asking consent is usually viewed as unethical, but some argue that under certain 
circumstances, that we feel are met here, Zelen’s design has been brought forward as 
an ethical option.(5) Several studies in past decades undertaken in the United States, 
the Netherlands, and other Western countries applied this design.(5) We propose 
the Zelen’s design as the alternative in future deprescribing trials to improve patient 
participation, validity, and generalizability of results.   
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Eric C.T. Geijteman 
Denying the inevitability of 
death
10
My father was 61 when he died. He was diagnosed in the mid-1990s with heart 
failure due to hereditary hypertrophic cardiomyopathy. Over the last years, he had 
to be admitted several times for atrial fibrillation and dyspnea due to fluid retention. 
Cardioversion and intravenous treatment with diuretics made his condition more 
bearable, after which he always returned home. But subsequent severe dyspnea and 
tiredness led to re-admission.  
This admission was different from all earlier admissions. This time medication 
failed to relieve his dyspnea. He felt exhausted and had no appetite. In addition, he had 
fever caused by pneumonia and antibiotics were prescribed. While the daily worsening 
of his condition had me and my mother worried, his treating physicians were rather 
positive as his laboratory results were improving. They told my father that he should 
have confidence in the outcome. The possibility of further deterioration was not 
mentioned. So, my father remained hopeful and continued to fight against his physical 
decline. He panted for breath, struggled to slurp his nourishing foods and to take his 
pills. Yet my father’s condition continued to deteriorate.   
It was day 20 of his admission – my father’s respiratory rate had gone up to 
30 breaths per minute and he was receiving high-flow oxygen therapy – when he 
underwent various diagnostic tests, including a transabdominal ultrasound and 
laboratory tests. These diagnostics were done in a vain attempt to identify the cause of 
his persistent fever and dyspnea.
The night that followed my mother – a nurse in a nursing home – decided on 
her own to stay with him. During the night his dyspnea worsened and he became 
restless. After several hours of struggle, my father’s condition declined even further. 
The cardiac monitor detected ventricular fibrillation and alerted the night nurses. 
When two of them rushed into the room to start resuscitation, my brave mother told 
them not to. She based this tough decision not only on the severe condition of my 
father, but also on several discussions she and my father had had on this topic. My 
father died several minutes later in my mother’s arms. 
Unfortunately, my father’s story is not an isolated case. Too many patients die 
an undignified death, especially in hospitals.(1) There is no question that a bad dying 
process has negative consequences on patients themselves. They may suffer from pain 
and other symptoms and they may not have time to prepare for the end of life.(2) But 
a bad death also has negative consequences on patients’ relatives, who may find it 
more difficult to cope with their bereavement.(2) It is not without reason that Dame 
Cicely Saunders, the founding mother of modern hospice care, said that ‘how people 
die remains in the memory of those who live on’. When I think of my father’s final days, 
I picture him suffering from pain and dyspnea. I will never forget the terrible scene of 
him having to hold his breath during the abdominal ultrasound in order to get a good 
picture of his intra-abdominal organs, at a time when he was already enormously short 
of breath. 
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Although the definition of a good death mainly reflects the personal values of 
the patient, many of us agree on common factors. For example, a good death involves 
attending pain and other suffering, and the patient being aware of impending death 
and able to direct his or her treatment.(2) For me personally, as a resident in internal 
medicine with an interest in end-of-life care, my father’s death made me aware of two 
important reasons why all too many patients still die an undignified death. 
The first is a failure to recognize that a patient is dying or to delay such 
recognition. In patients who die of chronic diseases such as heart failure, cancer or 
COPD, death is usually preceded by a period of imminent dying, and it is this period 
just days before the patient’s actual death that physicians might be aware of.(1) 
Research has shown that the number of undesirable interventions is significantly lower 
in patients whose impending death is recognized than in patients in whom the dying 
phase is not recognized.(3) Recognizing dying is, however, a highly challenging task 
for physicians as there is no single symptom pathognomonic for dying.(2) As a result, 
the diagnosis of dying is often made at a stage very close to death, when a patient is 
already comatose. Another possible reason why doctors do not diagnose dying is that 
death is still seen as a failure, as the culture of medicine is focused on cure and life 
prolongation.(1) Paradoxically, this may well mean that the imminence of inevitable 
death results in an increase in medical efforts to prevent death. 
About six months after my father died, I spoke to the likeable cardiologist who 
treated my father during the last four days of his life. He acknowledged that when he 
saw my father for the first time, he was already aware of his presumably impending 
death. While that awareness grew as death approached, he did not inform us and did 
not adapt my father’s treatment as he was not 100% sure of the diagnosis because he 
knew of cases where patients in similar conditions had survived such critical moments. 
This reasoning corresponds with reports in the literature.(2) Indeed, a devastating 
condition may return to near-baseline after treatment, especially in patients with heart 
failure.(1) However, if a physician estimates that a patient is about to die, very often 
that patient will indeed die. Since the diagnosis of dying has crucial implications, dying 
must be placed high on the differential diagnosis list if a patient’s condition worsens 
despite optimal therapy. 
Which brings me to the second reason why patients die an undignified death: 
in terms of informing patients and their relatives of the possibility of impending 
death, communication by physicians is inadequate. Although diagnosing dying is very 
difficult, it is still essential that in the gray zone, in which a patient may be dying, the 
possibility of dying is discussed with patients and their relatives. This can be done by 
applying the ‘hope for the best, and prepare for the worst’ strategy,(4) that originates 
from oncology setting. Such strategy leaves also room for patients to exchange their 
views on appropriate end-of-life care with caregivers. Patients, in general, do not talk 
about their end-of-life preferences with their physicians until physicians broach this 
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theme.(5) Studies have shown that communication about imminent death and about 
end-of-life care goals not only improves quality of life but also reduces non-beneficial 
medical care.(5, 6) Such communication also increases the chances of upholding the 
principles of a good death.(6) During his final days, my father told us that while he 
really wanted to fight his illness and live a longer life, he was no longer capable of 
doing so because of his severe dyspnea and fatigue. If at the time he had been informed 
about the probability of dying, I think – however strange that sounds – he would have 
been relieved. He may then have been able to resign himself to impending death and 
to find peace. As a result, the last days of his life, aided by sufficient symptom control 
and avoidance of futile interventions, would likely have been far more satisfactory and 
have given us enough time to say our goodbyes. 
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This thesis is aimed at providing more insight into the practice of withholding and 
withdrawing medical interventions in the last phase of life. The first part of the thesis 
focused on current end-of-life practices. In part two, we explored the perspectives of 
patients, their relatives and physicians regarding potentially inappropriate medications 
in the last phase of life. In the third part, possible solutions for improvement of medical 
care at the end of life are described. In the current chapter, the main findings of the 
different studies will be summarized and discussed. In addition, recommendations for 
clinical practice and directions for further research are presented. 
Part I Current practice
Do-not-resuscitate decisions
Do-not-resuscitate (DNR) decisions can be made when the likelihood of a successful 
resuscitation is limited.(1) A DNR decision is an anticipatory decision to withhold a 
medical treatment. Since the introduction of the DNR code in the 1970s, the frequency 
of DNR decisions has increased.(2) Ideally, patients are involved in a DNR decision in 
order to respect patients’ autonomy.(2) When a physician decides that resuscitation 
would be medically useless, patients and their relatives should be informed that this 
decision has been taken.(3) In chapter 2, we assessed trends in the frequency of 
individual DNR decisions and the extent of patient involvement in such decisions over 
the past two decades. Based on subsequent nationwide Dutch questionnaire studies 
on end-of-life decision making practices in 1990, 2001, and 2010,(4) we found that the 
frequency of individual DNR decisions among non-sudden deaths rose from 46% in 
1990 to 81% in 2010. The proportion of DNR decisions that were made with patient 
involvement increased from 23% (1990) to 45% (2001), to 55% (2010). In most of 
the cases in which the DNR decision was made without involving the patient this 
decision was made by the attending physicians in consultation with relatives. In 1990, 
of all cases in which DNR decisions were made without patient involvement, half of 
the patients were incompetent to make end-of-life decisions; this increased to 72% in 
2010. The main causes of incompetency were that the patient was in a state of reduced 
consciousness or was unconscious, or that the patient had dementia.
Our findings were in line with other, smaller studies in which patient involvement 
varied from 25% to 82%.(5) In most of the cases in which a DNR decision was made 
without involvement of the patient, the patient was incompetent.(5) This indicates 
that DNR decisions are often made late in the illness trajectory.(6) It is important 
that physicians talk timely with patients about their preferences for and expectations 
about care at the end of life. Patients, in general, tend not to talk about their end-of-life 
preferences until physicians broach this theme.(7) With the increasing frequency of 
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DNR decisions, it may be expected that the percentage of successful cardiopulmonary 
resuscitations will increase as only patients with good chances of success will be 
resuscitated.(2) Unfortunately, exact percentages of successful resuscitations in the 
Netherlands and their trend in the last decades are lacking. A study in the United States 
has shown that the percentage of successful in-hospital resuscitations increased between 
2000 (13.7%) and 2009 (22.4%),(8) after decades of stagnating success percentages. In 
this period the technique of cardiopulmonary resuscitation remained the same, but the 
awareness of making DNR decisions increased. The increased rate of DNR decisions 
may very well have led to an increase of the percentages of successful resuscitations. 
Medication discontinuation
Another type of treatment that should be reconsidered in the last phase of life is the 
use of medication.(9-13) In this phase, treatment objectives and organ functions may 
change. Several studies have shown that many potentially inappropriate medications 
are continued until the very end of life.(9, 14-18) To investigate whether the number 
and type of (potentially) appropriate and inappropriate medications in patients with 
a limited life expectancy depend on the place where end-of-life care is provided, we 
did a retrospective chart review study that is described in chapter 3. This study was 
part of the MEDILAST study. MEDILAST was a multicenter mixed methods research 
project with the aim of understanding current medication use in the last phase of life. 
This project was carried out by VU University Medical Center, Erasmus University 
Medical Center, and Radboud University Medical Center in the Netherlands and 
lasted from February 2013 until December 2015. In our retrospective chart review 
study we found that the mean number of medications used per patient was nine at 
day 7 before death and six on the day of dying. The number of medications aimed 
at symptom relief increased in the final week, whereas the number of preventive 
medications and medications to treat chronic diseases slightly decreased. However, 
in all three settings, some patients used preventive medications, including long-term 
preventive medications, until the day of dying. Fewer patients dying in the hospice 
used preventive medications than patients dying in the home setting or in the hospital. 
Moreover, in the hospice setting patients used more medications for symptom relief. 
During the past years, many other retrospective chart review studies were done. 
All studies have shown high percentages of patients using potentially inappropriate 
medication in the last months of life.(19-26) Recently, different systematic reviews 
were published regarding the use of preventive medications in patients with a limited 
life expectancy.(27-29) These studies confirmed the results of our chart review study.
Fueled by awareness that in the last phase of life medications to prevent or 
treat chronic diseases need to be reconsidered, I had, as a resident during my round 
on an inpatient ward, a discussion with a patient who was diagnosed with metastatic 
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pancreatic cancer. She also had a history of type 2 diabetes mellitus. This patient 
is described in chapter 4. The case shows that the discussion on optimization of 
medication may induce a broader discussion on the patient’s values and wishes in the 
last phase of life. It also illustrates that physicians need to consider both the physical 
and psychosocial effects of withdrawing treatment.(30) A reflection on this process is 
described in part II of the thesis. 
Care in the dying phase 
If the imminence of death in incurably ill patients is recognized, it is important 
that care is adapted. In the dying phase, care aimed at modifying the course of the 
underlying disease – which can be undignified and distressing – is ideally no longer 
given.(31, 32) In chapter 5 we describe a study in which we investigated how many 
and which diagnostic and therapeutic interventions were applied by physicians in 
patients with cancer in a hospital in the last 72 hours of life. In addition, we studied 
whether awareness of impending death of the attending physician is associated with the 
application of interventions. We found that in the last 72 and 24 hours of life, 59% and 
24% of the patients, respectively, received one or more diagnostic interventions. The 
interventions that were most often applied were blood tests and radiological procedures. 
Furthermore, in the last 72 hours and 24 hours of life, 47% and 31% of the patients 
received one or more therapeutic interventions, respectively, mostly intravenous 
hydration and enteral tube feeding. On average, patients used 7.2 types of medication 
in the last 72 hours of life, and 5.8 in the last 24 hours of life. Patients of whom the 
physician had been aware of impending death received less diagnostic interventions. 
In addition, fewer medications were used by patients of whom the physician had been 
aware of their impending death in the last 24 hours of life. However, in both groups 
patients were still using preventive medications during the last days of life. 
Our study shows that many patients with cancer who die in hospital receive 
interventions in the last days of life. Some of these interventions are aimed at 
prolonging life. Most interventions are potentially burdensome. The results were in 
line with an earlier study on interventions in the last days of life.(33) The number of 
medications used in the last days of life was comparable with the number we found in 
our retrospective chart review study that is described in chapter 3. One of the proposed 
strategies to decrease the number of potentially burdensome interventions in the last 
days of life is to increase physicians’ awareness of impending death.(34-36) Indeed, our 
study highlights that physicians’ awareness of patients’ impending death was associated 
with reduced use of diagnostic interventions and life-prolonging medications. It was 
striking, however, that even patients of whom the attending physician was aware of 
their impending death still received interventions that have doubtful benefits in the 
last days of life. 
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Part II Perspectives on medication management in the last 
phase of life
The perspectives of patients, their relatives and physicians regarding the use of 
potentially inappropriate medications in the last phase of life are largely unknown. 
In addition, barriers and considerations which contribute to continued use of these 
medications have not been identified. We therefore performed an interview study that is 
described in chapter 6. We interviewed 17 patients with an estimated life expectancy of 
less than three months, 12 relatives, 20 clinical specialists, and 12 general practitioners, 
who cared for these patients. Physicians mentioned several reasons for not considering 
withdrawal of potentially inappropriate medications: limited awareness, low priority, 
and uncertainty about the consequences. Patients and their relatives stated that they 
were willing to discontinue inappropriate medications. In their communication with 
patients about discontinuation of inappropriate medications, physicians tend to focus 
on the inappropriateness of continuing medications, instead of on the appropriateness 
of discontinuing.
In another interview study, it was found that physicians prefer to wait with 
the discontinuation of medication until patients have accepted their limited life 
expectancy.(37) Physicians are afraid to give patients the impression that they are 
being abandoned.(38) Our study, however, suggests that patients and their relatives 
are open to discuss discontinuation of medications. This is in line with a questionnaire 
study in individuals with multiple chronic morbidities, that showed that more than 
90% of the participants were willing to discontinue medications.(39) In addition, in a 
study on discontinuation of statins in patients with a life expectancy of less than a year, 
it was shown that less than 10% of the patients expressed concerns that deprescribing 
potentially inappropriate medications could suggest that the physician abandons 
them, or that the physician thought they were going to die.(40) Another study also 
showed that the large majority of patients with advanced cancer do not object to the 
discontinuation of unnecessary medications.(41) 
In chapter 7 we describe a questionnaire study to assess physicians’ opinions on 
and experiences with discontinuation of medication during the last phase of life, and 
identified factors influencing the continuation of potentially inappropriate medications 
at the end of a patient’s life. The questionnaire consisted of a vignette about a patient 
with multimorbidity, and several statements about medication discontinuation for 
patients in the last phase of life. This study was conducted among general practitioners 
and clinical specialists in geriatrics, cardiology, pulmonology, medical oncology, and 
neurology. The response rate of the questionnaire study was 37% (total n=321). For 
the vignette, the majority of physicians preferred to stop preventive medications. For 
medications to treat chronic diseases, respondents’ preferences varied widely: some 
physicians would continue such medications, others would discontinue them. Only a 
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small minority of respondents recognized potential drivers of continuing potentially 
inappropriate medications in the last phase of life as derived from medical literature on 
this topic, e.g. the unknown consequences of withdrawing medication and physicians’ 
expectation that patients may feel abandoned if medications are discontinued.
Our results were in line with retrospective chart review studies, that physicians 
tend to continue potentially inappropriate medication in the last phase of life. Especially 
for medications to treat chronic diseases, e.g. diabetes mellitus and hypertension, 
more scientific evidence about the consequences of continuing or discontinuing 
is needed. It was striking that only few respondents recognized potential drivers of 
continuing inappropriate medications in the last phase of life. It might be possible 
that lack of awareness of considering withdrawal of medications is an important cause 
of continuing potentially inappropriate medications in clinical practice, which is 
consistent with the interview study results (chapter 6).
Part III Solutions
To further improve care at the end of life, part III of this thesis describes solutions that 
may improve care at the end of life. In chapter 8 recommendations for improvement 
of medication management in the last phase of life are presented, based on an 
international Delphi study. A Delphi study is a structured process aimed at achieving 
consensus among experts on a particular topic.(42) In our two round Delphi study, we 
used a questionnaire with 58 possible solutions to optimize medication management 
at the end of life. A total of 42 experts from 13 countries participated. In the first 
round, agreement between experts for all solutions was very high (mean 87% (range 
62-100%)). Key solutions indicated by the experts in the second round concerned the 
central role of the physician in medication management, the necessity of improving 
physicians awareness of the importance of adequate medication management at 
the end of life, the need for education on medication management for health care 
professionals, and the importance of open and honest communication with the patient 
and/or family. A suggestion for research included development of a list of medications 
that could be tapered or discontinued at the end of life. 
So far only one randomized controlled study on discontinuing medication in 
patients with a limited life expectancy has been published.(43) This study evaluated the 
safety of discontinuing statins for patients without recent cardiovascular events and an 
estimated life expectancy between one month and one year. The results demonstrated 
that statins can be safely stopped in this patient population and discontinuation was 
even associated with improved quality of life. Chapter 9 contains a letter in which 
we criticize the method that was used in this study. This method was a so-called 
conventional block randomized clinical trial (RCT). In such a design, full informed 
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consent of patients to participate is needed prior to randomization. As a result, 
participants in the control group and their physicians are aware of the intervention 
being studied. This may be problematic in deprescription trials, where contamination, 
i.e. participants in the control arm adopting the intervention, is likely to occur. 
The main message of our letter is that to prevent suboptimal research outcomes in 
deprescription trials, researchers should use appropriate study designs. We stated that 
Zelen’s design may be a promising design for future deprescription trials. In Zelen’s 
design, patients’ informed consent to participate is sought after randomization. 
Participants in the control group are not informed about the intervention and, as a 
result, the risk of contamination is substantially reduced. 
Chapter 10 contains a personal account of my father’s final days of life. This 
story provides important reasons why too many patients die an undignified death: 
failure to recognize that a patient is dying and inadequate communication with 
the patient and their relatives about the possibility that death may come soon. My 
father's story also underscores that medical interventions were continuously offered, 
which created the false hope that he had a long time to live. These interventions were 
proposed without any discussion of their pros and cons. In the case of my father, it 
concerned interventions that would normally have few negative effects, such as an 
abdominal ultrasound. However, due to his very poor condition, they still had a major 
influence on his well-being. Rather than simply providing medical interventions to 
patients with a limited life expectancy, physicians should discuss their pros and cons, 
with patients and their families. 
Overall discussion
Part I of this thesis shows that patients with a limited life expectancy are exposed to 
potentially futile and even harmful medical interventions. This specifically concerns 
medical interventions that were originally used for other indications in other patient 
groups. Over the course of time, the use of some medical interventions has expanded 
without evidence on their added value. An example is cardiopulmonary resuscitation. 
After its introduction in the 1960s, cardiopulmonary resuscitation was reserved to 
otherwise healthy individuals who experienced a cardiopulmonary arrest,(44, 45) as a 
result of, among others, acute myocardial infarction, anesthetic accident, surgery, and 
untoward effects of drugs.(44) Soon it became common practice to resuscitate every 
patient with a cardiac arrest, also those with a poor health condition. As a result, the 
outcomes of resuscitation are unsuccessful in most cases,(46-53) especially in patients 
with irreversible serious medical conditions.(52, 54) 
As for medication that is prescribed for other indications and to other patient 
groups than those originally investigated in pharmaceutical studies, their value for 
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patients with a limited life expectancy is often unclear. Given the negative effects that 
medical interventions might have and the positive consequences of the optimisation 
of the medical policy (chapter 4) for patients with a limited life expectancy, physicians 
should reconsider whether or not medical interventions should be used or may be 
discontinued in these patients. Considerations pertaining to the use or withdrawal 
of medical interventions should be discussed well in advance. A specific form of 
such early communication is advance care planning (ACP).(55) ACP is a process of 
communication between the patient and their health care professionals in which the 
patient’s end-of-life goals and values are discussed.(56) This communication process 
may help determine the appropriate care in the short term and provides directions 
for appropriate care in future scenarios. ACP should not be established in a single 
conversation between health care professionals and patients and their relatives, but in 
a continuing process of communication.(55, 57) It has been found that ACP improves 
quality of end-of-life care and of patient-physician communication.(58, 59) The best 
moment to start a discussion about ACP may be the occurrence of milestones in a 
patient’s disease trajectory, such as (repeated) hospital admission, or progression of 
disease.(60) 
An advance decision about resuscitation is an example of ACP. There has been 
some outcry in recent years with regard to resuscitation decisions, especially in the 
hospital setting. In the Netherlands and according to current practice, it is required to 
individually agree on a policy for potential resuscitation whenever a patient is admitted 
to hospital. Some experts suggest that it is undesirable to discuss this issue with each 
and every admitted patient.(61) They regard it as a serious, incommensurate and, 
therefore, disproportionate breach of privacy, as a patient’s resuscitation preferences 
may not be important for their current treatment.(61, 62) In addition, the resuscitation 
question may cause significant distress to patients as they might get the idea that they 
have a poor prognosis or a limited life expectancy.(63) The discussion of resuscitation 
policy is only relevant and appropriate for patients with a significant risk of respiratory 
and cardiac failure.(61, 62) This policy would be in line with resuscitation policies in 
other countries, for example United Kingdom.(3) The proposal to discuss resuscitation 
decisions solely with people with a risk of respiratory and cardiac failure may have 
the disadvantage that physicians usually overestimate life expectancy and focus on 
curing disease and postponing death.(35, 64) It may thus have the consequence that 
resuscitation decisions, particularly the decision not to resuscitate, will be taken at an 
even later stage than at present (chapter 2), or not at all. 
A plausible reason for the use of potentially inappropriate medical interventions 
until shortly before death, shown in chapter 5, may be that health care professionals persist 
in their daily routine of work.(33, 65) In order to avoid this persistence and to optimise 
symptom management for patients in the dying phase, health care professionals may use 
the Care Programme for the Dying (CPD), a Dutch instrument for multidisciplinary 
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care for patients in the dying phase that was originally based on the Liverpool Care 
Pathway for the dying patient (LCP).(66-68) This care pathway is controversial in the 
United Kingdom due to its misuse outside palliative care settings.(69) In the Netherlands 
and other countries, however, derivates of the LCP (such as the CPD) have been proven 
to have some positive effects on end-of-life care.(70, 71) As a result, the care programme 
has been implemented in multiple healthcare institutions.(72)
The results in part II of this thesis underline that limited awareness among physicians 
seems to be an important factor to explain why many patients use one or more 
potentially inappropriate medications in the last months before their expected death. 
The results of chapter 6 highlight that physicians insufficiently contemplate the 
discontinuation of medications at the end of life. Such awareness should obviously 
be enhanced, not only through (continuous) education of physicians, but also by 
specifically including discontinuation of medications in guidelines and protocols. 
This would make physicians ask themselves the standard question as to whether a 
specific medication should be discontinued in order to optimize care and ideally also 
discuss this with the patient. Our interview study (chapter 6) revealed that physicians 
are afraid that such discussions might give patients the idea that the physician has 
‘given up’ on them and has 'thrown in the towel'. To decrease the likelihood of patients 
worrying about being abandoned it may be important to emphasize the positive aspects 
of stopping potentially inappropriate medications. We therefore suggest that when a 
physician considers deprescribing medications, the advantages of discontinuation – 
e.g. to reduce the risk of adverse effects and the burden of taking pills –, rather than 
the uselessness of continuation should be at the forefront of communication. This 
‘positive’ communication style might also be applied when discussing forgoing other 
types of treatment at the end of life, such as cardiopulmonary resuscitation. Positive 
communication is also promoted in other medical fields.(73) A study among children 
with acute respiratory tract infections highlighted that providing well-founded positive 
reasons to refrain from medications may result in increased patient/parent satisfaction 
with the received care.(74) 
Low priority and uncertainty about the consequences were other important 
causes of not considering withdrawal of potentially inappropriate medications that 
were found in our interview study. Uncertainty seems the most important factor 
to explain why physicians greatly vary in their deprescription of medication, as the 
findings in chapter 7 showed. This especially holds for deprescription of medication 
for the treatment of chronic diseases, such as anticoagulants and blood glucose 
lowering medications, for which discontinuation may have a direct negative impact on 
the patient’s underlying disease. Until now, there is hardly any guidance to support the 
physician in their deprescription policies. Recently, two guidelines were published to 
manage discontinuation of medication in patients with a limited life expectancy. The 
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first is the OncPal deprescribing guideline. This guideline was developed and validated 
to assist in discontinuation of inappropriate medications in patients with advanced 
cancer.(75) The second is the Screening Tool of Older Persons Prescriptions in Frail 
adults with a limited life expectancy (STOPPfrail). This tool contains 27 criteria for 
medications that are potentially inappropriate in frail older patients with a limited 
life expectancy. The criteria were developed in a Delphi consensus process.(76) The 
effects and safety of the OncPal deprescribing guideline and the STOPPfrail have not 
been evaluated yet. In addition to these guidelines, an expert-opinion based guideline 
is available that provides explicit guidance for patients with diabetes mellitus who are 
in the final phase of life.(77) This guideline states, among others, that if a patient’s 
life expectancy is only weeks to months, metformin can be discontinued, as it barely 
reduces glucose levels and is especially aimed at preventing long-term complications. 
More of this guidance is needed to optimise the use of medication for patients with a 
limited life expectancy. 
The results in Part III of this thesis reveal that there is a great need of research into the 
consequences of deprescribing medication at the end of life, but that there are some 
important methodological hurdles to be taken. Research among patients in the final 
stage of life has its difficulties, since it is a very vulnerable patient population. Studying 
the consequences of stopping statins in patients with a life expectancy of less than a year 
has been a landmark, the potential beginning of a ‘new wave of research’.(78) However, 
deprescribing studies require research methods that limit the risk of contamination, 
i.e. participants in the control arm adopting the intervention. In chapter 9, we 
suggest to use Zelen’s design in future research, in which patients’ informed consent 
is asked after randomisation rather than in advance.(79) Since only the patients in 
the experimental group are fully informed about the study, Zelen’s design has been 
criticised. The cohort multiple RCT design may be another appropriate design.(80) 
The basis of a cohort multiple RCT design is an observational cohort of patients in 
whom outcome measures are regularly assessed. Within this observational cohort, 
patients eligible for an intervention are randomized. Patients who are randomized to 
receive the intervention are informed about the intervention, which they can accept or 
refuse. Patients not randomized to the intervention arm will receive usual care. This 
process can be repeated for randomized evaluation of other interventions within the 
cohort. In case of a cluster cohort multiple RCT, where the unit of randomization is e.g. 
a care institution, both patients in the control group and their physicians would not be 
aware of the trial intervention, which would prevent contamination. 
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Methodological considerations
The methods used in this thesis have some limitations. First, the limited response rates 
for the questionnaire studies. The response rate for the questionnaire study that is 
described in chapter 7 remained low at 37%, despite intensive reminder procedures. 
When asked for the reasons why physicians did not complete the questionnaire, they 
mentioned their lack of time or that the topic had a low priority in the midst of many 
requests to fill in questionnaires. The response rate for the PalTeC-H questionnaire 
study that is described in chapter 5 was 45%. Currently, a questionnaire study among 
physicians hardly ever achieves a response rate of 70% or higher.(81) This percentage 
is often seen as the limit above which it is assumed that the results are generalizable.
(82) Any result below this percentage increases the chance of non-response bias. In our 
questionnaire studies it might be possible that especially physicians with affinity for 
end-of-life care participated in the studies. In recent years, researchers have searched 
for strategies to increase response rates. None of the interventions they examined, such 
as reducing the number of questions,(83) or digitising the questionnaire,(84) had a 
significant impact. The only intervention that seems to increase the response rate is a 
financial compensation.(81, 85) Second, in our interview study described in chapter 
6, selection bias cannot be ruled out, because we interviewed patients who knew that 
they were going to die soon and were prepared to participate. Third, the questionnaire 
studies and interview study might be influenced by so-called social desirability bias, 
i.e. that respondents have answered questions based on their views of what is socially 
most acceptable. Fourth, recall bias may have influenced data from the PalTeC-H 
questionnaire study, described in chapter 5, because physicians were asked to fill in 
the questionnaire after the patients’ death. Because the questionnaires were distributed 
within one week after the patient’s death, this form of bias may be limited.  
Recommendations for clinical practice
Awareness  
Physicians should acknowledge that every patient with an incurable disease will die at 
some time during the progression of their disease. Death usually comes earlier than 
physicians expect.(64, 86) Physicians often seem to persist in the provision of care 
that is focused on modifying the course of the underlying disease.(33, 65) As a result, 
end-of-life care too often involves overuse of medical interventions,(33, 87-89) which 
is a barrier to patient's experience of a good death.(90) As long as death is mostly 
seen as a medical failure,(31) the care provided to dying patients will remain below 
par. Physicians must be more aware that interventions aimed at life-prolongation are 
not in a patient’s best interest in all cases. Providing less or no interventions aimed at 
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prolonging life may be the better option. This requires physicians to openly discuss 
thoughts and feelings of hope with the patient, but also the pros and cons of therapies 
– instead of suggesting the next intervention on the list. Patients nowadays sometimes 
have to convince their treating physician that not choosing for treatment aimed at 
prolonging life might be a better choice.(94, 95) It is important that physicians 
move away from ‘we did everything we could’ to prevent dying, towards striving at 
‘we avoided doing too much’ to fight an inevitable death. Various initiatives to raise 
physicians’ awareness came to fruition in recent years.(91-93) In 2013, the Royal 
Dutch Medical Association (KNMG) published a report to promote the provision of 
appropriate end-of-life care in the Netherlands.(91) Such awareness should also be 
included in medical curricula. 
On the other hand, physicians may also be put under pressure by patients 
and their relatives to start or continue futile medical treatments in the last phase of 
life. Patients and their relatives sometimes have unrealistic expectations about the 
effectiveness of medical interventions.(94) For example, many patients have been 
shown to believe that more than 60% of patients will survive in-hospital resuscitation, 
which is three times higher than the actual rate.(95) After receiving information about 
realistic survival rates, some patients wanted to change their code status into a do-
not-resuscitate code.(95) Another important reason for demanding futile treatment in 
the last phase of life is patients’ hope for cure and life prolongation.(96) Although it is 
stated that maintaining hope is important for patients in the last phase of life,(97, 98) 
this does not mean that physicians should not reveal the truth to their patients as other 
forms of hope, e.g. hope to be free of pain, may replace unrealistic hopes.(96)  
Decision-making and communication 
The ultimate treatment decision is the responsibility of the attending physician and 
should be based on the medical utility of the treatment and the patient’s values, goals, 
and beliefs.(99) Physicians are never obligated to provide interventions which are 
seen as medically futile.(54, 100) The model of medical decision making in which the 
physicians unilaterally determine what treatment is given, is called the paternalistic 
medical model. This model was common in the 1950s. Nowadays, shared decision 
making is a widely supported model.(101) In this model, the physician and the patient 
together decide about medical treatment and care. The shared decision making model 
especially applies to so-called preference sensitive decisions, in which there is no single 
best choice but, rather, different options with different (side) effects.(102) Temel’s 
landmark study among patients with metastatic non-small cell lung cancer showed 
that patients who are actively involved in the decision making as to whether or not to 
start certain treatments, were not as inclined to opt for aggressive treatments as control 
patients.(103) This result may underline the abovementioned suggestion: if patients are 
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informed adequately about the pros and cons of different treatment options in light of 
their life expectancy, they may choose for less aggressive treatment. It was striking that 
not only this group's quality of life but also their survival outshone those of the control 
group. A Dutch questionnaire study among patients and relatives showed that when 
care in the last phase of life is seen as inappropriate this is most commonly associated 
with overtreatment.(104) However, this study also showed that continuing (potentially) 
life-prolonging treatment may be seen as appropriate care by both patient and relatives 
in case treatment led to severe side effects and not to prolongation of life.(104)
Some critics state that health care has gone overboard in putting the patient’s 
role in medical decision making at the centre.(105, 106) They argue that not all 
patients may be able to adequately make medical choices, as they e.g. might be too 
ill to do so. It has been found that the majority of patients overestimate the benefits 
of medical interventions and underestimate the harms.(95, 107) Another reason 
for criticising the shared decision making model is that it may make patients with a 
limited life expectancy and their relatives feel that they have to make a choice between 
life and death, or that they opt for a premature death when they refuse life-prolonging 
treatment.(108)
In the last decade, the so-called model of libertarian paternalism has been 
introduced.(109) In this model, the treating physician acts as a choice architect, by 
encouraging the patient to choose for the option that would be in their best interest 
as judged by the physician while still allowing the patient the freedom to choose 
otherwise. In other words, the physician sets a default option, without removing any 
options.(110) This way of exerting influence on choices is also referred to as ‘nudging’, 
since the person choosing is directed towards a (rational) choice.(111) Libertarian 
paternalism allows freedom of choice, but limits the aforementioned disadvantages of 
shared decision making. 
In both the shared decision making and the libertarian paternalism model, it is 
important to discuss medical decisions at an early stage, as this considerably increases 
the chance of patients’ input in the decision making process and enables patients to 
cope with the consequences of potential decisions. 
Recommendations for future research
In order to provide patients with good information about the pros and cons of 
treatments in the last phase of life, it is important to know the consequences 
of their continuation and discontinuation. The available data about in-hospital 
cardiopulmonary resuscitations are almost all American. Information about 
Dutch practices is still lacking. It is therefore promising that a Dutch study into the 
consequences of in-hospital resuscitation has recently started (the ‘Resuscitation 
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outcomes in the Netherlands’ (ROUTiNE) study). This study will look into the one-
year survival rate, quality of life and functional status of patients who were resuscitated 
in hospital.(112) Further, there is hardly any information on the experiences and 
thoughts of patients and their relatives about discussing resuscitation upon admission 
to the hospital. The limited literature shows that the question mainly comes across to 
patients as a choice between life and death.(108, 113-115) More research into patients' 
and relatives’ experiences and thoughts is needed. 
An important cause of the continuation of potentially inappropriate 
medications in the last phase of life is the lack of insight into the potential consequences 
of their discontinuation. More research on deprescribing medications, aimed at the 
prevention or treatment of diseases that are irrelevant in the light of patients’ limited 
life expectancy, is needed.(116) Results from such studies should feed into guidelines 
that support physicians and patients in the optimisation of the use of medication in 
the final stage of life.
In our study into medical interventions in the last few days before death 
(chapter 5), we found that the dying phase had been recognised more than 24 hours in 
advance in approximately 50% of the cases. More research is needed to further unravel 
the process of dying, to enable physicians to better recognise nearing death and to 
adjust care accordingly. 
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Het doel van dit proefschrift was om meer inzicht te krijgen in de praktijk van het 
niet-starten en het stoppen van medische interventies in de laatste fase van het 
leven. Het eerste deel van het proefschrift richtte zich op de huidige praktijk van 
beslissingen rond het levenseinde. Voor deel twee van het proefschrift hebben we de 
perspectieven van patiënten, hun naasten en artsen onderzocht op het gebruik van 
potentieel overbodige medicatie in de laatste fase van het leven. In het derde deel zijn 
mogelijke oplossingen om de medische zorg aan het einde van het leven te verbeteren 
beschreven. In dit hoofdstuk zullen de belangrijkste bevindingen van de onderzoeken 
worden samengevat en bediscussieerd. Verder worden adviezen voor de dagelijkse 
praktijk en suggesties voor toekomstig onderzoek gepresenteerd.
Deel I Huidige praktijk
Niet-reanimeerbeslissingen
Niet-reanimeer(NR)-beslissingen kunnen worden genomen wanneer de kans op een 
succesvolle reanimatie nihil is. Een NR-beslissing is een zogenaamde anticiperende 
beslissing om een medische behandeling niet in te zetten. Vanaf de introductie van 
de NR-code in de jaren 70 is het aantal NR-beslissingen toegenomen. Patiënten 
worden idealiter bij de NR-beslissing betrokken, waarmee patiëntautonomie wordt 
gewaarborgd. Als de behandelende arts besluit dat reanimeren op medische gronden 
zinloos is, moet de patiënt en zijn/haar naasten van deze beslissing op de hoogte 
worden gebracht.
Voor hoofdstuk 2 onderzochten wij de frequentie van individuele NR-
beslissingen en de mate van patiëntbetrokkenheid bij deze beslissingen in de 
afgelopen twintig jaar. Hiervoor maakten wij gebruik van het sterfgevallenonderzoek. 
Op basis van dit grootschalige vragenlijstonderzoek naar de praktijk van medische 
besluitvorming rond het levenseinde in Nederland vonden wij dat de frequentie 
van individuele NR-beslissingen bij patiënten die een niet-plotseling overlijden 
waren gestorven, was gestegen van 46% in 1990, naar 81% in 2010. Het percentage 
NR-beslissingen waarbij de patiënt betrokken was, steeg van 23% (1990) naar 45% 
(2001) en daarna naar 55% (2010). In de meeste gevallen waarin de NR-beslissing was 
gemaakt zonder betrokkenheid van de patiënt, werd deze beslissing genomen door 
de behandelende arts samen met de naasten. In alle gevallen in 1990 waarin er een 
NR-beslissing was gemaakt zonder patiëntbetrokkenheid, was 50% van deze patiënten 
incompetent voor het maken van beslissingen rond het levenseinde. Dit percentage 
steeg naar 72% in 2010. De belangrijkste redenen voor incompetentie waren dat de 
patiënt een verminderd bewustzijn had of buiten bewustzijn was, of dat de patiënt 
dementerend was.
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Onze resultaten waren in overeenstemming met andere, kleinere onderzoeken, 
waarin de patiëntbetrokkenheid varieerde van 25 tot 82% en waarin ook de meeste 
patiënten incompetent bleken op het moment dat de NR-beslissing was gemaakt. Deze 
uitkomsten wijzen erop dat de NR-beslissing pas laat in het ziektetraject wordt gemaakt. 
Het is belangrijk dat artsen tijdig met patiënten praten over hun voorkeuren voor en 
verwachtingen over de zorg rond het levenseinde. Patiënten geven hun voorkeuren 
voor de zorg rond het levenseinde over het algemeen niet aan tot de behandelende 
arts een dergelijk gesprek aansnijdt. Met de toename van NR-beslissingen kan worden 
voorspeld dat het percentage succesvolle reanimaties zal stijgen omdat alleen patiënten 
met een hoge succeskans zullen worden gereanimeerd. Het is echter niet bekend wat 
het percentage succesvolle reanimaties in Nederland is en wat dit percentage in de 
afgelopen decennia is geweest. Een Amerikaans onderzoek heeft aangetoond dat het 
percentage succesvolle reanimaties in ziekenhuizen is gestegen van 13,7% in 2000 
naar 22,4% in 2009, nadat het percentage in de decennia ervoor gelijk was gebleven. 
Omdat de reanimatietechniek in de periode 2000-2009 niet was gewijzigd, maar het 
bewustzijn om NR-beslissingen te nemen wel was toegenomen, zou de stijging van 
het percentage succesvolle reanimaties het gevolg kunnen zijn van een toename in 
NR-beslissingen.
Stoppen van medicijnen
Een andere medische interventie die in de laatste fase van het leven heroverwogen moet 
worden, is medicatiegebruik. Gedurende de laatste maanden en weken van het leven 
veranderen de behandeldoelen en lichaamsfuncties, waardoor medicijnen mogelijk niet 
meer zinvol zijn. In de praktijk vindt heroverweging van medicatiegebruik in de laatste 
fase van het leven onvoldoende plaats. In hoofdstuk 3 onderzochten we of het aantal en 
het type medicijnen dat patiënten in de laatste fase van het leven gebruiken afhankelijk zijn 
van de plaats waar patiënten hun zorg krijgen. Hiervoor verrichtten we een retrospectief 
dossieronderzoek van de laatste levensweek van 179 patiënten die een verwacht 
overlijden stierven, van wie een derde was opgenomen in het ziekenhuis, een derde thuis 
zorg kreeg en een derde in een hospice verbleef. Dit retrospectieve dossieronderzoek 
maakte onderdeel uit van het MEDILAST-onderzoek: een multicentrisch, ‘mixed 
methods’-onderzoeksproject dat als doel had om tot een beschrijving van de huidige 
praktijk te komen en om aanbevelingen te formuleren om het medicijngebruik in 
de laatste fase van het leven te optimaliseren. Het onderzoek werd uitgevoerd in een 
samenwerkingsverband tussen het VU medisch centrum, Radboudumc en Erasmus MC 
en werd verricht in de periode februari 2013-december 2015.
Uit het retrospectieve dossieronderzoek bleek dat patiënten gemiddeld 
negen medicijnen per dag gebruiken in de laatste week van het leven. Op de dag van 
overlijden gebruiken patiënten gemiddeld zes medicijnen. Gebruik van medicatie die 
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gericht is op verlichting van de symptoomlast nam in de laatste week van het leven 
toe, terwijl medicatie gericht op de preventie en behandeling van ziekten enigszins 
afnam. Het gebruik van symptoombestrijders was het grootst in het hospice. In alle 
drie de zorgsettings gebruikte een aantal patiënten een of meerdere medicijnen gericht 
op preventie tot aan overlijden, met name patiënten die thuis of in het ziekenhuis 
verbleven. Sommige van deze medicijnen hebben hun werking echter pas vele jaren 
na inname.
In de laatste jaren zijn er vele andere retrospectieve dossieronderzoeken verricht 
naar het gebruik van medicijnen in de laatste fase van het leven. Al deze onderzoeken 
hebben aangetoond dat veel patiënten potentieel overbodige medicijnen gebruiken 
in de laatste maanden van hun leven. Recentelijk zijn er verschillende systematische 
reviews verschenen naar het gebruik van preventieve medicijnen bij patiënten met 
een beperkte levensverwachting. Deze reviews onderstrepen de conclusie van 
ons dossieronderzoek, namelijk dat veel patiënten in de laatste fase van het leven 
preventieve medicijnen gebruiken.
Aangewakkerd door het bewustzijn van heroverweging van medicijnen die zijn 
gericht op de preventie en behandeling van ziekten, had ik als arts-assistent op de 
verpleegafdeling een gesprek met een patiënt met gemetastaseerd pancreascarcinoom. 
Zij was enkele jaren eerder gediagnosticeerd met diabetes mellitus type 2. Deze 
patiëntcasus is beschreven in hoofdstuk 4. De casus laat zien dat met het optimaliseren 
van het medicijngebruik er een gesprek kan ontstaan over de waarden, voorkeuren en 
behoeften van de patiënt in diens laatste fase van het leven. De casus laat ook zien dat 
dokters rekening moeten houden met de psychische en psychosociale effecten van het 
aanpassen en het stoppen van de behandeling.
Zorg in de stervensfase
Als het naderend overlijden onomkeerbaar is, is het belangrijk dat de zorg wordt 
aangepast. In deze stervensfase dient zorg die is gericht op curatie en levensverlenging 
– die ellendig en onwaardig kan zijn – idealiter niet ingezet te worden. In hoofdstuk 5 
wordt een onderzoek beschreven waarin wij nagingen hoeveel en welke diagnostische 
en therapeutische interventies worden ingezet in het ziekenhuis bij patiënten met 
kanker in de laatste 72 uur van hun leven. Daarnaast onderzochten we of herkenning 
van de stervensfase door de behandelende arts van invloed is op de inzet van deze 
interventies.
We vonden dat in de laatste 72 uur 59% en in de laatste 24 uur van het leven 24% 
van de patiënten een of meer diagnostische interventies onderging. De interventies 
die het meest werden ingezet, waren bloedafname en radiologische onderzoeken. 
Therapeutische interventies werden bij 47% (in de laatste 72 uur), respectievelijk 31% 
(in de laatste 24 uur) van de patiënten toegepast. Dit betrof in de meeste gevallen 
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intraveneuze vochttoediening en sondevoeding. Gemiddeld kregen patiënten in de 
laatste 72 uur van het leven 7,2 verschillende medicijnen; op de dag van overlijden 
waren dit gemiddeld 5,8 medicijnen. Het bleek dat herkenning van de stervensfase 
tot gevolg had dat patiënten minder diagnostische interventies ondergingen. Ook 
gebruikten patiënten bij wie de stervensfase was herkend minder medicijnen in de 
laatste 24 uur voorafgaand aan het overlijden. Zowel patiënten bij wie de stervensfase 
was herkend als patiënten bij wie deze fase niet was herkend, gebruikten op de dag van 
overlijden preventieve medicijnen.
Ons onderzoek laat zien dat bij veel patiënten met kanker die in het ziekenhuis 
overlijden medische interventies worden ingezet in de laatste dagen van hun leven. Een 
aantal van deze interventies heeft als doel levensverlenging. De meeste interventies 
zijn potentieel schadelijk. Onze resultaten zijn in overeenstemming met die van eerder 
onderzoek naar de inzet van medische interventies in de laatste dagen van het leven. 
Het aantal medicijnen dat in de laatste dagen werd voorgeschreven, is vergelijkbaar 
met het aantal medicijnen dat patiënten uit het retrospectieve dossieronderzoek, 
beschreven in hoofdstuk 3, gebruikten.
Een van de voorgestelde opties om het aantal potentieel schadelijke medische 
interventies te verminderen is het vergroten van de herkenning van de stervensfase 
door artsen. Ons onderzoek laat inderdaad zien dat herkenning van de stervensfase 
leidt tot minder gebruik van diagnostische interventies en van medicijnen die gericht 
zijn op preventie en behandeling van ziekten. Het was wel opvallend dat ook bij 
patiënten van wie de behandelende arts de stervensfase had herkend, interventies 
werden ingezet waarvan de meerwaarde zeer twijfelachtig is in de laatste dagen van 
het leven.
Deel II Perspectieven op het stoppen van medicijnen
De perspectieven van patiënten, hun naasten en artsen op het gebruik van potentieel 
overbodige medicijnen in de laatste fase van het leven zijn vrijwel onbekend. Ook 
is het niet duidelijk wat de belemmeringen en overwegingen zijn die bijdragen 
aan het continueren van deze medicijnen. Om dit te analyseren hebben we een 
interviewonderzoek verricht, dat is beschreven in hoofdstuk 6. We namen diepte-
interviews af bij 17 patiënten met een geschatte levensverwachting van minder dan 3 
maanden en bij 12 van hun naasten. Ook interviewden we 20 medisch specialisten en 
12 huisartsen die aan de geïnterviewde patiënten zorg verleenden.
Artsen gaven verschillende redenen voor waarom patiënten in de praktijk 
meestal niet stoppen met potentieel overbodige medicijnen: de mogelijkheid van 
stoppen wordt niet overwogen, stoppen heeft geen prioriteit en de gevolgen van stoppen 
zijn vaak onzeker. Patiënten en hun naasten gaven aan dat zij in principe openstaan 
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voor het stoppen van potentieel overbodige medicijnen. Ook kwam naar voren dat 
als artsen de mogelijkheid van stoppen van medicijnen bespreken met patiënten, zij 
vooral de nadruk leggen op de medische zinloosheid van het continueren, in plaats 
van op de zinvolheid van het stoppen.
Uit een eerder gepubliceerd onderzoek kwam naar voren dat artsen het 
liefst wachten met het stoppen van medicijnen totdat patiënten hun beperkte 
levensverwachting hebben geaccepteerd. Artsen zijn bezorgd om patiënten de indruk te 
wekken dat zij in de steek gelaten worden. Ons onderzoek laat echter zien dat patiënten 
en hun naasten openstaan voor het stoppen van medicijnen. Dit komt overeen met de 
resultaten van een vragenlijstonderzoek onder patiënten met multimorbiditeit, waaruit 
bleek dat vrijwel alle patiënten (> 90%) bereid zijn om medicijnen te stoppen. Een 
onderzoek naar het stoppen van statines bij patiënten met een levensverwachting van 
minder dan een jaar maakte daarnaast duidelijk dat minder dan 10% van de patiënten 
door het stoppen van potentieel overbodige medicijnen gevoelens van ‘in de steek 
gelaten te worden’ of ‘dat het naderend einde in zicht is’ ervaart. Een ander onderzoek 
liet ook zien dat de overgrote meerderheid van de patiënten met gevorderde kanker 
openstaat voor het stoppen van overbodige medicijnen.
In hoofdstuk 7 beschrijven we de uitkomsten van een vragenlijstonderzoek dat 
als doel had om de opvattingen over en ervaringen met het stoppen van medicijngebruik 
in de laatste fase van het leven van artsen te achterhalen. Het vragenlijstonderzoek had 
daarnaast als doel om factoren te identificeren die van invloed zijn op het continueren 
van het gebruik van potentieel overbodige medicijnen aan het einde van het leven. 
De vragenlijst bestond uit een vignet over een patiënt met multimorbiditeit en uit 
verschillende stellingen over het stoppen van medicijnen bij patiënten met een 
beperkte levensverwachting. We stuurden de vragenlijst naar een aselecte steekproef 
van 500 huisartsen en 500 medisch specialisten (geriaters, cardiologen, longartsen, 
internisten-oncologen en neurologen). In totaal respondeerden 321 artsen. Omdat 
ruim 100 van de in totaal 1000 aangeschreven artsen niet (meer) werkzaam waren als 
zorgverlener of verhuisd waren en de vragenlijst dus niet hadden ontvangen, was het 
responspercentage 37%.
De meerderheid van de respondenten zou stoppen met het gebruik van 
preventieve middelen bij de patiënt beschreven in het vignet. De respondenten 
waren veel verdeelder over of en wanneer medicijnen gericht op het behandelen van 
chronische ziekten gestopt kunnen worden. Slechts een kleine minderheid van de 
respondenten herkende zich in de voorgestelde factoren die van invloed kunnen zijn 
op het continueren van medicijnen aan het einde van het leven. Voorbeelden van deze 
potentiele factoren waren: onduidelijke gevolgen van het stoppen van medicijnen en 
het gevoel hebben dat patiënten zich in de steek gelaten voelen als medicijnen worden 
gestopt.
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Onze resultaten kwamen overeen met die van de retrospectieve 
dossieronderzoeken, waaruit bleek dat artsen over het algemeen het gebruik van 
potentieel overbodige medicijnen continueren in de laatste fase van het leven. 
Toekomstig onderzoek naar de gevolgen van het stoppen van medicijnen is 
noodzakelijk, met name van medicijnen gericht op het behandelen van chronische 
ziekten, zoals diabetes mellitus en hypertensie. Het was opvallend dat slechts een klein 
percentage van de respondenten zich kon vinden in de voorgestelde factoren die van 
invloed kunnen zijn op het continueren van medicijnen. Het is hierdoor mogelijk dat 
een gebrek aan bewustzijn om medicijnen te stoppen een belangrijke oorzaak is van 
het continueren van medicijnen in de dagelijkse praktijk, zoals ook naar voren kwam 
uit het interviewonderzoek (hoofdstuk 6).
Deel III Oplossingen
In deel III zijn oplossingen beschreven die de zorg aan het einde van het leven kunnen 
helpen optimaliseren. In hoofdstuk 8 staan aanbevelingen voor het optimaliseren 
van het medicijngebruik aan het einde van het leven, naar aanleiding van een 
internationaal Delphi-onderzoek. Een Delphi-onderzoek is een gestructureerd proces 
dat als doel dient om consensus onder experts te bereiken op een specifiek thema. In 
ons Delphi-onderzoek, dat uit twee ronden bestond, maakten we gebruik van een lijst 
met 58 mogelijke oplossingen om het medicijngebruik aan het einde van het leven te 
optimaliseren. In totaal waren 42 experts, uit 13 verschillende landen, bereid om mee 
te doen aan het onderzoek.
In de eerste ronde was er een hoge mate van overeenstemming tussen de 
experts voor een groot deel van de voorgestelde oplossingen (gemiddelde: 87%; 
bereik: 62-100%). De belangrijkste oplossingen die in de tweede ronde door de 
experts werden aangegeven, betroffen de centrale rol die artsen moeten hebben in het 
medicijngebruik aan het einde van het leven, de noodzaak het bewustzijn onder artsen 
om het medicijngebruik te optimaliseren te vergroten, het belang van onderwijs in 
medicijngebruik aan zorgverleners en het belang van een open en eerlijk gesprek met 
de patiënt en familie. De experts stelden tevens voor om een lijst te ontwikkelen met 
medicijnen die afgebouwd of gestopt kunnen worden.
Tot op heden is er slechts één gerandomiseerd onderzoek verricht naar het 
stoppen van medicijnen bij patiënten met een beperkte levensverwachting. Hierin 
werd de veiligheid van het stoppen van statines onderzocht bij patiënten zonder 
recente cardiovasculaire gebeurtenis en met een levensverwachting tussen een maand 
en een jaar. Dit onderzoek toonde dat statines veilig gestopt kunnen worden bij deze 
patiëntcategorie. Het stoppen van het medicijn was zelfs geassocieerd met een betere 
kwaliteit van leven dan het continueren ervan.
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Hoofdstuk 9 bevat een ingezonden brief waarin we de onderzoeksmethode die 
was gebruikt in dit ‘stoponderzoek’ bekritiseren. Deze methode was een zogenoemd 
conventioneel blok-gerandomiseerd klinisch onderzoek. Bij dit type onderzoek 
dient voorafgaand aan de randomisatie ‘informed consent’ aan de patiënt gevraagd 
te worden. Dit heeft als gevolg dat zowel de patiënten in de controlegroep als hun 
behandelende artsen zich bewust zijn van de interventie die wordt onderzocht. Dit 
kan problematisch zijn bij zogenaamde ‘stoponderzoeken’, waarin contaminatie, dat 
wil zeggen dat deelnemers in de controlegroep de interventie overnemen, op de 
loer ligt. De belangrijkste boodschap van onze brief is dat onderzoekers de juiste 
onderzoeksmethoden moeten gebruiken om te voorkomen dat de uitkomsten van 
toekomstige ‘stoponderzoeken’ suboptimaal zijn. We stelden het ‘Zelen’s design’ voor 
als mogelijk alternatief. Met deze onderzoeksmethode wordt pas na randomisatie 
aan patiënten om informed consent gevraagd. Hierdoor worden de deelnemers in de 
controlegroep niet geïnformeerd over de interventie en is de kans op contaminatie 
veel kleiner.
Hoofdstuk 10 bevat een persoonlijk verhaal over de laatste dagen van het 
leven van mijn vader. In dit verhaal staan enkele redenen waardoor te veel mensen 
onwaardig sterven, namelijk: niet herkennen dat een patiënt stervende is en 
ontoereikende communicatie met de patiënt en diens naasten over de mogelijkheid 
van het naderend overlijden. Het verhaal over mijn vader onderstreept bovendien 
dat er voortdurend medische interventies werden aangeboden, waardoor valse hoop 
over zijn toekomstperspectieven werd gecreëerd. Bovendien werden deze interventies 
aangeboden zonder dat de voors en tegens van deze interventies werden besproken. 
Bij mijn vader betrof het interventies, zoals een echo abdomen, die normaal gesproken 
relatief weinig schadelijke effecten tot gevolg hebben. Door de zeer zwakke conditie 
van mijn vader hadden deze in andere situaties beperkte negatieve effecten echter 
grote invloed op zijn welzijn. In plaats van medische interventies bij patiënten met een 
beperkte levensverwachting aan te bieden, zouden veel vaker de voor- en nadelen van 
deze interventies besproken moeten worden. 
Algemene discussie 
De resultaten in deel 1 laten zien dat patiënten met een beperkte levensverwachting 
worden blootgesteld aan potentieel overbodige en zelfs schadelijke medische 
interventies. Dit betreffen veelal medische interventies die oorspronkelijk op de 
markt zijn gekomen voor heel andere indicaties en voor andere patiëntcategorieën. 
In de loop van de tijd is de indicatiestelling steeds verder verruimd, zonder dat hierbij 
de meerwaarde is bewezen. Een voorbeeld is reanimatie. Na de introductie van de 
reanimatietechniek in de jaren 60 was reanimeren voorbehouden aan voorheen 
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gezonde patiënten die een hartstilstand doormaakten als gevolg van bijvoorbeeld een 
acuut myocardinfarct, anesthesiologische complicaties, een operatie of een ernstige 
bijwerking van medicatie. Al snel werd de indicatiestelling verruimd en werd het 
gemeengoed om iedere patiënt met een hartstilstand te reanimeren, ook patiënten 
met zeer slechte gezondheidstoestand. Het is gebleken dat het percentage succesvolle 
reanimaties bij deze patiënten zeer laag is.
Ook medicijnen zijn in de loop van de tijd voorgeschreven voor hele andere 
indicaties en bij andere patiëntcategorieën dan oorspronkelijk zijn onderzocht. Wat de 
waarde van medicijnen is bij patiënten met een beperkte levensverwachting, is veelal 
niet bekend. Vanwege alle nadelige effecten die het gebruik van medische interventies 
met zich mee kan brengen en de positieve gevolgen van het optimaliseren van het 
medische beleid (hoofdstuk 4), zouden zorgverleners meer stil moeten staan bij de 
toepassing van medische interventies bij patiënten met een beperkte levensverwachting. 
De overwegingen om bepaalde interventies wel of niet in te zetten zouden tijdig met 
patiënten met een beperkte levensverwachting besproken moeten worden.
Een specifieke vorm van deze vroege communicatie is anticiperende 
besluitvorming (‘advance care planning’). Anticiperende besluitvorming kan worden 
gezien als een ontmoeting tussen de patiënt en diens behandelende arts rond de 
levensdoelen van die patiënt. Hierdoor kan worden vastgesteld wat passende zorg is 
voor de korte termijn en wordt richting gegeven aan passende zorg in toekomstige 
scenario’s. Anticiperende besluitvorming moet vooral niet worden gezien als één 
gesprek tussen zorgverleners en patiënten en hun naasten, maar als een continu proces 
van communicatie die veelal uit meerdere gesprekken bestaat. Het is gebleken dat 
anticiperende besluitvorming onder andere de kwaliteit van zorg aan het einde van 
het leven kan verbeteren. Het beste moment waarop een gesprek over anticiperende 
besluitvorming kan plaatsvinden is als er een mijlpaal in het beloop van het leven van 
de patiënt is, zoals tijdens of kort na een ziekenhuisopname of bij ziekteprogressie.
Een reanimeerbeslissing is een voorbeeld van anticiperende besluitvorming. In 
de afgelopen jaren is er enige ophef ontstaan over de reanimeerbeslissing, met name in 
de ziekenhuissetting. In de huidige praktijk is het noodzakelijk dat voor elke patiënt die 
in het ziekenhuis wordt opgenomen, een beleid is afgesproken met betrekking tot het 
wel of niet reanimeren van deze patiënt op het moment dat hier een indicatie voor is.
Sommige experts zijn van mening dat dit beleid niet met elke patiënt die 
wordt opgenomen afgesproken moet worden. Zij zien een gesprek over reanimatie als 
ingrijpend en iets wat veel inbreuk maakt op de privésfeer van de patiënt. Bovendien 
is de mening van de patiënt over reanimatie ook lang niet altijd van belang voor de 
betreffende ziekenhuisopname. Daarnaast kan een gesprek over reanimeren patiënten 
veel onrust geven omdat zij het idee kunnen krijgen dat zij nog maar zeer kort te leven 
hebben. Een reanimeerbeslissing zou alleen gemaakt moeten worden met patiënten die 
daadwerkelijk een risico lopen op respiratoir of cardiaal falen. Dit beleid zou hiermee 
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in overeenstemming zijn met het beleid dat in andere landen, zoals Engeland, geldt. 
Met het voorstel om een reanimeerbeslissing alleen te nemen bij mensen met een risico 
op respiratoir of cardiaal falen ligt er een belangrijk gevaar op de loer omdat artsen de 
levensverwachting overschatten en zij vooral gefocust zijn op het genezen van ziekten 
en het uitstellen van het overlijden. Dit kan ervoor zorgen dat reanimeerbeslissingen, 
in het bijzonder het besluit om niet te reanimeren, in een nog later stadium – of 
helemaal niet – zullen worden genomen dan nu het geval is (hoofdstuk 2).
Een aannemelijke reden voor de inzet van medische interventies tot vlak 
voor het overlijden die in hoofdstuk 5 is beschreven, is dat zorgverleners volharden 
in hun dagelijkse werkroutine. Om te voorkomen dat zorgverleners dit blijven doen 
en om de symptoombehandeling voor patiënten in de stervensfase te optimaliseren, 
kunnen zorgverleners gebruikmaken van het Zorgpad Stervensfase. Dit zorgpad, dat 
is gebaseerd op de ‘Liverpool Care Pathway’, geeft handvatten voor multidisciplinaire 
zorg aan patiënten in de stervensfase. Het betreft een kwaliteitsinstrument dat 
bijdraagt aan de kwaliteit van zorg aan stervende patiënten. Vanwege verkeerd gebruik 
is de ‘Liverpool Care Pathway’ in Engeland controversieel geworden. In Nederland, 
en in veel andere landen, is echter gebleken dat afgeleiden van de ‘Liverpool Care 
Pathway’, zoals het Zorgpad Stervensfase, meerwaarde laten zien voor de zorg aan 
stervenden. Daarom is het Zorgpad Stervensfase in veel zorginstellingen in Nederland 
geïmplementeerd.
De resultaten in deel II van het proefschrift laten zien dat een gebrek aan bewustzijn 
om medicijnen te stoppen een belangrijke oorzaak lijkt te zijn van het gebruik van 
potentieel overbodige medicijnen in de laatste fase van het leven. De resultaten in 
hoofdstuk 6 tonen dat artsen onvoldoende de mogelijkheid en – wellicht – de 
noodzakelijkheid van het stoppen van medicijnen overwegen. Deze bewustwording 
zou moeten worden vergroot door (na)scholing aan artsen, maar ook door specifieke 
aandacht te besteden aan het stoppen van medicijnen in richtlijnen en protocollen. 
Hierdoor zouden artsen zichzelf de standaardvraag moeten stellen of een bepaald 
medicijn, in overleg met de patiënt, gestopt kan worden, waardoor de zorg kan worden 
geoptimaliseerd.
Het interviewonderzoek (hoofdstuk 6) heeft duidelijk gemaakt dat artsen angst 
hebben dat het bespreken van stoppen van medicijnen patiënten het idee kan geven 
dat zij ‘opgegeven’ zijn en dat ‘de handdoek in de ring is gegooid’. Om te voorkomen 
dat patiënten deze gedachten krijgen is het van belang om juist de positieve kanten 
van het stoppen te benadrukken, zoals het verminderen van het risico op bijwerkingen 
en van de last van het innemen van medicijnen, in plaats van de negatieve kanten 
van het continueren. Deze ‘positieve’ communicatiestijl zou ook meerwaarde kunnen 
hebben bij het bespreken van het stoppen of niet-starten van andere behandelingen, 
zoals reanimatie. 
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Andere redenen om potentieel overbodige medicijnen niet te stoppen die 
uit ons interviewonderzoek naar voren kwamen, waren onvoldoende prioriteit en 
onduidelijkheid over de negatieve gevolgen van het stoppen. Onduidelijkheid over 
het stoppen lijkt de belangrijkste oorzaak te zijn waarom artsen onderling sterk 
verschillen in het stoppen van medicijnen aan het einde van het leven (zie hoofdstuk 
7). Dit geldt met name voor medicijnen gericht op het behandelen van chronische 
ziekten, zoals anticoagulantia en bloedglucoseverlagende medicijnen, waarbij stoppen 
directe negatieve gevolgen kan hebben voor patiënten.
Tot op heden zijn er nauwelijks ondersteunende middelen om artsen te 
ondersteunen bij het stoppen van medicijnen. Onlangs zijn twee richtlijnen ontwikkeld 
die gebruikt kunnen worden bij het stoppen van medicijnen bij patiënten met een 
beperkte levensverwachting. De eerste richtlijn is de ‘OncPal-stoprichtlijn’. Deze richtlijn 
is ontwikkeld en gevalideerd om artsen te ondersteunen bij het stoppen van medicijnen 
bij patiënten met gevorderde kanker. De tweede richtlijn is de ‘STOPPFrail’, die 27 
verschillende medicijnen bevat die potentieel overbodig zijn bij kwetsbare ouderen 
met een beperkte levensverwachting. Deze richtlijn is ontwikkeld in een Delphi-
onderzoek. De effecten en veiligheid van de ‘OncPal-stoprichtlijn’ en de ‘STOPPFrail’ 
zijn nog niet geëvalueerd. Naast deze twee richtlijnen is een richtlijn verschenen voor 
de zorg aan patiënten met diabetes mellitus en een beperkte levensverwachting. In deze 
richtlijn staat onder andere dat als de levensverwachting enkele weken tot maanden is 
metformine gestopt kan worden, omdat het de glucosespiegel nauwelijks verlaagt en 
met name bedoeld is om langetermijncomplicaties te voorkomen.
De resultaten in deel III tonen aan dat er grote behoefte is aan onderzoek om na te 
gaan wat de gevolgen zijn van het stoppen van medicijnen aan het einde van het 
leven, maar dat voor het verrichten van dergelijk onderzoek er nog wel belangrijke 
methodologische horden te nemen zijn. Onderzoek bij patiënten in de laatste fase van 
het leven wordt bemoeilijkt doordat er sprake is van een zeer kwetsbare patiëntpopulatie. 
Het onderzoek naar de gevolgen van het stoppen van statines bij patiënten met een 
levensverwachting van minder dan een jaar is een ‘landmark-onderzoek’ geweest, dat 
het begin is van meer ‘stoponderzoeken’. Deze ‘stoponderzoeken’ vragen echter om 
onderzoeksmethoden waarbij de kans op contaminatie wordt geminimaliseerd.
In hoofdstuk 9 deden wij de suggestie om bij toekomstig onderzoek gebruik 
te maken van het ‘Zelen’s design’, waarbij informed consent pas na randomisatie 
wordt gevraagd. Omdat alleen de patiënten in de experimentele groep om consent 
wordt gevraagd, is het ‘Zelen’s design’ bekritiseerd. Een andere onderzoeksopzet 
waarmee contaminatie kan worden voorkomen, is de ‘cohort multiple randomized 
controlled trial’. De basis van de ‘cohort multiple randomized controlled trial’ is 
een observationeel cohort van patiënten bij wie uitkomstmaten op vaste tijdstippen 
worden gemeten. Binnen dit cohort kunnen voor een interventie geschikte patiënten 
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worden geïdentificeerd. Patiënten die gerandomiseerd worden om de interventie te 
krijgen, worden geïnformeerd over deze interventie, die zij kunnen accepteren of 
weigeren. Patiënten die niet worden gerandomiseerd om de interventie te krijgen, 
zullen niet benaderd worden en de standaardbehandeling ondergaan. Dit proces kan 
voor meerdere interventies gelijktijdig herhaald worden. In het geval van een cluster 
‘cohort multiple randomized controlled trial’, waarin bijvoorbeeld zorginstellingen 
gerandomiseerd worden, zullen zowel patiënten in de controlegroep als hun 
behandelende artsen niet op de hoogte zijn van de interventie, waardoor de kans op 
contaminatie nog kleiner wordt.
Methodologische overwegingen
De onderzoeksmethoden die zijn gebruikt in dit proefschrift, hebben enige 
beperkingen. De eerste beperking betreft het matige responspercentage van de 
vragenlijstonderzoeken. Het responspercentage van het vragenlijstonderzoek 
beschreven in hoofdstuk 7 bleef steken op 37%, ondanks dat we zeer actief waren om 
‘non-responders’ te vragen de vragenlijst alsnog in te vullen. Een belangrijk argument 
waarom artsen de vragenlijst niet invulden was dat zij geen tijd en behoefte hadden om 
de lijst in te vullen, vooral omdat zij al zo vaak gevraagd worden om een vragenlijst in 
te vullen. Het responspercentage van de PalTec-H-vragenlijstonderzoek, beschreven 
in hoofdstuk 5, was 45%. Zelden haalt een grootschalig vragenlijstonderzoek onder 
artsen een responspercentage van 70% of hoger. Dit percentage wordt veelal gezien als 
de grens waarmee wordt verondersteld dat de onderzoeksresultaten generaliseerbaar 
zijn. Bij alle lagere percentages is de kans op ‘non-response bias’ vergroot. In onze 
vragenlijstonderzoeken was het mogelijk dat vooral artsen met affiniteit voor 
levenseindezorg de vragenlijst invulden en retourneerden.
In de afgelopen jaren is onderzocht op welke manier het responspercentage 
van vragenlijstonderzoeken onder artsen te verhogen is. Geen van de interventies, 
zoals het verkorten van de vragenlijst of het digitaliseren van de lijst, had echter grote 
invloed. Een interventie die er mogelijk wel voor zorgt dat de respons hoger wordt, is 
de respondent een geldbedrag te overhandigen.
De tweede beperking is dat we niet kunnen uitsluiten dat er in het 
interviewonderzoek, beschreven in hoofdstuk 6, sprake is geweest van selectiebias 
omdat de geïnterviewde patiënten wisten dat zij op korte termijn zouden komen te 
overlijden en zij bereid waren om geïnterviewd te worden.
Een derde beperking is dat de vragenlijstonderzoeken en het interviewonderzoek 
mogelijk beïnvloed zijn door zogenaamde ‘sociale wenselijkheidbias’, dat wil zeggen dat 
respondenten op specifieke vragen een sociaal wenselijk antwoord hebben gegeven.
Een vierde beperking is dat ‘recall bias’ mogelijk van invloed is geweest op 
de resultaten van het PalTec-H-vragenlijstonderzoek (hoofdstuk 5) omdat artsen na 
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het overlijden van de patiënt werd gevraagd om de vragenlijst in te vullen. Omdat 
de vragenlijst al binnen een week na het overlijden naar de behandelende arts werd 
gestuurd, is de kans dat er daadwerkelijk sprake was van ‘recall bias’ klein.
Aanbevelingen voor de praktijk
Bewustzijn
Er moet een algemeen besef bij artsen komen dat iedere patiënt met een niet te genezen 
ziekte op een zeker moment in het ziekteproces komt te overlijden. Het overlijden 
komt veelal veel eerder dan artsen verwachten. In de huidige zorgverlening neigen 
artsen ernaar zorg te geven die is gericht op genezing en levensverlenging. Dit heeft tot 
gevolg dat de zorg in de laatste fase van het leven gepaard gaat met overbehandeling. 
De focus op genezing en levensverlenging staat een goede dood van de patiënt in 
de weg. Zolang het overlijden wordt gezien als een medische fout, zal de zorg aan 
stervende patiënten ondermaats blijven.
Artsen moeten zich ook bewuster worden van het gegeven dat de inzet 
van medische interventies niet altijd in het belang is van patiënten. De inzet van 
minder of geen interventies die als doel genezing en levensverlenging hebben, is in 
specifieke situaties beter. Hiervoor is het van belang dat artsen openlijk met patiënten 
spreken over de voors en tegens van in te zetten medische interventies, in plaats van 
dat de volgende medische interventie die ingezet kán worden, voorgesteld wordt. 
Patiënten moeten tegenwoordig soms hun behandelende arts overtuigen dat niet 
kiezen voor levensverlengende behandeling de beste keuze is. Het is van belang dat 
artsen afstappen van het credo ‘we hebben er alles aan gedaan’ om het overlijden te 
voorkomen, en streven naar ‘we hebben voorkomen dat we te veel hebben gedaan’ om 
het onvermijdelijke overlijden te voorkomen.
In de afgelopen jaren zijn verschillende initiatieven ontplooid om het besef dat 
minder zorg soms betere zorg is onder artsen te vergroten. Zo is in 2013 een rapport 
verschenen van de artsenfederatie KNMG om te bereiken dat patiënten in de laatste 
fase van het leven passende zorg krijgen. Deze bewustwording moet ook meer in de 
medische curricula naar voren komen.
Het gebeurt ook dat patiënten en hun naasten eisen dat behandelingen 
ingezet of gecontinueerd worden die in de laatste fase van het leven als medisch 
zinloos worden gezien. Een belangrijke reden hiervoor is dat zij een onrealistische 
verwachting hebben over de effectiviteit van de betreffende medische interventie. Zo 
wordt het succespercentage van reanimaties in ziekenhuizen door patiënten geschat 
op iets meer dan 60%, een schatting die drie keer hoger ligt dan het daadwerkelijke 
percentage. Als patiënten informatie krijgen over het daadwerkelijke percentage 
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succesvolle reanimaties, willen sommige hun reanimeerbeleid wijzigen in een niet-
reanimeerbeleid.
Een andere belangrijke reden om behandelingen te eisen die als medisch 
zinloos worden gezien, is de blijvende hoop die patiënten hebben op genezing en 
levensverlenging. Hoewel wordt verondersteld dat het behouden van een vorm van 
hoop goed is voor patiënten in de laatste fase van hun leven, betekent dit niet dat 
artsen de waarheid niet moeten vertellen en bepaalde, medisch zinloze, behandelingen 
dienen in te zetten. Er zijn ook andere – realistischere – vormen van hoop, zoals de 
hoop om geen pijn te hebben en om goed afscheid te kunnen nemen.
Besluitvorming en communicatie
De uiteindelijke behandelbeslissing is de verantwoordelijkheid van de behandelende 
arts. Deze beslissing moet gebaseerd zijn op het medische nut van de interventie en 
de waarden en doelen van de patiënt. Artsen zijn nooit verplicht om interventies in te 
zetten die als medisch zinloos worden gezien. De vorm van medische besluitvorming 
waarbij de behandelende arts de behandelbeslissing bepaalt, wordt het paternalistische 
beslismodel genoemd. Dit beslismodel was in de jaren 50 gemeengoed.
Tegenwoordig is ‘shared decision-making’ (gezamenlijke besluitvorming) het 
basismodel van medische besluitvorming. Bij deze vorm van besluitvorming besluiten 
de patiënt en de behandelende arts samen over de medische behandeling. Gezamenlijke 
besluitvorming is met name van toepassing bij zogenaamde ‘preference-sensitive 
decisions’, wanneer er meer dan één behandeloptie is en het afwegen van voor- en 
nadelen dilemma’s kan geven. In een onderzoek bij patiënten met gemetastaseerd niet-
kleincellig longcarcinoom, werd aangetoond dat patiënten die actief betrokken waren 
in de medische besluitvorming minder vaak agressieve therapieën ondergingen dan 
patiënten die minder of niet actief waren betrokken. Dit laat zien dat als patiënten 
actief worden geïnformeerd over behandelopties zij minder vaak voor agressieve opties 
kiezen. Het was opvallend dat niet alleen de kwaliteit van leven van patiënten die actief 
betrokken waren in de besluitvorming toenam, maar ook de tijd tot overlijden.
Een Nederlands vragenlijstonderzoek onder patiënten en naasten toonde 
dat als de zorg in de laatste fase van het leven als ongepast wordt gezien, dit meestal 
geassocieerd is met overbehandeling. Hetzelfde vragenlijstonderzoek liet echter ook 
zien dat het continueren van een behandeling die (mogelijk) levensverlengend is door 
zowel patiënten als naasten als gepast wordt gezien als die behandeling leidt tot zeer 
veel bijwerkingen en uiteindelijk niet tot levensverlenging.
Critici hebben aangegeven dat de gezondheidszorg is doorgeslagen in het 
centraal stellen van de keuzevorming van de patiënt. Zij geven aan dat patiënten 
niet altijd in staat zijn keuzes te maken, bijvoorbeeld omdat zij op het moment van 
keuze te ziek zijn om een beslissing te nemen. Het is ook gebleken dat de meerderheid 
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van de patiënten de voordelen van medische interventies overschat en de nadelen 
ervan onderschat. Een ander punt van kritiek is dat patiënten met een beperkte 
levensverwachting en hun naasten het gevoel kunnen krijgen dat zij een keuze tussen 
leven en dood moeten maken, of dat zij kiezen voor een vroegtijdige dood als zij niet 
kiezen voor de levensverlengende behandeling.
In het laatste decennium is het libertair paternalisme geïntroduceerd. In dit 
beslismodel fungeert de behandelende arts als keuzearchitect, door de patiënt aan te 
sporen om voor de optie te kiezen die door het medische team als zinvolst wordt gezien, 
waarbij patiënten nog steeds vrij zijn om voor een andere behandeloptie te kiezen. Deze 
manier van keuzebeïnvloeding wordt ook wel ‘nudging’ genoemd, omdat de persoon 
die kiest in een (juiste) richting wordt geduwd. Met libertair paternalisme wordt 
keuzevrijheid behouden, maar worden de nadelen van gezamenlijke besluitvorming 
beperkt.
Onafhankelijk van het beslismodel dat wordt gebruikt, is het belangrijk dat 
medische beslissingen in een zo vroeg stadium worden bediscussieerd. Hiermee wordt 
de kans aanzienlijk vergroot dat patiënten mee kunnen denken met deze besluitvorming 
en in staat worden gesteld om te gaan met de gevolgen van de beslissing.
Aanbevelingen voor toekomstig onderzoek
Om goede voorlichting te kunnen geven aan patiënten over de voors en tegens van 
behandelingen in de laatste fase van het leven, is het van belang te weten wat de gevolgen 
zijn van het stoppen of continueren ervan. De beschikbare cijfers over reanimaties in 
het ziekenhuis komen vrijwel allemaal uit de VS; de Nederlandse situatie is tot op 
heden onbekend. Het is dan ook goed dat er recent een onderzoek is gestart naar de 
gevolgen van reanimatie in Nederlandse ziekenhuizen. Hierin wordt gekeken naar de 
1-jaarsoverleving, de kwaliteit van leven en de functionele status van patiënten die in 
het ziekenhuis worden gereanimeerd. Er is daarnaast vrijwel niets bekend over wat de 
ervaringen en gedachten van patiënten en hun naasten zijn over de reanimatievraag in 
het ziekenhuis. De beperkte literatuur laat zien dat patiënten deze vraag vooral zien als 
een keuze tussen leven en dood. Meer onderzoek naar de ervaringen en gedachten van 
patiënten en hun naasten is noodzakelijk.
Een belangrijke reden voor het continueren van potentieel overbodige 
medicijnen is dat nauwelijks bekend is wat de gevolgen zijn van het stoppen ervan. 
Het is noodzakelijk dat er meer onderzoek wordt verricht naar de gevolgen van het 
stoppen van medicijnen in de laatste fase van het leven die zijn gericht op de preventie 
en behandeling van ziekten. Resultaten van deze onderzoeken kunnen in richtlijnen 
worden verwerkt, waarmee artsen kunnen worden ondersteund om het gebruik van 
medicijnen in de laatste fase van het leven te optimaliseren.
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In ons onderzoek naar medische interventies in de laatste dagen van het leven 
(hoofdstuk 5) viel op dat de stervensfase bij ongeveer 50% van de patiënten was 
herkend. Toekomstig onderzoek moet trachten het stervensproces te ontrafelen, zodat 
artsen het naderend overlijden nog beter herkennen en de zorg geoptimaliseerd kan 
worden.
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optimaliseren. Beste Marianne, duizendpoot, dank voor de samenwerking tijdens het 
MEDILAST-onderzoek en de fijne gesprekken.
Lieve Else en Siebe, wat bof ik dat jullie mij terzijde willen staan als paranimf! Else, jouw 
uitgebreide kennis op het gebied van argumenteren en presenteren, en al jouw hulp als 
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het eindproduct. Beste Roberto, veel te vroeg ben je van ons heengegaan.
De stafleden van de afdeling Interne Oncologie wil ik hartelijk danken voor de 
supervisie die ik tijdens mijn klinische tijd gedurende het promotieonderzoek mocht 
hebben. In het bijzonder wil ik prof. dr. S. Sleijfer en prof. dr. R.H.J. Mathijssen danken. 
Stefan, jouw voetbalsmaak vind ik al een stuk beter, al laat jouw voetbalkennis je nog 
weleens in de steek: op het moment van schrijven sta ik nog steeds een koffie voor. 
Ron, veel dank voor het delen van je ideeën en je nuttige tips. Ook de collega-arts-
assistenten en de secretaresses, in het bijzonder José en Eline, wil ik danken voor de 
fijne samenwerking en gezellige praatjes.
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mooie tijd en samenwerking. Specifiek wil ik de directe collega’s van MBLL bedanken, 
met wie ik veel interessante discussies heb mogen voeren over goede zorg in de laatste 
fase van het leven.
Beste oud-collega’s van het Nederlands Tijdschrift voor Geneeskunde, veel dank voor 
de fijne tijd die ik bij jullie heb mogen doorbrengen en voor de vele dingen die ik mocht 
leren. Prof. dr. Y. van der Graaf, beste Yolanda, veel dank voor het vertrouwen in mij 
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Kees, en dr. B.M. Lodde, Beatrijs, dank voor de fijne eindredacteursopleiding die 
jullie mij gegeven hebben en voor het controleren van de Nederlandstalige passages 
in dit proefschrift. Kees, je zeer uitgebreide kennis over met name de flora en fauna is 
indrukwekkend!
Ik wil mijn collega’s van het Reinier de Graaf Gasthuis hartelijk danken voor de mooie 
tijd en de fijne leeromgeving die ik tijdens het eerste deel van de internistenopleiding 
mocht hebben. In het bijzonder dank aan dr. H. Boom, opleider, en drs. A. Vulink, met 
wie ik de passie voor goede zorg rond het levenseinde deel. Sinds 1 juli 2018 ben ik in 
het Erasmus MC werkzaam. Hoewel ik er nog niet zo lang werkzaam ben, voel ik mij 
er al thuis.
Mijn vrienden van zaalvoetbalvereniging Spartak Pancras: de vriendschap is heel veel 
meer dan teamgenoot zijn van een team dat gemiddeld één keer in de maand (jaar, 
decennium?) op zaterdagavond in de overdekte wei te vinden is. Van een aantal van 
die vriendschappen is het fundament al op de kleuterschool gelegd. Ik kan vele slappe 
verhalen vertellen over onszelf en onze escapades, maar dat is misschien beter iets 
voor ‘bij de borrel’.
Lieve ooms, tantes, nichten en neven, veel dank voor jullie belangstelling. Lieve oma, ik 
ben zeer trots dat u bij deze gelegenheid aanwezig kunt zijn. Ik hoop dat u ervan geniet!
Lieve Ko en Gerie, schoonpapa en -mama, vanaf de eerste keer dat ik bij jullie langs-
kwam voel ik mij thuis. Jullie zullen in eerste instantie vast jullie twijfels gehad hebben 
over de relatie van jullie Janneke met de ‘motormuis’… De fijne gesprekken aan de 
eettafel brengen mij zeer veel vreugde. Lieve Else, Evelien, Ilse, Luthwin, Dirk Jan en 
Maarten, wat bof ik met jullie als schoonzussen en zwagers. Bo, Tom, Fender en Milos, 
wat zijn jullie prachtige kinderen!
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Lieve Marc, broer en makker, in een aantal opzichten zijn we elkaars tegenpolen, maar 
in heel veel meer opzichten zijn we zó gelijk. Ik hoop dat jij met het gezin spoedig kunt 
genieten van jullie promotie naar jullie prachtige nieuwe stulp!
Lieve Marit, als zogenaamde nakomer binnen het gezin zal het vast niet altijd even 
gemakkelijk voor je zijn geweest. Ik vind het knap dat je jouw eigen weg hebt gevonden 
en geniet van de dingen die het leven te bieden heeft.
Lieve papa, het is zo verdrietig dat je al op jonge leeftijd getroffen werd door niet meer 
te genezen lichamelijke problemen. En wat is het ontzettend wrang dat je onderdeel 
moet uitmaken van mijn proefschrift. Wat had ik graag gewild dat je hier aanwezig kon 
zijn. Je had het ‘skitterend’ gevonden. Ik hoop dat ik ooit in de buurt mag komen van 
jouw enorm innemende karakter, zodat ik daadwerkelijk mag zingen wat ik vroeger 
al zong op de achterbank van de auto na een – gewonnen – voetbalwedstrijd op de 
zaterdagochtend: ‘Maar papa, ik lijk steeds meer op jou’.
Mama, ik ben zo ontzettend blij met de liefde waarmee ik ben opgegroeid. Je bent zo 
zorgzaam en enorm krachtig, hoewel je dat niet snel van de daken zult schreeuwen. Ik 
vind het erg knap van je hoe je papa terzijde stond tijdens zijn ziekte en hoe je je door 
de verdrietige afgelopen jaren hebt geworsteld.
Lieve Herre, Julius en Casper, tijgers, papa sluit met deze slotalinea een prachtig 
onderzoekstraject af. Ik hoop van harte dat jullie in de toekomst ook alle dingen 
kunnen realiseren die jullie graag willen doen!
Janneke, je bent mijn alles. Mijn drang om te excelleren is niet altijd gemakkelijk voor 
jou. En al helemaal niet in een periode waarin wij aan baby bunching hebben gedaan. 
Vanaf de eerste keer dat we elkaar ontmoetten ben ik zo verliefd op je. Ik hoop dat we 
met elkaar nog ontzettend veel plezier mogen beleven!
184
Chapter 13
13
About the author
Eric Geijteman was born on October 7th 
1982 in Alkmaar, the Netherlands. After 
graduating from the Petrus Canisius College 
in Alkmaar in 2001, he studied Human 
Movement Sciences and Nursing. From 2004 
he studied Medicine at the VU University 
Medical Center, Amsterdam. During his study 
he worked as student assistant at the section 
Pharmacotherapy, part of the department 
Clinical Pharmacology and Pharmacy, at 
the VU University Medical Center. In 2010, 
he obtained his qualification as a Medical 
Doctor with cum laude honor. From July 
2010 until July 2011, he worked as a resident 
at the department of Internal Medicine at the 
Medical Center Alkmaar. Next, he became 
involved in the research project ‘second 
evaluation of the termination of life on request 
and assisted suicide act’. In February 2013, he 
started his PhD trajectory under supervision 
of Prof. dr. A. van der Heide, Prof. dr. C.C.D. 
van der Rijt, Prof. dr. T. van Gelder, and dr. C. 
van Zuylen. During his PhD trajectory he did 
a fellowship in Clinical Pharmacology under 
the supervision of Prof. dr. T. van Gelder. 
In the second half of 2015, he worked as a 
resident scientific editor at the Dutch Journal 
of Medicine (Nederlands Tijdschrift voor 
Geneeskunde). As of January 2016, he started 
with his medical specialist training at Reinier 
de Graaf Hospital, Delft (program director 
dr. H. Boom), and Erasmus MC University 
Medical Center, Rotterdam (program directors 
dr. S.C.E. Klein Nagelvoort-Schuit and dr. 
A.A.M. Zandbergen).
185
Appendices

